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Abstract 
 
Introduction: Evidence from pre-clinical studies and observational data suggest that 
metformin and aspirin are good candidates for adjuvant therapies, though definitive phase III 
trials have not been completed. Prior to the initiation of this work, the Add-Aspirin trial had 
been conceived and funded with several potential challenges related to the implementation 
and design identified. Evidence to support the evaluation of metformin in a phase III adjuvant 
basket trial had not been systematically evaluated.  
Methods: I examined the implementation and conduct of the Add-Aspirin trial during its first 
year at individual UK research centres. Baseline clinical characteristics, and the feasibility and 
effect of the run-in period, in the first 500 participants was also examined. Additionally, I 
conducted a systematic review and meta-analysis to investigate the effect of metformin use 
on survival outcomes for individual tumour types in the adjuvant setting. 
Results: Centres recognised the efficiencies offered from a basket trial design particularly in 
terms of gaining approvals, staffing and data entry, though some unanticipated set-up and 
recruitment challenges have been identified. The baseline clinical characteristics were largely 
as expected. Overall, 88% of participants were randomised. The run-in period was effective 
in identifying, and preventing randomisation of participants who had less than 80% adherence 
(5.0%), and participants who developed significant aspirin related toxicities (1.2%). Other non-
randomisations were mostly due to minor toxicity and/or personal choice. A systematic review 
and meta-analysis found that metformin use was associated with significant benefits in 
recurrence-free survival, overall survival and cancer-specific survival in early-stage colorectal 
and prostate cancer. 
Conclusion: Opening a large multi-tumour type basket trial with an active run-in period was 
found to be feasible, but minor conduct modifications have been recommended and protocol 
amendments implemented. Metformin could be a useful adjuvant agent, and randomised-
control trials in colorectal and prostate cancer are advocated. 
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1.1 The global burden of cancer 
In 2014, there were around 357,000 new cancer diagnoses and 163,000 cancer deaths in the 
United Kingdom (UK) (1). Earlier cancer detection, combined with developments in cancer 
treatment have meant that survival after a cancer diagnosis has doubled in the last 40 years, 
however despite this about half of those diagnosed with cancer in the UK still die from their 
disease within 10 years (1).  
 Cancer is not just a disease of well-resourced countries, in 2012 there were an estimated 
14.1 million new cancer diagnoses and 8.2 million cancer deaths globally (2). Cancer is an 
increasing problem in low and middle income countries (LMIC), which accounts for 57% of 
cancer diagnoses, and 65% of cancer deaths worldwide (2). To examine trends in the global 
distribution of cancer, the Human Development Index (HDI) (based on life expectancy, 
education and gross domestic product per capita), has been used to group countries into four 
categories of socioeconomic development, ranging from low HDI (resource poor countries) to 
very high HDI (resource rich countries). Between 2008 and 2030 the absolute incidence of 
cancer is predicted to increase by 93%, 78%, 60% and 39% in low, medium, high and very 
high HDI countries respectively (3). The shift in the global burden of cancer towards lower HDI 
countries is thought to result from rapid increases in population growth, life expectancy, and 
exposure to risk factors including alcohol, infectious diseases, diet, industrial exposures, and 
smoking (4). Cancer survival rates are also poorer in low HDI countries, which has been 
attributed to a later stage at diagnosis (due to inadequate access to healthcare, health 
education and screening programmes) and limited access to affordable cancer treatments (5).  
 
1.2 The treatment of cancer 
When feasible, the cornerstone of treatment for many cancer types is surgical resection. 
Beyond surgery, there are a number of other modalities of cancer treatment which can be 
Chapter 1. Introduction 
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broadly divided into cytotoxic therapy (e.g. chemotherapy and radiation therapy), treatment 
that interferes with tumour growth and survival pathways (e.g. hormone therapy and 
molecularly targeted therapy), and treatment that modifies the host environment (e.g. 
immunotherapy). 
Cytotoxic cancer therapies work by causing damage to cancer cells to a greater extent than 
normal tissue. Radiation therapy does this through the administration of ionising radiation to 
damage the deoxyribonucleic acid (DNA) of cancer cells leading to cell death. To spare normal 
tissue, radiation is applied either using a shaped beam or directly through the use of 
radioactive implants (brachytherapy). Radiation therapy is also administered in temporally 
separated doses (fractions) to utilise the greater ability of normal tissue to recover between 
administrations. Chemotherapy uses chemical substances as cellular poisons, mainly through 
oral or intravenous administration and very occasionally through intrathecal or intraperitoneal 
routes. Like radiation therapy, chemotherapy also damages normal tissue, but due to 
biological differences between cancer cells and normal tissue (for example cancer cells 
undergo rapid cellular division), cancer cells are subjected to greater and more irreversible 
damage. Chemotherapy is also administered in temporally separated doses (cycles) to allow 
normal tissue to recover between administrations. Traditional chemotherapy acts either by 
causing damage to DNA (for example alkylating agents or topoisomerase inhibitors), or by 
preventing cell division/DNA replication (anti-metabolites or anti-mitotic agents). Different 
chemotherapeutic agents are often used in combination to minimise the chance of resistance 
developing and to allow lower doses to be given whilst maintaining/maximising therapeutic 
benefit. Combining chemotherapy and radiation therapy can lead to therapeutic synergy. 
Cancer can also be treated by interfering with the molecular pathways involved in tumour 
growth and survival. Hormone therapy involves the disruption of endocrine signalling through 
the administration of exogenous hormones, or medications which inhibit the production or 
actions of hormones, thereby inhibiting cancer growth for some tumour types (examples 
include prostate cancer and hormone receptor positive breast cancer). Targeted therapy uses 
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small molecules or monoclonal antibodies, designed to target and interfere with specific 
proteins or enzymes involved in the molecular pathways controlling tumour growth and 
survival. Examples include the small molecule pazopanib, which inhibits the enzyme tyrosine 
kinase, reducing  growth signalling in renal cell carcinoma (6), and the monoclonal antibody 
bevacizumab, which inhibits vascular endothelial growth factor, reducing blood vessel 
formation in a number of tumour types (7). Targeted therapy can also be combined with 
chemotherapy, as a single molecule, to allow targeted cancer cell cytotoxicity, for example the 
antibody-cytotoxic conjugate ado-trastuzumab emtansine (T-DM1) used in the treatment of 
human epidermal growth factor 2 (HER-2) receptor positive metastatic breast cancer (8). 
Most recently, developments in the treatment of cancer have focused on modifying the host 
environment to exert an anti-cancer effect. Immunotherapy is a treatment strategy that 
stimulates a patient’s immune system to target cancer cells. This can either be achieved 
actively, by directing the immune system to target specific proteins and other macromolecules 
on the surface of cancer cells, or passively, by enhancing an existing immune response to 
cancer cells. Recent successes in the field of cancer immunotherapy for the treatment of 
melanoma (9) highlight the potential efficacy of new therapies that modify the host and tumour 
microenvironment rather than working through direct tumour cytotoxicity. 
1.2.1 The adjuvant treatment of cancer 
Those diagnosed with cancer at an early stage often have primary treatment administered 
with curative intent (surgery or another radical treatment), however a risk of cancer returning 
(recurrence) remains for many cancer types. Adjuvant therapy, (therapy given in addition to 
primary treatment) can reduce the risk of recurrence, thus avoiding the burden of subsequent 
treatment and associated morbidity and mortality.  
A number of distinct modalities of adjuvant treatment have been shown to be effective in 
decreasing cancer recurrence and improving survival outcomes. Combinations of 
chemotherapeutic agents are often given for a number of tumour types including colorectal, 
breast, soft tissue sarcoma, endometrial, pancreatic, testicular and non-small cell lung cancer 
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(10). Other treatment modalities include hormone therapy (for example in prostate cancer), 
radiotherapy (for example in endometrial cancer) or molecularly targeted therapy (for example 
trastuzumab for the treatment of HER-2 receptor positive breast cancer). Improvements in 
adjuvant cancer outcomes have been made by combining modalities, either concurrently or 
sequentially, for example, a combination of chemotherapy and radiation therapy is used in the 
adjuvant treatment of small cell lung cancer, glioblastoma multiforme and head and neck 
cancer (11).  
The incremental benefits of combining treatment modalities can be illustrated by examining 
estimated survival gains in the adjuvant treatment of breast cancer using an on-line 
prognostication tool (12). After surgery alone for a patient with T4N2M0 luminal-B breast 
cancer, and without any adjuvant therapy, 77 out of 100 women are estimated to have died at 
five years. The use of adjuvant combination chemotherapy results in an extra 18 women alive 
at five years, and the addition of adjuvant radiotherapy can also improve local control rates 
further. Moreover, by adding a year of molecularly targeted therapy (trastuzumab), and five 
years of hormone therapy (tamoxifen), a further 10 and 13 extra women are alive at five years 
respectively. Further gains are also possible by extending adjuvant hormone therapy to 10 
years (13). Despite the benefits of combining adjuvant therapies in this scenario, 27 women 
out of 100 will still not be alive at five years. Likewise, adjuvant therapy only partially reduces 
the risk of recurrence for most tumour types (10), added to which, some cancers, including 
renal cell carcinoma and hepatocellular carcinoma, currently have no proven adjuvant 
therapies available. As a consequence, new adjuvant cancer treatments that can be given in 
isolation or combined with existing therapies, are urgently needed. 
 
1.3 Drug discovery and development 
In ancient times, medicines are thought to have been discovered through trial and error 
experimentation using natural products (often herbs, plants, roots or fungi) and observation of 
their biological effects (14). In the late 19th century, developments in medicinal chemistry 
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resulted in the discovery of new drugs through the identification of the active chemical 
ingredients that are responsible for the biological activity of traditional remedies, for example 
acetylsalicylic acid (aspirin). In the mid-20th century, the advent of classical pharmacology 
allowed drugs to be discovered through the use of chemical libraries administered to cell 
cultures or organisms, to look for a desired biological effect, which led to the development of 
traditional chemotherapy, for example paclitaxel. Later in the twentieth century, advances in 
the understanding of the molecular pathways underlying cancer, led to the era of modern drug 
discovery and the development of biological cancer therapies (15). 
Modern cancer drug discovery usually starts with laboratory based research to find and 
characterise a biological target that has been implicated in the growth and development of 
malignancy. A molecular screening library is then searched for a compound that has the 
greatest affinity for that target. Once identified, the compound then undergoes a process of 
chemical optimisation using pre-clinical studies designed to investigate and potentially 
improve absorption, distribution, metabolism, excretion and toxicity (ADMET) (16). When a 
potential candidate therapy is selected, pre-clinical studies (in-vivo and in-vitro) then evaluate 
its safety, efficacy and potential toxicity before beginning clinical testing. Phase I trials test the 
drug in people for the first time to identify side-effects and determine a safe dosage range. 
This is normally done by escalating the dose given to successive people to establish the 
highest dose that does not cause unacceptable side effects (called the maximum tolerated 
dose). If no concerning toxicities develop, the drug will enter phase II trials to examine efficacy 
and investigate side-effects further. Agents shown to be sufficiently effective and tolerated in 
phase II trials then enter phase III testing. Phase III trials are designed to compare a new 
treatment to the current standard of care in terms of efficacy, toxicity, and often resource 
requirements and quality of life. If shown to be beneficial, an application is then made for a 
licence for routine use (regulatory approval). The path from the discovery of a drug to clinical 
use is a lengthy journey, and is estimated to take between 10 and 17 years (17) as illustrated 
in figure 1.1.  
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Figure 1.1 Modern drug development pathway timelines (17) 
 
 
In order to move through the drug development process, a new therapy needs to be successful 
at each of the steps outlined above. It is estimated that about 10% of new cancer treatments 
entering phase I trials pass through all the steps required to gain regulatory approval (18). 
Figure 1.2 illustrates the attrition rate for new drugs as they pass through the clinical trials 
process. 
Figure 1.2 Clinical trial phases and attrition rates (18) 
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10.4% of drugs entering phase I 
trials reach regulatory approval 
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Developing new medicines is not only time consuming, but is also expensive. A recent analysis 
estimates that it costs 350 million US (United States) dollars for the pharmaceutical industry 
to discover a new medicine and make it available to patients (19). The high attrition rate means 
that if you include the costs of all the medicines that fail during this process it is estimated to 
cost five billion US dollars per new medicine (19).  
1.3.1 The drug development process for adjuvant cancer therapies 
Phase III trials of adjuvant cancer therapies often investigate clinical outcomes which take a 
number of years to occur (for example cancer recurrence). This can extend the timelines for 
drug development, beyond those described in figure 1.1. The time and cost limitations of the 
modern drug development process can be illustrated by the pathway taken by trastuzumab 
from discovery to use in the adjuvant setting. Trastuzumab is now part of standard treatment 
for the adjuvant treatment of high risk, early stage, HER-2 receptor positive breast cancer. In 
the UK, for a patient to receive standard adjuvant treatment with trastuzumab (administered 
for 1 year) it currently costs £21,184 GBP (British pounds) for the drug alone (20). It took 14 
years from its discovery to gain regulatory approval in the adjuvant setting (21 years from the 
identification of its target), as illustrated in figure 1.3.  
Figure 1.3 Development timeline of trastuzumab (21-25) 
 
 
 1985 
 Discovery and characterisation of HER-2 receptor target in breast cancer (20) 
 1990 
 Murine antibody against HER-2 receptor created (20) 
 1992 
 First synthesis of Trastuzumab (humanised antibody against HER-2 receptor) (22) 
 1992 
 First phase I studies commence (22) 
 1993 
 Phase II studies commence (21) 
 1995 
 Phase III studies commence in metastatic breast cancer (22) 
 2000 
 European medicines agency (EME) approval in metastatic breast cancer (23) 
 2001 
 EME extension of indication to adjuvant use (further extension in 2008) (23)  
 Phase III studies commence in the adjuvant setting (24)  
 2006 
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To have any significant impact on the global cancer burden in the near future, new cancer 
treatments not only need to be efficacious but also need to emerge quickly and be universally 
affordable. To achieve this, therapeutic candidates for phase III trials need to successfully 
emerge from the drug discovery and development process more rapidly and cost-effectively.  
 
1.4 Repurposing of established medicines as anti-cancer therapies 
In the quest for new cancer treatments, a number of established and widely used medications 
taken for non-oncological indications have been considered for repurposing as anti-cancer 
therapies on account of evidence to suggest anti-cancer activity. Repurposing is the process 
of finding new uses beyond the original indication for an existing drug, and has also been 
referred to as repositioning, reprofiling, redeployment and redirecting.  Established medicines 
are more likely to be overlooked by modern drug discovery, firstly due to lack of commercial 
interest because of generic availability (as a result of patent expiry), and possibly because the 
modern drug development process is designed to detect short-term dramatic anti-cancer 
effects (for example tumour response rates in phase II trials), rather than more gradual long-
term anti-cancer effects (possibly through modification of the host environment), which may 
be associated with established medicines. 
Repurposing established medicines as cancer treatments is attractive for a number of 
reasons: 
i. Data on anti-cancer efficacy may already be available from data collected on existing users 
in other indications. 
ii. Safety, toxicity and interaction profiles are already well established through longstanding 
widespread use. 
iii. Existing clinical data (as described by i and ii above) has the potential to fulfil many of the 
roles of early phase trials making the drug development process quicker and more 
economical. 
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iv. Established medicines are normally available in a generic formulation and are therefore 
inexpensive compared to novel therapies. 
v. Most generic medicines are easily available world-wide, particularly in LMIC countries, 
widening their potential impact on the global burden of cancer. 
Outside the field of oncology, there is a tradition of repurposing as a method of drug discovery, 
with new potential indications often emerging from unanticipated side-effects. Examples 
include sildenafil, originally used as a treatment for heart disease, now commonly used for 
erectile dysfunction, and minoxidil, developed as an anti-hypertensive, now used as a 
treatment for hair loss (26). 
Prior to the molecular and genomic era of cancer research, a number of new cancer 
treatments emerged from medicines in non-cancer indications. Thalidomide was first 
developed as a sedative and anti-emetic for use during pregnancy, but was found to cause 
phocomelia (congenital limb abnormality) and withdrawn from the market for that indication as 
a consequence. After the discovery that thalidomide had anti-angiogenic properties (27), in-
vitro studies investigated its potential as an anti-cancer therapy (28), eventually leading to its 
use as a treatment for multiple myeloma (29).  
In the adjuvant cancer setting there have also been some drugs that have been successfully 
repurposed. Tamoxifen, which was originally discovered as part of a contraceptive research 
programme (30), and is now commonly used in the treatment of breast cancer, and Bacillus 
Calmette-Guerin (BCG), first developed as a vaccine against tuberculosis, now also used as 
an adjuvant treatment for early stage bladder cancer (by direct administration into the bladder) 
(31). A number of candidate drugs have recently been identified for evaluation in the adjuvant 
cancer setting, examples include aspirin (32), vitamin D (33), statins (34), cimetidine (35), 
ketorolac (36), low molecular weight heparin (37), oestrogen patches (38) and metformin (39). 
A further example is the bisphosphonate, zoledronic acid, used in the prevention and 
treatment of osteoporosis. A number of phase III trials examining the adjuvant role of 
zoledronic acid, in breast cancer had conflicting results (40-42), however a recently published 
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meta-analysis (October 2015) showed significant benefits in breast cancer survival in post-
menopausal women, hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.73-0.93) (43). The 
use of zoledronic acid in this setting is beginning to be acknowledged in clinical guidelines 
(44), emphasising the value of meta-analysis in repurposing. Bisphosphonates are thought to 
prevent metastases by modifying the bone microenvironment (45), and provide another 
example of an adjuvant therapy that works by causing biological changes in the host rather 
than directly in cancer cells. 
1.4.1 Established medicines and the drug development process 
The aim of a phase I trial is to investigate safety and tolerability of a drug. For an established 
medicine, this information is often already available, either through historical clinical trials, or 
data on existing users, in non-cancer indications. In the cancer setting, phase I cancer trials 
usually aim to establish a maximum tolerated dose to optimise short-term anti-cancer effect, 
in-order to treat established malignancy. However, in the adjuvant setting, many therapies are 
also given long-term as maintenance against micrometastases (46), and in the primary 
prevention setting the priority is the long-term suppression of neoplastic processes. 
Consequently, long-term tolerability could be more of a priority in the adjuvant and primary 
prevention setting. Phase II cancer trials frequently aim to demonstrate efficacy by showing 
tumour shrinkage usually measured as response rates. In the adjuvant and primary prevention 
setting, short-term tumour shrinkage may not reflect efficacy (46), and therefore data on 
cancer incidence and outcomes in those who take an established medicine, long-term, in a 
non-cancer indication, could provide valuable insights. 
Aspirin is an example of an established medicine where there is now a considerable body of 
evidence underpinning its anti-cancer effect, which is considered sufficient to warrant a 
number of phase III trials. The evidence providing justification for phase III cancer trials did 
not emerge from the traditional steps of the drug development process, as illustrated in figure 
1.1, but emerged as described in the following section. 
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1.5 Evidence supporting aspirin as an intervention in phase III trials 
Aspirin has been taken by patients for almost 120 years (47), originally prescribed for its 
analgesic and anti-inflammatory properties, it is now mostly used for the secondary prevention 
of cardiovascular disease. Aspirin exhibits many of the attributes that make established 
medicines attractive as potential cancer therapies, including affordability, (it can be bought 
over the counter at three pence per tablet in the UK (48)), and widespread previous use, with 
a known toxicity profile.  
1.5.1 Aspirin - mechanistic hypothesis and pre-clinical evidence 
For a medication to be considered as a cancer therapy, a plausible mechanism of action in 
the intended treatment setting is required. The mode of action for novel cancer therapies is 
often known because they are designed to meet a particular mechanistic specification, 
however for established medicines, efficacy is often discovered before the underlying anti-
cancer mechanism, which then needs to be identified through pre-clinical research. 
Extensive in-vitro and in-vivo research into the biological effects of aspirin has already been 
undertaken as a result of interest in the mechanisms underlying its cardiovascular effects. 
Aspirin is known to inactivate both isoforms of the enzyme cyclooxygenase (COX) (49), also 
known as prostaglandin endoperoxide synthetase (PTGS). Many of the downstream 
mediators of the COX pathways are thought to be involved in the development and spread of 
malignancy (50), however, a divided daily dose of greater than 2000mg of aspirin would be 
required to achieve consistent inhibition of COX in tissues (51) because aspirin has a short 
half-life (approximately 20 minutes) and nucleated cells can resynthesize COX enzymes within 
a few hours. Aspirin has mostly been used in doses of 75-300 milligrams (mg) once daily over 
the last 40 years, therefore an indirect mechanism, possibly through modification of the host 
environment, rather than a direct cytotoxic effect may be more plausible. 
Aspirin is known to reduce platelet aggregation at commonly used doses (75-300mg), through 
inhibition of COX-1 (which is not re-synthesised by the anucleate platelet), which represents 
another potential mechanism for its anti-cancer effects (51). The first evidence suggesting 
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aspirin has anti-cancer activity emerged in 1972 from mouse models to suggest that aspirin 
prevented metastases, possibly through an anti-platelet mechanism (52, 53). This is 
consistent with more recent evidence showing that platelets are key mediators in the 
metastatic process (54).  Platelets are thought to promote the adhesion of cancer cells to 
leukocytes and endothelium leading to transmigration (55), and may also act as a barrier 
between circulating cancer cells and natural killer cells to prevent immune mediated clearance 
(56). It is also thought that platelets may play a more active role in promoting metastatic spread 
by active signalling to cancer cells through the TGF-β (transforming growth factor beta) and 
NF-kappa B (nuclear factor kappa B) pathways resulting in a pro-metastatic phenotype that 
facilitates tumour cell extravasation and metastasis formation (57).  
As well as COX inhibition, a number of additional COX-independent anti-cancer mechanisms 
have been proposed for aspirin (58). Aspirin is known to directly inhibit activation of NF-kappa 
B (59), which is thought to play a key role in tumour growth and invasion (60), as well as 
promoting apoptosis (61), and inhibiting angiogenesis (62). There is also in-vitro evidence to 
suggest that aspirin can directly influence other molecules and pathways involved in the 
development and growth of cancer, including Tumour Necrosis Factor, B-catenin, polyamine 
metabolism and the DNA mismatch repair and WNT (wingless-related integration site) 
signalling (63-65). 
1.5.2 Aspirin - observational evidence 
Being one of the most commonly used medications in the world, data on cancer incidence and 
outcomes in users of aspirin for existing indications has emerged. Case-control and cohort 
studies have been conducted using patient data from sources including hospital electronic 
health records, cancer registries, prescription databases, prospective surveys and 
concomitant medication data from clinical trials of other interventions. This has provided some 
evidence of an anti-cancer effect, and its relation to dose and duration, thus fulfilling many of 
the requirements of early phase trials. As the mechanisms underlying the anti-cancer effect of 
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aspirin could differ according to the therapeutic setting, evidence in the primary prevention 
setting and treatment setting are described separately in the following section. 
1.5.2.1 Aspirin - observational evidence in the primary prevention setting 
The first observational study to show that regular aspirin use was associated with a decreased 
risk of developing cancer was published in 1988 (66). Since then there have been well over 
100 case-control and cohort studies investigating the use of aspirin and cancer risk (67). 
A systematic review and meta-analysis of case-control and cohort studies in 2012 (67) 
examined the evidence in 12 individual tumour types and found evidence showing that aspirin 
was associated with a significantly lower risk of developing colorectal, oesophageal, gastric, 
breast and prostate cancer. There was no benefit seen in lung, pancreatic, endometrial, 
ovarian, bladder and kidney cancer, however this could be due to insufficient numbers to 
detect a treatment effect in these tumour types. Table 1.1 provides further details of these 
results. Findings also suggest that at least five years of aspirin use was required to convey 
these effects.  
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Table 1.1 Meta-analysis of observational data on aspirin in the primary prevention 
setting (67). 
 
Tumour type 
Observational 
studies (n) 
Diagnoses 
(n) 
Relative risk 
(95% Confidence 
interval) 
Breast cancer 32 52,926 0.90 (0.85-0.95) 
Colorectal cancer 30 37,519 0.73 (0.67-0.79) 
Prostate cancer 24 37,452 0.90 (0.85-0.98) 
Gastric cancer 13 4,519 0.67 (0.54-0.83) 
Oesophageal and gastric cardia adenocarcinoma 11 3,723 0.64 (0.52-0.78) 
Oesophageal squamous cell carcinoma 11 2,193 0.61 (0.50-0.76) 
 
Since this meta-analysis, a number of large observational studies have provided further 
supporting data. The Association of American Retired Persons Diet and Health study (AARP) 
included 301,240 adults aged between 50 and 71 years. An estimated 14% reduction in 
colorectal cancer incidence was observed with daily aspirin use (HR 0.86, CI 0.79-0.94) during 
10 years of follow-up (68). A Danish case-control study of 10,280 colorectal cancer cases and 
102,800 controls showed a reduction in the risk of colorectal cancer (odds-ratio (OR) 0.73, CI 
0.54-0.99) for those continuously taking aspirin for at least 5 years (69). In a US population 
based cross-sectional questionnaire based study, (n=11,657) regular aspirin use was 
associated with a significantly lower prevalence of prostate cancer (OR 0.60, CI 0.38-0.94) 
(70). 
1.5.2.2 Aspirin - observational evidence in the treatment setting 
Observational studies have also shown improvements in cancer outcomes with aspirin use 
after a diagnosis of cancer, suggesting efficacy in the adjuvant setting. Table 1.2 summarises 
the observational studies assessing the effects of aspirin after a cancer diagnosis. 
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Table 1.2 Summary of key observational data assessing the effects of aspirin after a 
cancer diagnosis by tumour type 
 
Cancer type 
 
Study 
(sample size) 
Treatment effect with aspirin  
(except where indicated) 
Colorectal cancer  
 
Nurses’ Health and HPFS (71) 
(n=1,279) 
Colorectal CSS- HR 0.71, CI 0.53-0.95 
OS- HR 0.79, CI 0.65-0.97 
Eindhoven Cancer Registry, 
Holland (72) (n=4,481) 
OS- RR 0.65 (0.50-0.84)  
Tayside, Scotland (73)  
(n=2990) 
Colorectal CSS- HR 0.58, CI 0.45-0.75 
OS- HR 0.67, CI 0.57-0.79 
Cancer registry of Norway (74) 
(n=23,162) 
Colorectal CSS- HR 0.85, CI 0.79-0.92 
OS- HR= 0.95, CI 0.90-1.01 
Breast cancer  
Nurses’ Health Study (75) 
(n=4164) 
Breast CSS- RR 0.36, CI 0.24-0.65 
OS RR- 0.54, CI 0.41-0.70 (daily users) 
Tayside, Scotland (76)  
(n=4,627) 
breast CSS- HR 0.42 (0.31-0.55) 
OS HR 0.53 (0.45-0.63) 
Prostate cancer  
Philadelphia, US (77) (post-
radiotherapy) (n=2,051) 
Interval to biochemical failure in aspirin 
non-users vs users- OR 2.05, CI 1.33-3.17 
CaPSURE study (78) 
(post-radical therapy)(n=5,995) 
Prostate CSS- HR 0.43, CI 0.21-0.87 
Cancer prevention study-II (79) 
(n=7,118) 
Prostate CSS- HR 0.60, CI 0.37-0.97 
(high risk non-metastatic) 
Gastro-oesophageal 
cancer 
Henbei University, China (80) 
(n=1,600) 
5-year OS aspirin 51.2%, placebo 41%, no 
tablet 42.3%. No HR/RR presented. 
Eindhoven Cancer Registry, 
Holland (81) (n=560) 
OS- RR 0.42, CI 0.30-0.57 
Non-small cell lung 
cancer 
Liverpool thoracic surgical 
database (82) (n=1,765) 
OS- HR 0.84, p=0.05 
Head and neck 
cancer 
Primary care electronic 
records, Scotland (83) 
(n=1,195) 
OS- HR 0.56, CI 0.44-0.71 
CSS=cancer specific survival, OS=overall survival, RR=relative risk 
 
The largest body of observational evidence in the treatment setting pertains to colorectal 
cancer. In the Nurses’ Health Study, and Health Professionals Follow-up Study (HPFS), two 
large, prospective studies, aspirin use after a diagnosis of colorectal cancer was associated 
with a significant reduction in colorectal cancer deaths (HR 0.71, CI 0.53-0.95), as well as 
overall mortality, with larger effects observed for daily users (71). Similar improvements in 
colorectal cancer outcomes from aspirin use after diagnosis have been seen in population 
databases including the Eindhoven Cancer Registry, Holland (OS RR 0.65, CI 0.50-0.84) (72), 
Tayside and Fife, Scotland (OS HR 0.67, CI 0.57-0.79) (73), Cancer Registry of Norway 
(colorectal cancer specific survival (CSS) HR 0.85, CI 0.79-0.92) (74), and the UK General 
Practice Research Database (All-cause mortality HR 0.83, CI 0.75-0.92 at 5 years) (84). Data 
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is also available in clinical trials designed to examine other interventions. The CALGB 89803 
trial (which compared two different adjuvant chemotherapy regimens in patients with stage III 
colon cancer), collected concomitant medication data on aspirin use. A post-hoc analysis of 
the trial found a trend towards improved OS (HR 0.63, CI 0.35-1.12) and disease-free survival 
(DFS) (HR 0.68, CI 0.42-1.11) in those patients using aspirin both during and after 
chemotherapy (85). Other population databases have not shown improvements, including the 
UK clinical practice research data link (all-cause mortality OR 1.06, CI 0.94-1.19, CSS OR 
1.06, CI 0.91-1.23) (86) and the Singapore Hospitals dataset (CSS HR 0.71, CI 0.43-1.17) 
(87) Figure 1.4 summarises the results of the observational studies investigating the effect of 
aspirin use after a colorectal cancer diagnosis. 
 
Figure 1.4 Observational studies investigating colorectal cancer outcomes according 
to aspirin use following diagnosis 
 
Footnotes: No summary statistic is presented given the high heterogeneity of studies. Multivariate (adjusted) 
statistics are presented in all cases.  a: All risk statistics are hazard ratios except the study by Cardwell 2013 which 
is an odds-ratios, and Bastiaannet 2012 which is a rate-ratio.  b: Studies have an overlapping population, both 
using UK General Practice Data. c: Cohort taken from randomised chemotherapy trial and  is limited to colon 
cancer.  d: Cohort only matched for CRC-specific mortality analysis.   
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In breast cancer, results from the Nurses’ Health Study indicated that 6-7 days of aspirin use 
per week following a diagnosis of breast cancer may improve breast CSS (RR 0.36, CI 0.24-
0.54), and the risk of distant recurrence (RR 0.57, CI 0.39-0.82) (75). Significant improvements 
have also been seen with post-diagnostic aspirin use in a population cohort study based in 
Tayside, Scotland (OS HR 0.53, CI 0.45-0.63, and Breast CSS HR 0.42, CI 0.31-0.55) (76).  
There is also observational evidence to support aspirin use after a diagnosis of prostate 
cancer. A large longitudinal observational study of men with prostate cancer (CaPSURE study) 
found that in men who had radical surgery or radiotherapy (n=5,955), aspirin was associated 
with a significant reduction in prostate CSS (HR 0.43, CI 0.21-0.87) (78). Additionally, an 
analysis of hospital data from Philadelphia showed that aspirin non-use after radiation therapy 
for prostate cancer is associated with early biochemical failure (OR 2.05, CI 1.33-3.17) (77). 
Most recently, an analysis of a large prospective cohort from the Cancer Prevention Study 
(n=7,118) found that post-diagnostic aspirin use in men with high risk non-metastatic prostate 
cancer resulted in a reduction in prostate CSS (HR 0.60, CI 0.37-0.97) (79). 
There is also evidence of improvement in cancer outcomes for post-diagnostic aspirin use in 
other tumour types including gastro-oesophageal cancer (80, 81), non-small cell lung cancer 
(88), and upper aerodigestive tract cancers (89). 
1.5.3 Aspirin - randomised evidence 
Whilst observational data can be adjusted for known confounding factors, the influence of 
unknown confounding factors cannot be eliminated. Randomised data (on an established 
medicine in other indications) reduces the chance of confounding and provides the most 
robust evaluation outside a phase III trial specifically designed to answer a question. Such 
evidence in the primary prevention and treatment setting are described separately.  
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1.5.3.1 Aspirin - randomised evidence supporting use in the primary prevention 
setting 
Meta-analyses of individual participant data on cancer incidence in randomised trials designed 
to investigate the effect of aspirin on vascular disease provide the strongest evidence for 
aspirin in the primary prevention setting. In a meta-analysis of four large vascular randomised 
controlled trials with aspirin as an intervention (n=14,033) a 24% relative reduction in the risk 
of developing colorectal cancer was identified (HR 0.76, CI 0.63–0.94), improving to 32% if 
taken for greater than five years (HR 0.68, CI 0.54–0.87) (90). A meta-analysis of six vascular 
randomised controlled trials with aspirin as an intervention (n=35,535) showed aspirin reduced 
the overall incidence of cancer from three years onwards (OR 0.76, CI 0.66-0.88) however 
numbers were insufficient for analysis according to individual cancer types (91). Since these 
meta-analyses were conducted, long-term follow-up from the Women’s Health Study (WHS), 
a randomised placebo-controlled trial designed to assess the effects of aspirin (100mg on 
alternate days) in the primary prevention of cardiovascular disease, has also showed that 
allocation to aspirin reduced the incidence of colorectal cancer by 20% (HR 0.80, CI 0.67–
0.97) after 18 years of follow-up, with survival curves suggesting the benefit emerged after 10 
years, suggesting a delayed effect (92). 
Phase III trials investigating the role of aspirin for cancer prevention in the general population 
are likely to be challenging due to the low event rate and the associated length of follow-up 
and number of participants required, however randomised trials are more feasible in groups 
that are at higher risk of developing a particular type of cancer. For example, in Lynch 
syndrome (Hereditary Non-Polyposis Colorectal Cancer), the most common inherited 
colorectal cancer syndrome, the CaPP2 (Cancer Prevention Project 2) trial randomly allocated 
patients with Lynch Syndrome to 600mg aspirin daily or placebo and found a reduction in 
colorectal cancer incidence in those that remained on aspirin for more than two years (HR 
0.41, CI 0.19-0.86), again suggesting a delayed effect (93). Another familial colorectal cancer 
syndrome, Familial Adenomatous Polyposis (FAP), has also been the subject of a randomised 
controlled trial. The CaPP1 trial randomised patients with FAP (prior to preventive surgery), in 
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a 2x2 factorial design, to 600mg daily aspirin, resistant starch, or placebo. They found a trend 
towards reduced polyp load in aspirin users, however this did not reach statistical significance 
(relative risk 0.77, CI 0.54-1.10) (94). The median duration of aspirin use was only 17 months 
and it is plausible that a treatment effect may have emerged with longer exposure. 
1.5.3.2 Aspirin - randomised evidence supporting use in the treatment setting 
Meta-analyses of data on cancer outcomes in randomised trials designed to investigate the 
effect of aspirin on vascular disease have also provided potential evidence in the cancer 
treatment setting. 
A meta-analysis of individual participant data from seven trials (n=23,535) showed a reduction 
in deaths from all cancers after five years of follow up (HR 0.66, CI 0.5-0.87) and at 20 years 
of follow-up (HR 0.80, CI 0.72-0.88). The effect was largest for adenocarcinomas (HR 0.53, 
CI 0.35-0.81) and for gastro-intestinal cancers (HR 0.65, CI 0.54-0.78). For those aged over 
65 years and over, absolute reduction in 20 year risk of cancer death was 7% (95). 
A further meta-analysis of individual participant data from five trials (n=17,285) revealed a 
reduction in the risk of having metastases when an adenocarcinoma is diagnosed (HR 0.69, 
CI 0.50-0.95) and of subsequently developing them during follow-up when not present at 
diagnosis (HR 0.45, CI 0.28-0.72) (96), which is supportive of efficacy as a treatment for 
cancer, particularly in the adjuvant setting. Analyses for individual cancers showed some 
evidence of improvements in mortality in colorectal (HR 0.27, CI 0.11-0.66), breast (HR 0.16, 
CI 0.02-1.19) and prostate cancer (HR 0.34, CI 0.12-0.99) (96) however these results are 
based on very small numbers and therefore need to be interpreted with caution. 
1.5.4 Aspirin - existing safety data 
A major advantage of an established medicine is the pre-existence of an abundance of safety 
data which can be used to fulfil the safety role of early phase trials, and often provide more 
detailed and accurate information, because an established medicine has been widely used for 
a long period of time allowing sufficient efficacy and safety data to accumulate. 
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Regulatory agencies including the Medicines and Healthcare products Regulatory Agency 
(MHRA), EMA and US Food and Drug Administration (FDA) already provide extensive safety 
information on aspirin from existing indications and list the main contraindications to aspirin 
use as a history of active or recurrent peptic ulceration, active gastrointestinal bleeding, 
previous intracranial haemorrhage, a haemorrhagic diathesis or a coagulation disorder (97). 
Co-administration of other NSAIDs (Non-steroidal anti-inflammatory drug), anti-coagulants or 
corticosteroids is known to increase the risk of adverse effects. The most common concern in 
relation to aspirin use is the risk of bleeding. Due to the large number of clinical trials in other 
indications, extensive safety data has accumulated from clinical trial adverse event reporting 
allowing a number of meta-analyses of existing safety data. A meta-analysis of data from six 
cardiovascular primary prevention randomised controlled trials, (n=95,000) found that aspirin 
increased the risk of serious bleeding (excluding intracranial haemorrhage) by 0.04 % per year 
(from 6.6 events per year in 10,000 individuals to 10.2 events) and intracranial haemorrhage 
by less than 0.01 % per year (from 2.7 events in 10,000 individuals treated for a year in the 
control groups to 3.5 events in the aspirin groups), HR 1.39, CI 1.08–1.78) (98). The meta-
analysis also revealed that elevated mean blood pressure is associated with an increased risk 
of intracranial haemorrhage (rate ratio 2.18, CI 1.65–2.87 for every 20mmHg elevation) (99). 
Systematic review has been used to examine risk factors for bleeding and age has been 
shown to be a key predictor with the finding that the risk of major bleeding increases between 
three- and four-fold between the ages of 50–54 and 70–74 years (98). Long-term and 
widespread use of aspirin has allowed enough data to accumulate to rarer side-effects of 
aspirin including an increased risk of macular degeneration (100) and tinnitus (97), which are 
unlikely to have been identified by phase I and II trials due to the association with long-term 
exposure. This safety information can be used to design eligibility criteria for phase III trials to 
protect those at the highest risk of aspirin related toxicity. 
1.5.5 Aspirin - risk benefit considerations 
Existing data from aspirin use in other indications might also be used to identify sub-
populations who stand to benefit most, and those who do not benefit, influencing subsequent 
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clinical trial design, for example, observational data has suggested that tumour PIK3CA 
(Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha) mutation status, 
expression of COX-2 (71) and Human Leukocyte Antigen (HLA) class-I (101), along with 
certain germline polymorphisms, might all help to identify individuals with colorectal cancer 
who stand to gain most from aspirin use after diagnosis. PIK3CA mutation status (affecting 
approximately 15% of those with colorectal cancer (101-103)) has been implicated as a 
biomarker of benefit in both a large cohort study (102) and in a small ad hoc analysis of the 
VICTOR trial, where rofecoxib (a COX-2 inhibitor) was being evaluated after colorectal cancer 
resection but the trial was closed early when rofecoxib was withdrawn from the market due to 
concerns about cardiovascular toxicity (103). Data on PIK3CA mutation status as a potential 
predictive biomarker is encouraging, but comes from small numbers of participants and 
findings are inconsistent, which are summarised in table 1.3.  
Table 1.3 Studies examining PIK3CA mutation status, aspirin use and colorectal 
cancer outcomes 
 
  Study  PIK3CA   
 mutation 
(%) 
PIK3CA Mutant PIK3CA Wild-Type 
No 
aspirin 
 Aspirin  Outcome HR  95% CI 
p value 
No 
aspirin 
Aspirin  Outcome HR 95% CI 
 p value 
NHS & 
HPFS 
(102) 
16.7% 95 66 
OS 0.54 
0.31-0.94 
p=0.01 
466 337 
OS 0.94 
0.75-1.17 
p=0.96 
CSS 0.18 
0.06-0.61 
P<0.001 
CSS 0.96 
0.69-1.32 
p=0.76 
VICTOR  
Trial 
(103) 
11.6% 90 14 
OS 0.29 
0.04-2.33 
P=0.19 
681 111 
OS 0.95 
0.56-1.61 
p=0.26 
CSS 0.11 
 0.001-0.83 
p=0.027 
CSS 0.94 
0.59-1.49 
p=0.79 
MCS & 
RMH 
(104) 
12.4% 136 49 
OS 0.96 
0.58-1.57 
p=0.86 
Study of PIK3CA mutated tumours only 
CSS 0.60 
0.34-1.16 
p=0.14 
ECR** 
(101) 
15.8% 73 27 OS 0.73* 
0.33-1.63 
p=0.4 
348 147 OS 0.55 
0.40-0.75 
P<0.001 
Multivariate (adjusted) statistics are presented in all cases. *=rate ratio, **colon cancer only, OS=overall survival, 
CSS=colorectal cancer-specific survival,  RFS=recurrence-free survival, NHS= Nurses’ Health Study, HPFS=Health 
Professionals Follow-up Study, MCS=Moffitt Cancer Centre, RMH=Royal Melbourne Hospital, ECR=Eindhoven 
Cancer Registry. 
 
Another potential predictive biomarker is HLA class-I antigen expression. It has been 
hypothesised that aspirin, through its anti-platelet effects, could expose circulating tumour 
cells to immune-mediated destruction by natural killer cells (105) and that this effect would be 
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restricted to tumours with low or absent HLA class I expression. Analyses of a randomly 
selection of colon tumour samples (n=999) from the Eindhoven Cancer Registry found that 
the benefit in OS from aspirin therapy was largely restricted to tumours expressing HLA class-
I antigens (OS risk ratio 0.53, CI 0.38-0.74), and benefit was not seen in those who had lost 
expression (OS risk ratio 1.03; CI 0.66-1.61) (101). This interesting observation, contrary to 
the original study hypothesis, requires validation. HLA class-I expression is seen in about a 
third of colorectal tumours and so could identify a sizeable group who might benefit from 
aspirin after a colorectal cancer diagnosis.   
Observational data can also be used to identify individuals who might be at increased risk of 
aspirin related toxicity. A history of gastro-oesophageal reflux disease or dyspepsia prior to 
starting aspirin has been shown to be strongly predictive of upper gastrointestinal symptoms 
on aspirin (OR 17.6, CI 11.52-26.88) (106) which is useful to guide eligibility criteria in phase 
III trials. Helicobacter pylori infection has been proposed to be a marker of increased risk of 
developing dyspepsia and a bleeding gastrointestinal ulcer with aspirin (98), however most 
data supporting this association relates to non-aspirin NSAID (non-steroidal anti-inflammatory 
drug) use, therefore further data is needed to confirm a relationship with aspirin (107). The 
HEAT trial (Helicobacter Eradication Aspirin Trial) (ISRCTN10134725), examining 
helicobacter pylori eradication to prevent ulcer-related bleeding and dyspepsia in aspirin users 
is ongoing.  
Genome-wide association studies can identify genetic variants that are associated with 
developing side-effects. These studies have identified certain genetic polymorphisms, 
proposed as potential biomarkers for NSAID induced gastrointestinal ulceration and bleeding 
(including aspirin). A study in a Japanese population (n=480) found that a functional single 
nucleotide polymorphism (SNP) of the COX-1 gene (rs1330344) were significantly associated 
with gastric ulceration (OR 5.80, CI 1.59–21.1) (108). Additionally, two polymorphisms of 
Cytochrome P450 2C9 (an enzyme responsible for the metabolism of aspirin) have been found 
to be significantly associated with bleeding risk in NSAID users (108, 109).  
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1.5.6 Dose considerations 
The mechanism of action underlying the anti-cancer effects of aspirin is unproven and it is 
plausible that there may be different mechanisms that act to prevent metastases and the 
development of the primary tumour which could be dose dependent. Meta-analyses of cancer 
outcomes in cardiovascular trials where aspirin is an intervention have evaluated low dose 
aspirin (75-100mg daily) and shown beneficial effects on cancer outcomes (91, 95). However, 
the Nurses’ Health Study and Health Professionals Follow-Up Study suggest that higher doses 
of aspirin (greater than 6 x 325mg tablets per week) have a greater effect than lower doses 
(0.5-5 x 325mg tablets per week) on both colorectal cancer and overall mortality (75). The 
dose of aspirin needs to be balanced against the risks of aspirin toxicity which is thought to 
increase with both age and aspirin dose (98). Another key consideration is the acceptability of 
prescribing different doses of aspirin. A recent survey of General Practitioner (GP) attitudes 
towards prescribing aspirin for carriers of Lynch syndrome found that 91.3%, 81.8% and 
62.3% of GPs were comfortable prescribing 100mg, 300mg and 600mg of daily aspirin 
respectively (110). Further research is needed to investigate the relationship between dose 
and the potential anti-cancer effects of aspirin. 
The evidence supporting a phase III trial with aspirin as an adjuvant therapy for cancer is 
significant, and includes data to suggest how the risk/benefit profile might be optimised, 
however a phase III trial in this setting presents a number of challenges. 
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1.6 Challenges to evaluating aspirin in an adjuvant phase III cancer trial 
There are a number of methodological and practical challenges presented by an adjuvant 
phase III cancer trial with aspirin as an intervention, many of which may apply to other trials of 
generic medicines. The main challenges are summarised below: 
1. Lack of commercial interest in generic interventions from pharmaceutical companies 
mean that all financial support for the trial is required from governmental, academic 
and charity sources, and significant cost-efficiencies need to be incorporated into trial 
design and conduct.  
2. Operational procedures including drug packaging, labelling, blinding, distribution, 
supply management and unblinding provision need to be provided without industry 
support. 
3. Maintained long-term adherence is likely to be required for the anti-cancer effects of 
aspirin to emerge (90, 92, 93), posing challenges including length of follow-up, 
maintained adherence, and  extended exposure increasing the risk of developing 
toxicity.  
4. Aspirin is available for purchase over the counter without the need for a prescription, 
and as such there is the potential for control arm contamination.  
5. Large numbers of participants are required to achieve adequate power to detect a 
long-term treatment effect in individual tumour types.  
 
1.7 Overview of the Add-Aspirin trial 
Add-Aspirin is a randomised phase III trial which aims to assess whether regular aspirin use 
after standard potentially curative primary therapy can prevent recurrence and prolong survival 
in individuals with common early stage solid tumours. The trial employs a number of 
methodological approaches to meet the challenges described in the previous section. 
Traditionally, clinical trials have been designed to evaluate a single intervention in a 
homogenous group of patients. A basket trial design investigates a single intervention in 
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different types of patients, whereas a platform trial design uses a single master protocol in 
which multiple interventions (or doses) are evaluated simultaneously (111). The design for the 
Add-Aspirin trial incorporates a single protocol across four tumour types, and investigates two 
doses of aspirin (compared to placebo) both across and within each tumour type, and as such, 
incorporates elements of both platform and basket trial design, but the term “basket design” 
will be used from this point onwards. The tumour types selected for the trial were based on 
the following factors: 
(i) The strength of the evidence relating to potential benefit of aspirin (section 1.5).  
(ii) The size of the potential impact (numbers of cases diagnosed at an early stage).  
(iii) Feasibility of recruitment.  
Four tumour types were selected, (breast, colorectal, gastro-oesophageal and prostate 
tumours) which, together, accounts for approximately one third of all cancer cases and cancer 
deaths (1). 
There is uncertainty surrounding the optimal aspirin dose required to achieve anti-cancer 
effects as described in section 1.5.6. Given this, the length of time needed to for sufficient 
events to occur, evaluating only one dose would not allow dose effect to be investigated, 
potentially wasting valuable research time and resources. To answer this question, two doses 
of aspirin were selected (100mg daily and 300mg daily, compared with matched placebo) to 
be investigated both within, and across cohorts. The dose of aspirin in its lowest formulation 
varies between countries, with 75mg, 81mg and 100mg commonly used in the UK, US and 
Europe respectively. A 100mg dose was selected over 75mg and 81mg because it could be 
provided by Bayer AG. These small differences in dose are not anticipated to be clinically 
significant.   
Uncommonly for a cancer trial, the design includes a run-in period where all potential 
participants are asked to take aspirin 100mg daily for 8 weeks to assess adherence and 
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tolerance, prior to being selected for the randomised phase of the trial. Figure 1.5 shows a 
summary schema of the trial design.  
Figure 1.5 Add-Aspirin trial schema 
 
 
DFS = disease free survival, OS = overall survival, RFS = recurrence free survival. 
 
Funding for the trial has been secured from charity and governmental sources. All doses of 
the blinded active intervention and matched placebo have been donated by industry (Bayer 
AG), but not the packaging, labelling, blinding or distribution, which therefore represented a 
major operational and funding challenge. These challenges were met by outsourcing some of 
these processes and development of an in-house drug supply management system to track 
stock levels at sites and automatically trigger re-orders based on projected demand. 
To ensure recruitment is sufficient to detect trial outcomes in individual tumour types, it is 
necessary for the trial to open in most centres treating cancer across the UK as well as 
additional centres in India, where patients will be recruited to the breast and gastro-
oesophageal cohorts. The design for the Add-Aspirin trial also has the capacity to add 
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additional interventions alongside aspirin, presenting the opportunity to evaluate other 
established medicines where sufficient supporting evidence exists. 
 
1.8 Metformin as an adjuvant anti-cancer therapy 
There is a growing body of evidence to suggest that metformin, commonly used to treat type 
II diabetes mellitus (DM), has anti-cancer activity. Like aspirin, metformin also has many of 
the qualities that make established medicines in non-cancer indications, attractive as anti-
cancer treatments. Metformin is available generically worldwide, and is generally well tolerated 
with long term use. It is also low in cost, in the UK it is available to the National Health Service 
(NHS) at two pence per tablet (500mg) (112).  
There have been a number of calls for systematic reviews and meta-analyses to be conducted 
as part of the scientific justification, and to inform the design, of new clinical trials (113, 114), 
and these are likely to provide the most objective evaluation of a drug candidate, and represent 
the corner stone of the evidence that supports aspirin as an intervention in phase III trials. The 
utility of meta-analysis to detect more subtle, but important treatment effects of a repurposed 
cancer agent has also been demonstrated with bisphosphonates as described in section 1.4 
(16). The ability to perform a meaningful systematic review and meta-analysis relies on the 
availability of sufficient homogenous data. A robust evaluation of observational data needs to 
be conducted in a population and disease setting that most closely reflects that which is 
proposed for repurposing, therefore data is best analysed separately for the primary 
prevention, adjuvant and advanced setting. Many anti-cancer effects are also tumour specific, 
and therefore it is important to examine observational data in the context of individual tumour 
types rather than across them. To-date, evidence to support the use of metformin as an 
adjuvant therapy in individual cancer types has not been presented.  
  
46 
 
1.9 Aims and objectives of thesis  
I joined the Add-Aspirin trial team in September 2013, at which point the funding for the trial 
was in the process of being secured, and the protocol was in development. I led the writing for 
the clinical aspects of the protocol (appendix A) and the design for the trial procedures 
investigated by this thesis including; the method for assessing adherence and tolerance in the 
trial run-in period; the timing of trial registration across tumour types; and the management of 
toxicity and guidance around concomitant medication. I also designed the trial case report 
forms (CRF) (available in appendix D) and coordinated applications for regulatory approval, 
which was granted by Research Ethics Committee on the 4th June 2014 and the MHRA on 
25th November 2014. I led clinical site training and managed the clinical aspects of the trial on 
a day to day basis, with support from the Chief Investigator. I was the first point of contact for 
clinical and eligibility queries and clinical review of adverse events between the trial opening 
and September 2016.  
During my research fellowship (September 2013—September 2016), I formulated four 
research questions to improve the conduct of this and similar trials. Each of the following 
research questions is addressed in the subsequent chapters of this thesis. 
1) What are the advantages and challenges of delivering the Add-Aspirin trial design at 
site, and how is the trial design perceived? 
2) How accurate are the anticipated recruitment rates provided by sites for each tumour 
type, and how might this be improved? 
3) Are patients entering the trial as expected and are any adjustments to the run-in period 
design necessary? 
4) Is there sufficient evidence to undertake a phase III trial of metformin in the adjuvant 
setting, or add metformin as an intervention to the Add-Aspirin trial? 
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Chapter 2. An evaluation of the set-up processes and 
delivery of the Add-Aspirin trial at sites, and the 
acceptability of the design  
 
2.1 Introduction 
Some aspects of the Add-Aspirin trial design may present both advantages and challenges to 
the conduct of the trial at NHS research sites. An evaluation was undertaken to investigate 
the benefits, obstacles, and perceptions of the trial design in the first year of the trial. 
The basket design of Add-Aspirin aims to address multiple questions in a single study, 
including dose, toxicity, cancer and non-cancer benefits, both within and across tumour types, 
and is the first major UK phase III trial in cancer using this design. Keeping all four cohorts 
within a single protocol aims to keep the management of each cohort as comparable as 
possible (with the exception of some tumour type specific procedures) and save many years 
of research time. This also allows a combined analysis across cohorts, providing a much larger 
sample size to study small effects, which are of interest since aspirin is low cost and easy to 
administer. These include cross cohort secondary analyses of toxicity, cardiovascular, 
cognitive, and other health benefits, thus increasing the overall potential impact of the trial. A 
combined analysis also allows a co-primary outcome measure of overall survival to be 
investigated across tumour types. To deliver these benefits, the trial needed to be successfully 
set-up and recruit to multiple tumour cohorts at the majority of UK NHS research sites that 
treat cancer. A trial conduct survey was designed to examine the experience at site of trial set-
up and recruitment, both overall, and to individual tumour cohorts, with the intention of 
improving the conduct of this and other similar trials. 
The basket design also has the potential to provide economies of scale both centrally and at 
site, including site set-up, regulatory approval, central staffing, coordination, oversight and 
data management. The resulting potential cost efficiencies improve the financial viability of the 
trial given the lack of industry support, and provide value for money for charitable and 
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governmental funders. The second objective of the trial conduct survey is to examine whether 
there were efficiencies in opening and running the trial at site through the use of a basket 
design.  
The trial design also includes an active run-in period where all participants take 100mg aspirin 
(one tablet per day) in an open-label manner for a period of approximately eight weeks prior 
to randomisation. This approach aims to identify those individuals who are unlikely to be able 
to tolerate aspirin, as well as those who are unlikely to be able to adhere to the protocol 
treatment schedule. The background and methodology for the run-in period are described in 
detail in chapter four. The third objective of the trial conduct survey is to establish the views of 
site staff on the effectiveness of the run-in period in selecting a population with enhanced 
adherence and tolerance to trial treatment. 
Allowing participants who are already taking part in other trials to co-enrol in the Add-Aspirin 
trial provides a greater pool of potential participants and maximises the opportunities for 
patients to participate in trials. Trial co-enrolment also allows an assessment of the efficacy of 
aspirin in participants who have received both current and potentially future standard of care 
treatment, helping to ensure the future relevance of both trials. Whilst co-enrolment has a 
number of potential benefits, it is not routinely adopted by the majority of trials. The fourth 
objective of the trial conduct survey is to determine the attitudes of NHS research site staff 
towards trial co-enrolment. The objectives of this chapter are summarised below. 
2.1.1 Objectives 
1. Examine the challenges experienced at site in setting up and recruiting to the Add-
Aspirin trial overall, and to individual tumour cohorts. 
2. Establish whether there are efficiencies in the conduct of the Add-Aspirin trial at site 
through the use of a basket design. 
3. Establish the views of site staff on the effectiveness of the run-in period in selecting a 
population with enhanced adherence and tolerance to trial treatment. 
4. Determine the attitudes of NHS research sites towards trial co-enrolment. 
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2.2 Methods 
2.2.1 Setting up the Add-Aspirin trial 
After gaining full regulatory approval, the first Add-Aspirin trial site training was conducted on 
the 5th May 2015. To allow sites to open promptly, weekly online training sessions were 
conducted via a video link, and a training video was provided on the trial website (training 
slides and the training video is available at www.addaspirintrial.org). To open, sites had to 
have a tumour-specific lead investigator for each recruiting cohort, and an overall Principal 
Investigator (PI), selected from the tumour specific lead investigators, who has responsibility 
for trial oversight and regulatory approval. This approach was designed and implemented to 
provide the individual tumour type expertise required to manage and provide oversite for each 
cohort effectively, whilst maintaining efficiency in gaining regulatory approval with one overall 
PI.  
2.2.2 Evaluation of site opening 
Data on the opening of individual cohorts at UK NHS research sites was collected between 
the 8th October 2015 and the 1st November 2016, and includes the first 12 full months of the 
trial. 
2.2.3 Trial conduct survey 
A survey was designed to meet the aims and objectives described in section 2.1.1 An email 
containing a web link to an online survey was sent to the main points of contact of 184 UK 
NHS research sites (237 individuals), where the trial was open, or where an interest in opening 
had been previously expressed. Completion of the survey was voluntary and instructions were 
given to seek input from other colleagues at their site as necessary. The survey was sent to 
sites on the 26th August 2016, with responses accepted until the 1st November 2016. 
The survey was created using an on-line survey platform (www.surveymonkey.co.uk), and 
consisted of 30 questions overall, with some questions automatically skipped depending on 
previous responses to ensure applicability. Question types included single answer multiple 
choice (n=5), multi-answer multiple choice (n=10), rating scale (n=9), open ended free-text 
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(n=5), and ranking of options (n=1) style questions. Multi-answer multiple choice questions 
presented a list of pre-set options, created based on common themes that emerged from 
communication with sites during the set-up of the trial, and also included an option to provide 
other answers using free-text which were not available as existing options. Free-text 
responses were analysed using a qualitative approach and coded according to common 
themes. Where free-text responses matched the theme of a pre-set option that was already 
selected, it was excluded from the analysis to avoid duplication, however if a matching pre-set 
option had not already been selected, then it was counted with that pre-set option. 
Rating scale questions used a five-point Likert scale which allows respondents to specify their 
level of agreement or disagreement on a symmetric agree-disagree scale for a series of 
statements, with a scale from one for strongly agree, through to five for strongly disagree. The 
results were interpreted by calculating a median response for each question to capture the 
intensity of opinions for a given question, rather than the mean, because the data is categorical 
and therefore unlikely to be normally distributed (115).  
Ranking questions were used to allow respondents to compare options by placing them in an 
order of preference. A mean ranking was calculated for each option to determine the preferred 
choice by weighting each response according to the ranking attributed (with weighting of one 
for first ranked response through to a weighting of five for fifth ranked response) and 
calculating the mean. Where “not given as a reason” was selected, these we not factored into 
mean rankings. This approach was used so that the options could be compared in a way which 
reflects all the ranking given by respondents for each option, rather than just comparing the 
most frequent response (mode), which could be misrepresentative.  
Trial conduct survey responses were linked to individual NHS research sites through a site 
code to determine the number of separate sites that had responded and their participation 
status, but all other analyses were blinded to site, and no other identifiers were collected for 
individual respondents. Statistical analysis for numerical data was mostly descriptive with 
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percentages being reported. A copy of the trial conduct survey is available in appendix B. All 
data were analysed using Microsoft Excel.  
 
2.3 Results 
2.3.1 Site opening at one year 
The trial recruited its first participant on the 8th October 2015 and, in the first year of opening 
(by 1st November 2016), 155 sites had opened to recruitment, meaning that 66.7% of NHS 
trusts and boards in the UK had at least one recruiting site (NHS trusts in England, Health 
Boards in Scotland and Wales, and Social Care Trusts in Northern Ireland). 81.3% of these 
sites were able to open in at least three of the four tumour cohorts. For trusts in England, the 
National Institute for Health Research (NIHR) Clinical Trials Network has set a 30 day target 
from NHS permission to first subject recruited as a higher level objective (116). The median 
time from a site opening to recruiting its first participant (censoring sites yet to recruit) was 43 
days (IQR 27-71 days), exceeding the NIHR higher level objective. Table 2.1 shows the 
number of sites open to the trial, broken down by each devolved nation. Table 2.2 shows the 
number of individual cohorts open at sites. Table 2.3 summarises site opening at one year by 
cohort. 
Table 2.1 NHS trusts and boards* open to the Add-Aspirin trial at one year 
 
 
NHS sites 
open (n) 
NHS Trusts and boards* 
with an open site (n) 
Total number of NHS trusts 
or boards* in the UK 
Percentage of all NHS 
trusts and boards* open 
England 133 106 154 68.9% 
Scotland 10 7 14 50% 
Wales 12 7 7 100% 
Ireland 0 0 5 0% 
UK total 155 120 180 66.7% 
*NHS trusts and boards (NHS trusts in England, Health Boards in Scotland and Wales, and Social Care 
Trusts in Northern Ireland). 
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Table 2.2 Add-Aspirin trial cohort opening after one year, by cohort 
Cohort Sites with cohort open (%) 
Open sites with at least one 
participant (%) 
Breast 144 (92.9%) 114 (79.2%) 
Colorectal 143 (92.3%) 101 (70.65%) 
Gastro- 
oesophageal 
114 (73.5%) 31 (27.2%) 
Prostate 128 (82.6%) 68 (53.1%) 
Total 155 127 
 
Table 2.3 Add-Aspirin cohorts open at individual sites after one year of being open 
 
Number of open 
cohorts 
Number of sites  
(Total 155) 
Percentage of sites 
Four cohorts 97 62.6% 
Three cohorts 29 18.7% 
Two cohorts 17 11.0% 
One cohort 12 7.7% 
 
2.3.2 Data return from the trial conduct survey  
Between the 26th August 2016, and the 1st November 2016, 54.0% (128/237) of the individuals 
approached completed the trial conduct survey. Responses were available from 58.0% 
(90/155) of open sites, and 39% (16/41) of sites yet to open (which had expressed interest). 
The data therefore provides a broad reflection of UK site experience of the Add-Aspirin trial.  
Surveys were mostly completed by clinical trial nurses or sisters (60.9%), or by clinical trial 
practitioners or coordinators (28.1%), suggesting that respondents were directly involved with 
delivering the trial at site. A breakdown of the job title of those completing the trial conduct 
survey is provided in table 2.4. No data is available on the job title of non-responders. 
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Table 2.4 Job title of trial conduct survey respondents 
 
Job title Respondents (%) Job title Respondents (%) 
Clinical trials nurse 53 (41.4%) Clinical trials manager 2 (1.6%) 
Clinical trials sister 25 (19.5%) Clinical trials administrator 2 (1.6%) 
Clinical trials coordinator 19 (14.8%) Research and development lead 2 (1.6%) 
Clinical trials practitioner 17 (13.3%) Clinical trials assistant 2 (1.6%) 
Clinical trials officer 3 (2.3%) Data manager 1 (0.8%) 
Clinical trials pharmacist 2 (1.6%) Total 128 
 
 
2.3.3 Barriers to opening the Add-Aspirin trial at site 
The vast majority of sites expressing an interest in the trial had completed set-up and were 
open by the end of the first year of recruitment (84.7%). Respondents identifying their site as 
yet to open (n=16, 57.1% of all sites yet to open overall), were directed to a question to 
establish the reasons for this. Respondents were asked to select all the reasons that applied 
from a list, and were given the option to specify additional reasons as free-text. Table 2.5 
shows the reasons given to account for not opening the trial.  
 
Table 2.5 Reasons given for not opening the Add-Aspirin trial at sites expressing an 
interest  
Reasons given for not opening 
(n=16, able to select multiple options) 
n (%) Reasons offered but not selected n (%) 
Delay in sponsor opening site 4 (25.0%) Lack of interest in study 0 (0%) 
Insufficient staff 4 (25.0%) Competing trials 0 (0%) 
Concerns about excess trial costs 2 (12.5%) Lack of familiarity with a basket design 0 (0%) 
Unable to identify PI(s)  1 (6.3%) Lack of familiarity with a run-in period design 0 (0%) 
Other 7 (43.8%) Concerns about variations in follow-up schedules 0 (0%) 
 
Delays at the coordinating trial unit were attributed to be the reason for failing to open by four 
respondents (25%). Initially, site set-up was coordinated centrally by one trial manager and 
four data managers, which increased to two trial managers and four data managers by the 
end of the first year. This provided efficiencies in central staffing compared to that normally 
required for setting-up sites for four separate trials, but may have been the rate-limiting step 
in opening for some sites. Whilst central staffing didn’t prevent recruitment targets being met 
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in the breast, colorectal and prostate cohorts, opening sites earlier to the gastro-oesophageal 
cohort may have helped meet its recruitment target. Sites looking to open this cohort may 
have benefited from being prioritised. 
Insufficient staffing at site was a reason given by four respondents (25%) for failure to open 
the trial. Sites often have a fixed number of facilitators who are responsible for setting up all 
trials, and time allocated by the NIHR does not account for variation in the complexity of phase 
III trials (117). The use of a complexity score to allocate funding for study set-up facilitators 
could be considered by the NIHR to allow more sites to open.  
Only one site reported that difficulties finding a tumour specific cohort lead investigator 
resulted in a delay in opening, demonstrating that the model of having an overall PI with with 
a tumour-specific lead investigator for each cohort was not a common barrier. 
In a qualitative analysis of “other reasons” provided in free-text (n=7), four responses followed 
a theme that the trial had not opened due to delays in regulatory approval (either Health 
Research Authority (HRA) or local research and development approval). It is possible that the 
trial took longer to achieve local research and development approvals because of lack of 
familiarity with a basket design. In March 2016 the requirement for research ethics committee, 
MHRA and local NHS research and development approvals was replaced by a single HRA 
approval, which simplified the regulatory approvals process in England, and may prevent this 
being a cause for delays in the future for similar trials. The other three reasons given in free-
text were; “having four arms,” “difficult to find suitable patients”, and “study team to update 
Good Clinical Practice (GCP) training first”. 
2.3.4 Barriers to opening individual tumour cohorts at site 
Respondents indicating their site had opened to the trial (n=97, 62.6% of sites open overall), 
were asked which cohorts were yet to open. Opening all cohorts was optional, however sites 
were encouraged to open as many cohorts as possible. The most frequented unopened cohort 
was the gastro-oesophageal cohort (n=20), followed by the prostate (n=12), colorectal (n=3) 
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and breast (n=2), cohort(s). Respondents reporting that a particular cohort had not opened at 
their site were asked to select all the reasons for this from a list, and were given the option to 
specify additional reasons as free-text. Table 2.6 shows the reasons given to account for not 
opening each cohort.  
Table 2.6 Reasons for not opening individual Add-Aspirin cohorts at site 
 
Reasons given for not opening cohort 
Gastro-oesophageal 
(n=20) 
Prostate 
(n=12) 
Colorectal 
(n=3) 
Breast 
(n=2) 
Tumour cohort not treated at site 7 (35%) 5 (42%) 0 (0%) 0 (0%) 
Unable to identify PI 5 (25%) 1 (8%) 0 (0%) 0 (0%) 
Insufficient staffing 3 (15%) 2 (17%) 1 (33%) 0 (0%) 
Competing trials 1 (5%) 1 (8%) 0 (0%) 0 (0%) 
Differences in follow-up schedules 1 (5%) 0 (0%) 0 (0%) 0 (0%) 
Other 1 (5%) 0 (0%) 2 (67%) 0 (0%) 
Intention to open soon 6 (30%) 5 (42%) 2 (67%) 2 (100%) 
 
The most commonly cited reason for not opening the gastro-oesophageal and prostate cohorts 
was that these tumour types were not treated at their site (35% and 42% of respondents 
respectively), which was not a reason given for the breast and colorectal cohorts. It is more 
common for the primary treatment of gastro-esophageal and prostate cancer to be centralised 
at specialist centres, however where patients return to their local site for follow-up and/or 
adjuvant therapy, patients could be registered for the trial at both sites. Encouraging those 
sites that only manage part of the treatment pathway to open may enhance recruitment. 
In the gastro-eosophageal cohort, the second most common reason was the inability to identify 
a cohort specific lead investigator (25% of respondents), however this may reflect that not all 
sites are involved in the treatment pathway for gastro-oesophageal cancer. 
Insufficient staffing was identified as a barrier to opening most frequently for the gastro-
oesophageal cohort (three respondents), followed by the prostate (two respondents) and 
colorectal cohorts (one respondent), and was not reported in the breast cohort. This suggests 
that staffing might be prioritised to open particular cohorts over others. As previously 
proposed, the allocation of funding for study set-up facilitators according to the complexity of 
a trial could be considered, and may allow more cohorts to open. 
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Only one site cited a competing trial as the reason for not opening a cohort. That trial (Neo-
AEGIS), has subsequently agreed to co-enrolment, suggesting that competing trials are not a 
barrier to site opening. In “other” reasons given as free-text, a respondent reported that the 
colorectal cohort had not opened because a “5 year scan required by the study not being 
standard of care,” and another that “oncologist does not have sufficient time and capacity in 
his follow-up clinics”. A respondent suggested the gastro-oesophageal cohort had not opened 
because there was “Insufficient capacity in oncology service”.  
2.3.5 Recruitment in the gastro-oesophageal cohort 
At the time of designing the trial conduct survey, the gastro-oesophageal cohort had not met 
its monthly recruitment targets (chapter 3 table 3.1). Respondents reporting that the gastro-
oesophageal cohort had opened at their site (n=64), were directed to a question to establish 
the reasons for poor recruitment. Respondents were asked to select all the reasons that 
applied from a list, and were given the option to specify additional reasons as free-text. Table 
2.7 shows the reasons given to account for poor recruitment in the gastro-oesophageal cohort. 
Table 2.7 Reasons given for poor recruitment in the gastro-oesophageal cohort  
 
Reasons 
 (n=64, able to select multiple options) 
Respondents Percentage 
Few patients meet eligibility criteria 51  79.7% 
Easier to recruit patients in other tumour types (cohorts)  22   34.4% 
Concerns about toxicity 17   26.6% 
Gastro-oesophageal multidisciplinary team meeting is at a different site 8  12.5% 
Trial registration timelines 4  6.3% 
Workload from other Add-Aspirin tumour types 3  4.7% 
Other 5  7.8% 
 
 
The most common reason given for poor recruitment in the gastro-oesophageal cohort was 
that fewer patients meet the eligibility criteria (79.7% of respondents). The incidence of 
patients with early stage gastro-oesophageal cancer is expected be lower than the other three 
cohorts, and this was considered when calculating anticipated recruitment rates for the trial. 
To explore the possibility of expanding the pool of patients considered for the gastro-
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oesophageal cohort TMG discussions were held. Approximately 20% of patients with early 
stage gastro-oesophageal cancer have an R1 resection (118), but still have the potential for 
cure, and it was decided to adjust the eligibility criteria for the gastro-oesophageal cohort to 
patients with a positive surgical margins (R1 resection), and a protocol amendment has now 
been made.  
The second most common reason given for poor recruitment in the gastro-oesophageal cohort 
(34.4% of respondents) was that it was easier to recruit to other cohorts. It was also reported 
that the workload from other cohorts impacted on recruitment (4.7% of respondents). It may 
be that sites are prioritising staffing for cohorts that are easier to recruit to, and are not 
providing staff time to screen for patients in the gastro-oesophgaeal cohort. Developing 
incentives to ring-fence staffing levels for each cohort with sites, or encouraging sites to 
reallocate staff time from over-recruiting cohorts, might result in more even recruitment. 
26.6% of respondents reported concerns about toxicity as a cause of poor recruitment. 
Patients with gastro-oesophageal cancer commonly have tumour related ulceration or 
bleeding at first presentation, however once the tumour is treated, the risk of further ulceration 
and/or bleeding is minimised. Communication of interim safety data to sites in the early stages 
of the trial could act to reassure site staff about the risks of toxicity in this cohort, (see chapter 
4) and this could be emphasised in the trial protocol and training slides. 
 12.5% of respondents reported that the gastro-oesophageal multidisciplinary team meeting 
(MDT) was located at a different site. Cross-site communication about potentially eligible 
patients, possibly in a regional MDT could aid recruitment.  
Trial registration timelines were reported to inhibit recruitment by 6.3% of respondents. After 
further discussion with investigators, outside the trial conduct survey, it became apparent that 
patients receiving chemoradiotherapy often require a three month surveillance endoscopy, 
and recruitment could be improved by extending the timing of registration to be allowed up to 
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14 weeks after completing treatment (currently patients must register within twelve weeks of 
completion of chemoradiotherapy). 
In a qualitative analysis of “other” reasons provided as free-text (n=5), three responses 
followed the theme that patients undergo part or all of their treatment for gastro-oesophageal 
cancer at other research sites. Other free-text reasons include; “no available research nurse 
to support this arm”, and “competing non-compatible trial”. Three respondents expanded on 
the reason that it was easier to recruit to other tumour types, with the following responses; 
“(patients) decline more so than in other cohorts”, “are so exhausted after such intensive 
treatment and want a break”, “some have had pulmonary emboli and are ineligible”, 
emphasising the greater frequency of co-morbidities in this cohort.  
2.3.6 Reasons given by patients for not registering for Add-Aspirin 
A number of potential barriers to recruitment emerged from discussions with patient 
representatives and clinical staff during the development of the Add-Aspirin trial. These 
include; reluctance to be randomised to placebo, over the counter availability of aspirin, 
concern about toxicity, the need to take trial treatment for at least five years, and the number 
of follow-up visits. Establishing how frequently these reasons were expressed by patients can 
guide whether measures are necessary to address them. Respondents were asked to rank 
the five reasons above, in the order of how frequently they were given by patients for declining 
enrolment in the Add-Aspirin trial (n=86). The most frequent reason was allocated a rank of 
one, through to the least frequent reason being allocated a rank of five. Respondents could 
also select “not reported” if a particular reason had not been expressed by patients. Figure 2.1 
shows the ranking of how frequently reasons given by patients for not registering for the trial. 
 
 
 
59 
 
Figure 2.1 Ranking of reasons given by patients for not registering for Add-Aspirin by 
frequency 
 
 
Respondents identified the most frequent reason given (mean ranking 2.08) as a reluctance 
to be randomised to placebo. This may reflect the large amount of media coverage on the 
anti-cancer effects of aspirin, and highlights the importance of that the role of aspirin in the 
adjuvant setting is unproven. This is relevant to any placebo controlled trial, but is of particular 
prominence to the Add-Aspirin trial because patients are often aware they can obtain aspirin 
over-the-counter without a prescription (second most frequent reason given, mean ranking 
2.62). The requirement to take trial treatment for at least five years was ranked as the third 
most frequent reason given, (mean ranking 2.86). Concerns about toxicity (mean ranking 
2.91), and the number of follow-up visits, (mean ranking 3.53) were ranked fourth and fifth and 
were not as highly ranked as anticipated. Training documents could enable site staff to 
address the most common patient concerns, particularly to emphasise that patients are twice 
as likely to be allocated aspirin as placebo (that randomisation to aspirin or placebo on a 2:1 
basis), and the importance of taking an unproven investigational treatment within a clinical 
trial. 
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2.3.7 Efficiencies in trial set-up resulting from a basket design 
Respondents indicating that two or more tumour cohorts have open at their site (n=93), were 
asked to indicate how strongly they agreed or disagreed with the statement: "Opening Add-
Aspirin as one trial in multiple tumour types (cohorts) was more efficient than opening the 
same number of separate trials,” using a scale of 1-5 where 1=strongly agree and 5=strongly 
disagree. There were 93 respondents, with 80.6% either agreed or strongly agreed with the 
statement. The median response was 2; “agree”. Figure 2.2 shows the responses given. 
Figure 2.2 Views on whether the basket design led to efficiencies in opening the trial 
 
 
Respondents reporting that it was more efficient to open the Add-Aspirin trial as one trial with 
multiple tumour cohorts, were asked to identify the efficiencies they had witnessed from a list, 
with the option to provide additional free-text answers. The efficiencies identified are shown in 
table 2.8.  
Table 2.8 Efficiencies in opening the Add-Aspirin trial resulting from a basket design 
 
Efficiency 
(n=64, able to select multiple options) 
Respondents Percentage 
Pharmacy set-up 54 84.4% 
Regulatory approval 49 76.6% 
Training 48 75.0% 
Staffing 34 53.1% 
Pathology departmental approval 30 46.9% 
Radiology departmental approval 26 40.6% 
Other 1 1.6% 
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When opening the trial, the majority of respondents witnessed efficiencies in pharmacy set-
up, regulatory approval, training and staffing, however less than half witnessed efficiencies in 
gaining radiology and pathology departmental approvals. The imaging schedule for the trial 
varies by cohort, and approvals may be required from tumour-type specific radiologists and 
pathologists, rather than single individuals which limits efficiency. “Less repetition of 
paperwork” was given as a free-text reason by one respondent. 
2.3.8 Inefficiencies in trial set-up resulting from a basket design 
All respondents were asked to identify any inefficiencies they had witnessed in opening the 
Add-Aspirin trial as one trial rather than as multiple trials using free-text responses, or 
alternatively, indicating if no inefficiencies were identified. Table 2.9 shows the inefficiencies 
identified, categorised according to common themes. 
Table 2.9 Inefficiencies in opening the Add-Aspirin trial resulting from a basket design 
 
Inefficiency 
(n=92) 
Respondents Percentage 
No inefficiencies identified 76 82.6% 
More difficult to coordinate with different research teams 5 5.4% 
Difficulties setting up one cohort delayed opening others 2 2.2% 
Additional documentation required 2 2.2% 
Burden of additional communications (email) not relevant to everyone 1 1.1% 
Less available staff 1 1.1% 
No difference  1 1.1% 
Less efficient, but no reason given 1 1.1% 
Unable to comment  3 3.3% 
 
The most common inefficiency reported related to the challenge of coordinating site set-up 
between different research teams, highlighting that individual research staff members often 
work on trials in specific tumour types. A potential benefit from opening a trial with a basket 
design spanning tumour types could be to encourage a collaborative approach between trial 
staff to work across tumour types and share workload and experience. 
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2.3.9 Efficiencies in running the trial resulting from a basket design 
Respondents indicating that two or more cohorts open at their site (n=93), were asked to 
indicate how strongly they agreed or disagreed with the statement; "Running Add-Aspirin as 
one trial in multiple tumour types (cohorts) was more efficient than running the same number 
of separate trials," using a scale of 1-5 where 1=strongly agree and 5=strongly disagree. There 
were 90 respondents, with 74.4% either agreeing or strongly agreeing with the statement. The 
median response was 2; “agree”. Figure 2.3 shows the responses given. 
Figure 2.3 Views on whether a basket design led to efficiencies in the Add-Aspirin trial 
 
Respondents reporting that it was more efficient to run the Add-Aspirin trial as one trial with 
multiple tumour cohorts were asked to identify the efficiencies they had witnessed from a list, 
with the option to provide additional free-text answers. Efficiencies identified are shown in 
table 2.10. 
Table 2.10 Efficiencies in running the Add-Aspirin trial, resulting from a basket design 
 
Efficiency 
(n=64, able to select multiple options) 
Respondents Percentage 
Familiarity with common trial processes 60 93.8% 
One overarching protocol 56 87.5% 
Drug dispensing 42 65.6% 
Staffing 39 60.9% 
Data entry 32 50.0% 
Other 2 3.1% 
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When running the trial, the majority of respondents witnessed efficiencies resulting from; a 
familiarity with trial processes common to all cohorts, the use of an overarching protocol, use 
of the same drug dispensing pathways, and shared staffing, however data entry was only 
thought to be an efficiency by half of respondents. A basket design would not be expected to 
reduce the amount of data required, but efficiencies might be possible for the collection and 
entry of data fields that are common to all tumour cohorts. Two free-text responses were 
provided, and followed the theme that amendments were easier to process as one rather than 
four separate protocols. 
 
2.3.10 Inefficiencies in running the trial resulting from a basked design 
All respondents were asked to identify inefficiencies they had witnessed in running the Add-
Aspirin trial as one trial rather than as multiple trials using free-text responses, or alternatively, 
indicating that no inefficiencies were identified. Table 2.11 shows the inefficiencies identified, 
categorised according to common themes. 
Table 2.11 Inefficiencies in running the Add-Aspirin, resulting from a basket design 
 
Inefficiency 
(n=90) 
Number of respondents Percentage 
No inefficiencies identified 73 81.1% 
Insufficient staffing to run multiple cohorts 7 7.8% 
Inefficiencies resulting from differences between cohorts 10 11.1% 
 
Insufficient staffing was the most common inefficiency identified, again emphasising the need 
to balance staffing levels at site to support all cohorts.  
11.1% of respondents reported that differences between cohorts led to inefficiencies in running 
the trial. Whilst trial processes and schedules were aligned as much as possible for all cohorts, 
some differences were necessary. Explaining the rationale for the differences between the 
cohorts in the protocol could prevent misunderstanding at site and minimise protocol 
violations. 
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2.3.11 Perceived effectiveness of a run-in period design 
Sites were asked about their views on how effective they anticipate the run-in period to be 
with respect to predicting and improving adherence and tolerance in the main trial, based on 
their experiences of its use. Respondents were asked about their level of agreement or 
disagreement to a series of statements using a scale of 1-5 where 1=strongly agree and 
5=strongly disagree (89 respondents). Responses are shown in figure 2.4. 
Figure 2.4 Views on the effectiveness of the run-in period design 
 
 
Respondents agreed (median response of 2) that the run-in period was likely to be a good 
predictor of adherence and tolerance, and improve both of these in the main trial. This is 
consistent with the aim of the run-in period and evidence of its effectiveness in other aspirin 
trials. Respondents neither agreed nor disagreed (median response of 3) that the trial run-in 
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period would reduce the number of participants who miss scheduled follow-up visits in the 
main trial. 
2.3.12 Attitudes towards co-enrolment in other trials 
Opportunities to offer patients already taking part in other trials the option to also register for 
the Add-Aspirin trial were sought from the outset of the trial. Co-enrolment is considered on a 
trial-by-trial basis, with an assessment of any conflicts in eligibility criteria, scheduling, and the 
potential impact on safety and the results of either trial, and a discussion with the relevant trial 
team. In the first year of the trial, co-enrolment has been agreed with 20 breast, 9 colorectal, 
5 gastro-oesophageal, and 6 prostate cancer trials. This variation between cohorts could be 
due to differences in the amount of trial activity between tumour types, or even variation in the 
acceptability of co-enrolment to researchers and patients in different tumour groups. Sites 
were asked about their views on co-enrolment with other trials using a scale of 1 to 5 where 
1=strongly agree and 5=strongly disagree (83 respondents). 95.2% either agreed or strongly 
agreed that “allowing co-enrolment with other trials maximises participant choice” (median 
response 2; “agree”). 83.1% of respondents either agreed or strongly agreed that; “Allowing 
co-enrolment with other trials improves recruitment to clinical trials” (median response 2; 
“agree”). Responses are shown in figure 2.5. 
Figure 2.5 Attitudes towards co-enrolment in other trials 
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In an optional question, sites were asked to describe any concerns they had about co-
enrolment in free-text and there were ten responses. Three respondents expressed concerns 
that there was additional burden for patients enrolling in multiple trials. Two respondents 
reported reservations about the challenge of aligning follow-up visits and schedules for 
multiple trials. Two respondents described perceptions about the risk of additional toxicity. 
Two respondents reported lack of clarity around which trials can be co-enrolled with, 
particularly with new trials. One respondent described apprehensions about the interpretation 
of trial results with the presence of additional confounding variables.  
 
2.4 Discussion 
One year after recruiting its first participant, the Add-Aspirin trial had successfully opened at 
least one site in the vast majority of NHS trusts and boards with cancer services, with most 
sites opening at least three of the four tumour cohorts. This proves that it is feasible to open a 
large multi-tumour type basket trial in the UK, and suggests that this type of design could be 
utilised for other phase III trials of other interventions with potential activity across tumour 
types. It also shows that appointing an overall site PI with tumour-specific cohort leads is a 
feasible strategy that could be applied effectively in similar trials.  
The trial conduct survey also provided insights into the views of site staff on the trial 
methodology. The majority of sites were supportive of the basket trial design and felt it was 
more efficient than opening and running the same number of separate trials, however there 
were concerns around allocation of staffing between cohorts. Finding a balance between 
potential staffing efficiencies at site, and ensuring adequate recruitment to all cohorts is 
essential to the success of a trial with a design of this type.  
On the whole, respondents were supportive of the use of a run-in period design and 
anticipated that the run-in period will select a population that is able to tolerate and more 
adherent with taking trial treatment. However the survey found that respondents didn’t 
necessarily anticipate that it would result in a population that is more adherent to a trial 
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schedule for the duration of the trial. An analysis of the correlation between treatment 
adherence in the run-in period and trial visit attendance later in the trial may provide further 
insight.  
Site staff were generally supportive of the principles of co-enrolment. There were a number of 
concerns about co-enrolment expressed by sites staff, which could be alleviated by providing 
specific information on trials approved for co-enrolment. This could include details of any 
additional burden in terms of follow-up visits and investigations, any extra risk of toxicity, and 
a summary of the perceived impact on the interpretation of the results of each trial. 
I have used the findings of the trial conduct survey to provide a list of recommendations: 
1) Developing incentives to ring-fence staffing time for each cohort with sites, to allow 
more cohorts to open and recruit more evenly. 
2) The use of a complexity score to allocate funding for study set-up facilitators could be 
considered by the NIHR to allow more complex trials to open sites promptly.  
3) Agreeing site staffing allocation with the Clinical Research Networks, according to the 
number of cohorts open, to encourage additional sites to open. 
4) The treatment pathway for some tumour types is often divided between sites. Trial 
conduct could be improved by: 
a. Encouraging sites that only manage part of the treatment pathway to open. 
b.  Promoting cross-site communication about potentially eligible patients at 
regional MDT meetings.  
c. Implementing processes centrally to ensure a smooth transfer of participants 
between sites.  
d. A national system of sharing credit for research activity and support costs more 
equitably when a patient’s care involves multiple sites to encourage more sites 
to open. 
5) Training documents to enable site staff to address common patient concerns, 
including: 
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a. Emphasising that there is twice the chance of being allocated aspirin as 
placebo in the trial. 
b. Highlighting the importance of taking an unproven investigational treatment 
within a clinical trial, rather than purchasing over the counter. 
c. Communication of existing safety data on the risks of toxicity, particularly in the 
context of aspirin and its high media profile. 
6) Where differences exist in the trial protocol between tumour cohorts, (for example the 
timing of entry criteria), the rationale could be explained to avoid accidental protocol 
violations. 
7) Concerns from patients and site staff about trial co-enrolment could be alleviated by 
providing specific information for each agreed trial on any additional burden in terms 
of follow-up visits and investigations, any extra risk of toxicity, and a summary of the 
perceived impact on the interpretation of the results. 
During the first year, recruitment exceeded monthly targets every month in the breast, 
colorectal, and prostate cohorts, but fell short for each month for the gastro-oesophageal 
cohort (chapter 3, figure 3.1), and only 27.2% (31/114) of sites which opened the gastro-
oesophageal cohort had recruited a participant.  
 
Using the results of the trial conduct survey I have provided a list of recommendations to 
improve recruitment in the gastro-oesophageal cohort: 
1) Sites proposing to open the gastro-oesophageal cohort could be prioritised for 
opening.  
2) Create incentives not to divert staffing away from the gastro-oesophageal cohort 
toward other cohorts where recruitment is easier, and to consider reallocating staff time 
from over-recruiting cohorts. 
3) Promote cross-site communication about potentially eligible patients who receive 
primary treatment and follow-up for gastro-oesophageal cancer at different sites. 
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4) Training about the eligibility of patients with a history of tumour related ulceration or 
bleeding, who have already had cancer treatment.  
5) Expansion of eligibility criteria so to not unnecessarily exclude patients: 
a. Inclusion of participants with an R1 resection (now implemented as a protocol 
amendment). 
b. Increase the end of the timing of entry (registration) window from 12 to 14 
weeks after completing radical chemoradiotherapy for gastro-oesophageal 
cancer, (now implemented as protocol amendment, see figure 2.6). 
 
Figure 2.6 Updated gastro-oesophageal cohort timing of entry flow diagram. 
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3.1 Introduction 
The success of the Add-Aspirin trial hinges on opening and recruiting to multiple tumour 
cohorts at the majority of UK NHS research sites that treat cancer. This represents a 
substantial undertaking for both research sites and the coordinating trial unit team.  
Anticipating recruitment is a key consideration for the planning and funding of any trial. It is 
common practice for sites to provide predicted recruitment rates as part of a site evaluation 
process. Accurate recruitment predictions at sites allow more reliable overall trial recruitment 
projections, however these are often over optimistic, with less than a third of publically funded 
trials meeting their original recruitment targets (119). A number of different models for 
predicting recruitment have been proposed. Examples include the conditional model, where 
variation in monthly recruitment, according to the number of sites open and the time to reach 
maximum recruitment are considered (120), a Poisson model, which simulates the number of 
patients recruited in a given month according to the Poisson distribution (121), and a Bayesian 
model which uses ongoing accrual data in calculations to refine anticipated recruitment rates 
as the trial proceeds (122). To date, none of the models proposed have proven consistently 
effective (123).  
Anticipated recruitment rates for each tumour cohort in the Add-Aspirin trial are largely based 
on recruitment rates in similar previous trials, incorporating a period for sites to reach peak 
recruitment and become familiar with recruiting to the trial. These estimates were made prior 
to site recruitment prediction becoming available for all sites. A trial with one protocol spanning 
four different tumour types represents an opportunity to understand how predicted recruitment 
rates relate to actual recruitment rates in different tumour types. The objectives for this chapter 
are as follows: 
 
 
Chapter 3. An evaluation of recruitment to the Add-Aspirin 
trial over the first year 
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3.1.1 Objectives 
1) Evaluate recruitment to the Add-Aspirin trial across cohorts over the first year.  
2) Determine the accuracy of site predicted recruitment rates by comparing them with 
actual recruitment rates, across tumour types. 
3)  Suggest how the accuracy of site recruitment predictions and anticipated recruitment 
projections might be improved. 
 
3.2 Methods 
3.2.1 Site opening and recruitment 
From the 1st November 2014, a site initiation form was sent, by email, to sites expressing an 
interest in opening the Add-Aspirin trial, and accepted if returned before the 1st of November 
2016. Sites were asked to report their predicted average monthly recruitment rates for each 
tumour cohort. If respondents quoted an average annual recruitment estimate, it was divided 
by 12 to give an anticipated monthly recruitment figure, and where a range was given, the 
lower figure was taken to give the most conservative estimate. A copy of the site initiation form 
is available in appendix C. 
The trial opened to recruitment on the 8th October 2015, and recruitment data were extracted 
from the trial registration server on the 1st of November 2016, providing data on the first 12 full 
months of trial recruitment. The mean and maximum monthly recruitment was calculated for 
individual tumour cohorts at each site, from the time of the first participant recruited for each 
cohort, until the 1st of November 2016. NHS trusts and boards (NHS trusts in England, Health 
Boards in Scotland and Wales, and Social Care Trusts in Northern Ireland), often comprise a 
number of separate research sites. Where one site initiation form contained combined 
predicted recruitment for a number of sites within a single NHS trust or board, actual 
recruitment data for those sites was combined to allow comparison. Data were analysed for 
sites that provided predicted recruitment and recruited at least one participant to a cohort. 
Monthly predicted recruitment was compared to the mean actual monthly recruitment as a 
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ratio. Monthly predicted recruitment was also compared to maximum actual monthly 
recruitment as a ratio. The data was summarised by calculating the median and interquartile 
range (IQR), rather than the mean and standard deviation, to minimise the influence of outliers.  
Data on recruitment to individual cohorts at UK NHS research sites was collected between the 
8th October 2015 and the 1st November 2016, and includes the first 12 full months of the trial. 
All data were analysed using Microsoft Excel and STATA version 14.  
 
3.3 Results 
3.3.1 Recruitment at one year 
After one year of the trial being open, 127 sites had registered at least one participant. A total 
of 1,605 participants had been registered, with recruitment ahead of projected targets in all 
but the gastro-oesophageal cohort. Table 3.1 shows, by cohort, recruitment after one year of 
the trial being open. The graphs in figure 3.1 show actual compared to projected recruitment 
rates. 
Table 3.1 Add-Aspirin trial recruitment after one year, by cohort 
 
Cohort Target recruitment 
Actual 
recruitment 
Percentage of recruitment target 
achieved 
Breast 363 785 216.3% 
Colorectal 400 419 104.8% 
Gastro- oesophageal 78 57 73.1% 
Prostate 261 344 131.8% 
Total 1,102 1,605 145.6% 
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Figure 3.1 Projected and actual recruitment in the first year of the add-Aspirin trial 
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3.3.2 Site initiation form data return 
168 site initiation forms were completed, and contained data on 183 different sites across the 
UK (some forms contained data for a number of sites within a single NHS trust or board). The 
site initiation forms provide predicted recruitment rates for 96.5% of the individual cohorts 
recruiting at sites after one year of the trial being open. This allows a near comprehensive 
comparison of predicted to actual recruitment rates in the first year of the trial. Table 3.2 shows 
the number of recruiting sites with predicted recruitment figures available. 
Table 3.2 Sites providing predicted recruitment rates by cohort 
 
Number of sites 
Breast 
cohort 
Colorectal 
cohort 
Gastro-oesophageal 
cohort 
Prostate 
cohort 
Sites providing predicted recruitment figures 155 160 118 142 
Sites that recruited at least one participant 114 101 31 68 
Recruiting sites with predictions available 109 99 29 66 
Percentage of recruiting sites with predictions 
available 
95.6% 98.0% 93.5% 97.1% 
Percentage of recruiting sites with 
predictions available 
96.5% 
 
3.3.3 Predicted recruitment 
The highest predicted median monthly recruitment per site was in the prostate cohort, followed 
by the colorectal and breast cohorts, with the smallest median predicted recruitment in the 
gastro-oesophageal cohort (3, 2, 2, 1 participants per month at each site respectively). Table 
3.3 summaries the predicted monthly recruitment by cohort. 
Table 3.3 Predicted monthly recruitment for each site by cohort 
 
Monthly  predicted recruitment Breast cohort 
Colorectal 
cohort 
Gastro-oesophageal 
cohort 
Prostate 
cohort 
Min 0.33 0.25 0.17 0.17 
Max 8.00 7.00 2.00 12.00 
Median 
(IQR) 
2.00 
(1.25-4.00) 
2.00 
(1.00-3.00) 
1.00 
(1.00-1.00) 
3.00 
(1.00-4.00) 
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3.3.3.1 Comparison of mean monthly recruitment to predicted monthly recruitment 
For each site, the mean monthly recruitment was calculated and compared to the predicted 
monthly recruitment in the form of a ratio. The dot plots provided in figure 3.2 show the ratio 
of the predicted to actual mean monthly recruitment for each site. A ratio below one suggests 
predicted recruitment is less than actual recruitment, and a ratio above one suggests predicted 
recruitment is greater than actual recruitment.  
Figure 3.2 Ratio of predicted to actual mean recruitment at each site 
Footnotes: Solid lines and numbers indicate the median and IQR. 
A ratio below one suggests predicted recruitment is less than actual mean recruitment, and a ratio 
above one suggests predicted recruitment is greater than actual mean recruitment. 
 
The median ratio of predicted to actual recruitment was 2.24, 2.27, 3.00 and 3.50 for the 
breast, colorectal, gastro-oesophageal and prostate cohorts respectively. It could be that sites 
over-estimate their ability to recruit in order to increase the attractiveness as a potential site to 
open a trial. Recruitment to the prostate cohort was the most over-estimated (median 3.5 fold). 
The reason for this is uncertain, but could be due to the fact that patients with prostate cancer 
are, on average, older than those in the other cohorts, and therefore may already be taking 
aspirin, or have co-morbidities, which would exclude them from the trial, and this may not have 
been taken into account in site recruitment predictions. Another consideration is that treatment 
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with radical radiotherapy and radical prostatectomy is conducted by different departments 
(clinical oncology and surgical departments respectively) and a number of different individuals 
would need to have been consulted to obtain an accurate prediction. 
3.3.3.2 Comparison of maximum monthly recruitment to predicted monthly 
recruitment 
In order to better understand why predicted recruitment figures significantly overestimate 
actual recruitment figures, I hypothesise that sites may be providing over-optimistic figures 
based on a maximum (or best possible) monthly recruitment. To investigate this, the actual 
maximum monthly recruitment for each site was compared to the predicted monthly 
recruitment in the form of a ratio for each site. The dot plots provided in figure 3.3 show the 
ratio of the predicted to actual maximum monthly recruitment for each site. A ratio below one 
suggests predicted recruitment is less than actual maximum recruitment, and a ratio above 
one suggests predicted recruitment is greater than actual maximum recruitment. 
Figure 3.3 Ratio of predicted to actual maximum recruitment at each site 
Footnotes: Solid lines and numbers indicate the median and IQR. 
A ratio below one suggests predicted recruitment is less than actual maximum recruitment, and a ratio 
above one suggests predicted recruitment is greater than actual maximum recruitment. 
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The median ratio of actual maximum to predicted monthly recruitment was found to be equal 
to one for all cohorts, suggesting that when sites are asked to predict average monthly 
recruitment, the value provided more accurately reflects the maximum possible monthly value.  
3.3.3.3 Trial recruitment timelines based on site predictions alone 
The original trial recruitment projections anticipated it would take between three and a half and 
six years for each cohort to reach their total trial recruitment targets. Based on the total 
predicted recruitment from the 127 UK sites that had recruited at least one participant to the 
trial, the breast, colorectal and prostate cohorts would reach their overall recruitment target 
within one year, and the gastro-oesophageal cohort within two years. Recruitment predictions 
from potential sites are often used to advise trial recruitment projections and targets, however 
this highlights how site predictions would have been over-optimistic. Table 3.4 shows the time 
taken for recruitment targets to be reached if the total predicted recruitment represented actual 
recruitment rates. 
Table 3.4 Time to reach overall recruitment targets based on site predictions alone 
 
 
Breast 
cohort 
Colorectal 
cohort 
Gastro-oesophageal 
cohort 
Prostate 
cohort 
Site predicted recruitment per month (n) 271.9 226.8 97.7 246.8 
Site predicted recruitment per year (n) 3262.5 3201.4 1164.8 2961.0 
Original recruitment target at one year (n) 363 400 78 261 
Total trial recruitment target (UK and India) (n) 2600 3100 2100 2120 
Time to reach total trial recruitment target based 
on original recruitment projections 
42  
months 
42  
months 
66  
months 
60  
months 
Time to reach total trial recruitment target 
based on site predicted recruitment 
9.4 
months 
11.8 
months 
21.9 
 months 
8.7 months 
 
 
3.4 Discussion 
The Add-Aspirin trial opened ten months after originally intended due to a number of 
contractual delays, however at one year, the trial has exceeded its overall target recruitment 
by 46% (503 participants), which goes some way to catch up with the original recruitment 
targets had the trial opened on time. Many of the sites providing predicted recruitment rates 
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had not recruited a participant at one year (44, 61, 89 and 76 sites for the breast, colorectal, 
gastro-oesophageal and prostate cohorts respectively). This suggests there is the potential to 
improve recruitment rates further if the reason that these sites have not recruited can be 
established and addressed (as discussed in chapter 2). 
3.4.1 Accuracy of site predicted recruitment rates and recommendations for 
improvement 
Sites were found to overestimate how many patients they can recruit per month by a median 
of 220-350% depending on tumour type (figure 3.2). The median time from site opening to 
recruiting its first participant (to any cohort), was 43 days (see chapter 2 section 2.3.1), which 
could suggest that sites under-estimate the time taken to reach maximum recruitment 
capacity, which could also account for over-estimated monthly recruitment rates.  
Predicted recruitment from sites for the Add-Aspirin trial was found to be very similar to 
maximum actual monthly recruitment (median ratio of 1.00 for each cohort, figure 3.3), 
suggesting that sites could be basing predicted recruitment on a best possible monthly figure. 
Selecting an anticipated recruitment rate by asking for a lowest and highest monthly 
recruitment prediction, and using the average may be a more accurate method, and would 
benefit from validation in future trials.  
Given that anticipated recruitment projections underestimated actual recruitment figures in 
three out of four cohorts, more accurate predictions may have been obtained by using the 
method of obtaining site predictions as suggested above in combination with data from 
previous similar trials. 
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Chapter 4. An evaluation of the first 500 participants 
entering the Add-Aspirin trial and the utility of the run-in 
period 
 
 
4.1 Introduction 
4.1.1 Characteristics of patients entering the trial 
The eligibility criteria for each cohort of the Add-Aspirin trial have been chosen to optimise 
safety, and strike a balance between selecting patients representative of the wider population, 
whilst having sufficient likelihood of a measurable treatment effect within the time-frame of the 
trial. It is important to examine baseline characteristics of patients actually enrolling in the trial 
to check that they match the characteristics on which prognostic predictions and sample size 
calculations were made. Identifying where particular characteristics are under-represented 
allows targeted recruitment to redress differences, or if necessary, allows re-assessment of 
the sample sizes required to adequately power the trial.  
 
4.1.2 The Add-Aspirin trial run-in period 
Maintaining adherence and minimising premature discontinuation of trial treatment represents 
a significant challenge to the Add-Aspirin trial. Data have consistently shown that long-term 
treatment with aspirin is required for the anti-cancer effects of aspirin to become identifiable, 
(a minimum of two years (124), and up to 5-10 years (92, 95)), therefore the trial requires 
participants to take trial treatment daily for at least five years. Long-term adherence is known 
to decline according to the length of time that adjuvant therapy is given (125), with one study 
investigating long-term persistence with adjuvant tamoxifen for breast cancer suggesting that 
only 49% of users completed the intended five years of treatment (126). Furthermore, the 
participants in an adjuvant trial will often be otherwise healthy and asymptomatic, and 
adherence is likely to be lower than for those with ongoing symptoms (127). Five years of 
treatment also extends exposure to potential toxicities.  
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To address these challenges, the trial design incorporates an active run-in period, where after 
registration, but prior to randomisation, all participants take 100mg aspirin (one tablet per day) 
in an open-label manner for a period of approximately eight weeks. At the end of the run-in 
period, the participant’s tolerance of aspirin and adherence to daily treatment is assessed. 
This approach aims to identify those individuals who are unlikely to be able to tolerate aspirin, 
as well as those who are less likely to adhere to the protocol treatment schedule (128). This 
strategy has also been used successfully in other aspirin trials (129, 130). The run-in period 
provides an early opportunity to assess feasibility, in terms of early toxicity, recruitment and 
patient acceptability. An initial assessment of how the run-in period is working in practice will 
advise whether any amendments to the process could be made as the trial progresses.  
4.1.3 Timing of trial registration across cohorts 
Whilst the four tumour cohorts in Add-Aspirin are individually powered, there are a number of 
outcome measures that combine data across all tumour cohorts. These include a co-primary 
endpoint of overall survival across all four cohorts at 15 years after the first randomisation, 
and secondary outcome measures, including cardiovascular events, thromboembolism, 
toxicity, cognition and functional capacity. The trial was designed such that the timing of 
registration is aligned where possible across the four cohorts, however there is variation 
around when registration occurs with respect to adjuvant chemotherapy. All participants must 
receive the standard primary therapy with curative intent for their cancer before trial entry. An 
assessment of how the timing of entry criteria are being applied will allow any adjustments to 
be made to the criteria to both better align the cohorts, and facilitate recruitment by making 
the timing of entry criteria as practical as possible.  
4.1.4 Recording concomitant medication 
It is increasingly recognised that commonly taken drugs, for example vitamin D, 
bisphosphonates, metformin and statins may have anti-cancer effects (chapter 1). Utilising 
data from randomised trials to inform the design of further studies, as was the case for aspirin, 
is potentially insightful, but collecting, and subsequently analysing, such data can be 
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challenging. The CRF forms for the Add-Aspirin trial were designed to collect concomitant 
medications at baseline and throughout the trial (appendix D). An analysis of this initial data 
with respect to metformin use during the run-in period is potentially useful to optimise how 
concomitant medication data is collected and provide a baseline for metformin use in this 
population, and advise the feasibility and design of future trials (see chapter 5). The objectives 
of this chapter are summarised below. 
 
4.1.5 Objectives  
1. To examine the baseline characteristics to check that the patients entering the trial are as 
expected. This is to ensure participants are representative of the wider population and the 
trial is powered as expected. 
2. To make an initial assessment of the design and utility of the run-in period. An overview of 
how this is working in practice will advise whether any amendments to the process are 
necessary. 
3. To make an assessment of when the run-in period is initiated across the four tumour 
cohorts to see if any adjustments are necessary as the trial progresses. 
4. To establish the pattern of metformin use in the Add-Aspirin trial to inform the potential 
design of a new metformin arm, and optimise the way concomitant medication data is 
collected in this and similar trials. 
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4.2 Methods  
4.2.1 Run-in period design 
The run-in period was designed so that all participants take 100mg aspirin (one tablet per day) 
in an open-label manner for a period of approximately eight weeks to assess adherence and 
tolerance (as described in chapter 2). To determine adherence during the run-in period, three 
different sources of adherence data were obtained to allow a more accurate assessment. 
These included a participant diary card, the return of used tablet blister packs, and a 
participant interview at an end of run-in assessment. Participants were suitable for 
randomisation if they had taken at least 80% of their run-in treatment, as judged by trial staff 
performing the end of run-in assessment, by considering all sources of adherence data 
available.  
To be eligible for randomisation, participants must also have not experienced any aspirin-
related severe toxicity (defined as greater than grade 3 CTCAE v4 (Common Terminology 
Criteria for Adverse Events)), or any grade of active gastrointestinal ulceration or bleeding, 
tinnitus, macular degeneration, intracranial bleeding or hypersensitivity to aspirin. Participants 
developing any of these toxicities were required to permanently discontinue aspirin 
immediately and will not be eligible for the trial.  
An extension to the run-in period was incorporated into the design to avoid unnecessarily 
exclusion participants who had a valid reason for inadequate adherence (e.g. unforeseen 
social circumstances) or the cause was temporary (e.g. due to toxicity resulting from 
concomitant treatment which has subsequently stopped, or a non-recurrent unrelated event). 
Where agreed by the coordinating trial unit, the run-in period would normally be extended by 
four or eight weeks, after which adherence and toxicity would be reassessed in the same way. 
Only one extension was permitted per participant. Those participants identified as suitable for 
further study participation, remained eligible, and were willing to continue in the trial then 
re-confirmed their consent to participate before being randomised.  
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4.2.2 Timing of trial registration 
The timing of entry criteria was designed so that aspirin can be started at the earliest 
opportunity to maximise the potential anti-cancer benefits, whilst starting at a time when it was 
considered safe to do so, and was unlikely to compromise the curative intent of standard 
primary treatment.  
For patients who have undergone surgery without any adjuvant therapies, a minimum time 
period of six weeks before trial registration (and the start of the run-in period) was mandated 
to reduce the risk of post-operative bleeding complications.  This follows standard surgical 
advice to recommend that patients refrain from strenuous physical activity for at least six 
weeks following major surgery to allow wound healing (131), and is consistent with evidence 
that wound tensile strength increases rapidly until six weeks after an operation (132).  
For patients who have received radical chemoradiotherapy or radical radiotherapy, the run-in 
period was only permitted to start once this treatment had been completed. This is based on 
the rationale that if complications of aspirin therapy develop during radical chemoradiotherapy 
or radiotherapy, there is the potential for this to interrupt, and therefore compromise, the quality 
of treatment.  
For patients receiving adjuvant chemotherapy, there was debate across the tumour cohorts 
as to whether the aspirin run-in period could be started before this had finished. For the 
colorectal and gastro-oesophageal cohorts it was agreed that if platelet counts after two cycles 
of chemotherapy remained greater than 100 x109/L on day one of each cycle then the run-in 
period could be started at that point, or later if preferred. For the breast cohort, there were 
concerns about chemotherapy related dyspepsia and the aspirin run-in was only allowed to 
start once adjuvant chemotherapy was finished.  
The time interval during which registration was allowed was restricted to six weeks to ensure 
that trial treatment was started promptly, but some flexibility was allowed for individual cases 
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where an acceptable reason was provided to the coordinating trial unit. The design for the 
timing of entry criteria for each cohort is described in figures 4.1 to 4.4. 
4.2.3 Data collection 
Cohort specific registration CRF forms (appendix D) were designed to collect information on 
the treatment pathway taken by each participant from cancer diagnosis onwards, and the 
timing of trial registration with respect to the treatment pathway taken. Data on the timing of 
the treatment pathway taken was summarised using the median and interquartile range which 
was selected to minimise the influence of extreme outlying values which may be due to CRF 
completion errors.   
Baseline and follow-up CRF forms were designed to collect concomitant medications at 
baseline and throughout the trial. Six drugs/classes of medications (metformin, statins, vitamin 
D, bisphosphonates, proton pump inhibitors and H2 (histamine receptor 2) antagonists) were 
selected for more detailed data collection because of emerging evidence of their anti-cancer 
activity (chapter 1, section 1.4).  Data collected includes dose and frequency information, 
which could be used to inform the design of further studies, as was the case for aspirin. Data 
on all other medications were collected using a free-text. This analysis focuses on the 
collection of information on metformin. An end of run-in CRF form was designed to collect data 
on adherence from diary cards, a participant interview, and returned tablet blister packs. CRF 
forms also collected data on the toxicities experienced and whether the patient was 
randomised in the trial, and the reason if they were not randomised. 
4.2.4 Data extraction 
Data was extracted from the trial database for all participants registered up to and including 
the 500th participant for whom end of run-in data had been received. This means that data was 
also extracted to include those participants registered during that time for whom a registration 
or an end of run-in CRF form was outstanding (an additional 104 participants). This was done 
because CRF return rate was better in those who were randomised than in those who were 
not, and so by including all participants, regardless of whether a registration or end of run-in 
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CRF form is available, an unbiased representation of the randomisation rates is obtained. 
Tables summarising baseline characteristics, adherence during the run-in period, toxicity 
during the run-in period and concomitant metformin use are just based on the first 500 
participants with registration and end of run-in data available. 
The date of randomisation for all included participants was extracted from the trial 
randomisation server. Permission for data release was sought from the Add-Aspirin Trial 
Management Groups (TMGs) for each cohort, the Trial Steering Committee (TSC) and 
Independent Data Monitoring Committee (IDMC).   
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Figure 4.1 Breast cohort timing of entry flow diagram. 
 
Figure 4.2 Colorectal cohort timing of entry flow diagram. 
 
Figure 4.3 Gastro-oesophageal cohort timing of entry flow 
diagram. 
 
 
 
Figure 4.4 Prostate cohort timing of entry flow diagram. 
87 
 
4.3 Results 
4.3.1 Patient characteristics at registration 
Tables 4.1 to 4.4 summarise the key characteristics at registration for the first 500 trial 
participants with registration and end-of run-in data, by cohort.  
Table 4.1 Characteristics at registration— breast cohort  
 
    n      % 
Gender    Male    2    <1% 
(n=252)    Female  250   >99% 
Age at registration      Median (IQR) 53 (47 - 62) 
(n=252)     Range      27 - 87 
Primary surgery    Mastectomy  103    41% 
(n=252)    Breast Conserving surgery  149    59% 
Morphological type    Invasive lobular   34    13% 
(n=252)    Invasive ductal  195    77% 
    Mixed invasive lobular/ ductal   10     4% 
    Missing   13     5% 
Tumour grade    Well   20     8% 
(n=252)    Moderate   88    35% 
    Poor  126    50% 
    Missing   18     7% 
Lymphovascular    Yes  108    43% 
invasion    No  126    50% 
(n=252)    Unknown   18     7% 
Pathological stage*    IA   42    17% 
(TNM 7th edition)    IB   14     6% 
(n=252)    IIA   60    24% 
    IIB   67    27% 
    IIIA   52    21% 
    IIIB    1    <1% 
    IIIC   16     6% 
HER-2 / ER status    HER-2 negative / ER negative   60    24% 
(n=252)    HER-2 negative / ER positive  126    50% 
    HER-2 positive / ER negative   24    10% 
    HER-2 positive / ER positive   38    15% 
    Missing    4     2% 
Chemotherapy received    No chemotherapy   14     6% 
(n=252)    Adjuvant  181    72% 
    Neo-adjuvant   56    22% 
    Both neo-adjuvant and adjuvant    1    <1% 
Hormone therapy    Not to be received    5     3% 
(ER / PR positive patients)    Adjuvant  161    94% 
(n=171)    Neo-adjuvant    1    <1% 
    Both    3     2% 
    Missing    1    <1% 
Footnote: *Neo-adjuvant chemotherapy resulted in the inclusion of some patients with very early T stage. 
 
Data on the baseline characteristics of breast cohort participants are generally consistent with 
data on populations studied in other adjuvant breast cancer trials (133-135), and there is no 
comparable national audit data available. Notably, the percentage of patients receiving 
neoadjuvant chemotherapy is higher than in the AZURE trial, (6% in AZURE vs 22% in Add-
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Aspirin), which has similar eligibility criteria (133). This may reflect a recent trend towards the 
greater use of neoadjuvant chemotherapy for early stage breast cancer (136). Additionally, 
the proportion of ER positive patients entering the Add-Aspirin trial (65%) is consistently lower 
than in similar studies (78% in AZURE trial (133), and 69% in the TACT trial (134)), which may 
slightly alter the anticipated event rate. 
Table 4.2 Characteristics at registration— colorectal cohort  
 
    n      % 
Gender    Male   70    56% 
(n=125)    Female   55    44% 
Age at registration     Median (IQR) 61 (54 - 69) 
(n=125)     Range          32 - 86 
Site of main tumour    Proximal Colon   38    30% 
(n=125)    Distal colon   52    42% 
    Rectum    35    28% 
Synchronous site of disease    No  114    91% 
(n=125)    Yes    7     6% 
    Missing    4     3% 
Type of surgery    Abdominal perineal resection    4    11% 
(rectal cancer only)    Anterior Resection   30    86% 
(n=35)    Extralevator abdominoperineal excision     1     3% 
Emergency operation    No  107    86% 
(n=125)    Yes   18    14% 
Resection of liver metastases    No  122    98% 
 (R0) (n=125)    Yes    3     2% 
Pathological stage*    0    1    <1% 
(TNM 5th edition)    I    2     2% 
(n=125)    IIA   23    18% 
    IIB    9     7% 
    IIIA   11     9% 
    IIIB   58    46% 
    IIIC   18    14% 
    IV    3     2% 
Differentiation grade    Well   12    10% 
(n=125)    Moderate  100    80% 
    Poor    9     7% 
    Missing    4     3% 
Lymphovascular     Present   39    31% 
invasion    Absent   42    34% 
(n=125)    Unknown    43    34% 
    Missing    1    <1% 
Footnote: *Neo-adjuvant chemotherapy resulted in the inclusion of some patients with very early T stage. 
 
Data on the baseline characteristics of colorectal cohort participants are in keeping with data 
on populations studied in other adjuvant colorectal cancer trials (137, 138) and the National 
Bowel Cancer Audit Annual Report 2016 (139). However, one noticeable difference is that 
National Bowel Cancer Audit data suggests that in the UK, 9.5% of patients with potentially 
operable colorectal cancer (non-metastatic or resectable liver metastases) undergo a liver 
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resection for metastatic disease (139, 140), however only 2% of participants registered for 
Add-Aspirin had undergone resection of liver metastases. It is possible that this difference 
reflects concerns at site about the potential toxicity of aspirin in those who have undergone 
liver surgery. However, the proportion of participants who underwent emergency surgery was 
similar to that identified in UK colorectal cancer registration databases (16.1% (141)), 
suggesting investigators are not deterred from entering patients who may have a more 
complex surgical pathway. It is also possible that investigators are not aware of the eligibility 
of this group. 
Table 4.3 Characteristics at registration— gastro-oesophageal cohort 
 
     n     % 
Gender    Male   13    68% 
(n=19)    Female    6    32% 
Age at registration     Median (IQR) 67 (56 - 72) 
(n=19)     Range     30 - 77 
    Upper third of oesophagus    0     0% 
Site of disease    Middle third of oesophagus    4    21% 
(n=19)    Lower third of oesophagus    9    47% 
    Siewert type I    1     5% 
    Siewert type II    0     0% 
    Siewert type III    0     0% 
    Fundus of stomach    2    11% 
    Body of stomach    3    16% 
Histology    Adenocarcinoma   13    68% 
(n=19)    Squamous    6    32% 
Differentiation grade    Moderate    5    26% 
(n=19)    Poor   11    58% 
    Missing    3    16% 
Lymphovascular invasion    Yes    6    32% 
(n=19)    No    4    21% 
    Unknown    8    42% 
    Missing    1     5% 
Primary therapy    Surgery   14    74% 
(n=19)    Chemoradiotherapy    5    26% 
Surgical procedure    Transhiatal oesophagectomy    1     7% 
(n=14)    Transthoracic oesophagectomy    3    21% 
    Oesophagogastrectomy    2    14% 
    Total gastrectomy    1     7% 
    Sub-total gastrectomy    4    29% 
    Other     3    21% 
Surgical technique    Open operation   12    86% 
(n=14)    Missing    2    14% 
 
Interpretation of the baseline characteristics of gastro-oesophageal cohort participants are 
limited by the number of participants (n=19). Once more data is available, this can be 
compared to data from the National Oesophago-Gastric Cancer Audit Annual Report 2016 
(142).  
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Table 4.4 Characteristics at registration— prostate cohort 
 
     n     % 
Age at registration     Median (IQR) 68 (62 - 73) 
(n=104)     Range      46 - 82 
D'Amico risk classification    Intermediate Risk   45    43% 
(n=104)    High Risk   56    54% 
    Missing    3     3% 
Pre-treatment stage     IIA   23    22% 
(TNM 7th edition)    IIB   51    49% 
(n=104)    III   29    28% 
    Missing    1    <1% 
Gleason score *    3+3   10    10% 
(n=104)    3+4   43    41% 
    3+5    4     4% 
    4+3   25    24% 
    4+4   11    11% 
    4+5    9     9% 
    5+4    2     2% 
Hormone therapy    None   40    38% 
(n=104)    Neo-adjuvant only   17    16% 
    Adjuvant only    8     8% 
    Neo-adjuvant and adjuvant   37    36% 
    Missing    2     2% 
Total duration of planned    Less than 6 months   20    32% 
Hormone therapy    1 year    6    10% 
(n=62)    2 years   13    21% 
    3 years   22    35% 
    Missing    1     2% 
Primary treatment type 
(n=104) 
   Prostatectomy 
   Radical radiotherapy 
 39     38% 
 65     62% 
PARTICIPANTS UNDERGOING SURGERY ONLY (n=39) 
Surgery type    Open radical prostatectomy    7    18% 
(n=39)    Laparoscopic radical prostatectomy    9    23% 
    Robotic radical prostatectomy    23    59% 
Resection margin clear    No    9    23% 
(R0)    Yes   29    74% 
(n=39)    Missing    1     3% 
Salvage radiotherapy following    No   33    85% 
prostatectomy    Yes    5    13% 
(n=39)    Missing    1     3% 
* Second score is maximum of the secondary pattern and tertiary pattern (if performed) 
 
Data on the baseline characteristics of prostate cohort participants are generally consistent 
with data from the National Prostate Cancer Audit Annual Report 2016 (143) and similar trials 
in patients undergoing radical prostatectomy (144), and radical radiotherapy (145). Notable 
differences include the proportion of patients undergoing a prostatectomy compared to radical 
chemoradiotherapy. 46.3% (2525/5452) of the men having radical treatment in England in 
2016 had a prostatectomy, whereas 38% of participants had a prostatectomy in the Add-
Aspirin trial. There are fewer surgeons (who manage the prostatectomy pathway) have 
registered as cohort leads than oncologists (who manage the radical radiotherapy pathway) 
91 
 
which could account for this difference, and might be addressed by promoting the trial amongst 
surgeons.  
4.3.2 Run-in period 
4.3.2.1 Duration of the run-in period  
The duration of the initial run-in period, and details of run-in extensions, for the first 500 
participants for whom registration and end of run-in data are available, is summarised in table 
4.5. 
Table 4.5 Duration of the run-in period 
 Breast 
(n=252) 
Colorectal 
(n=125) 
Gastro-
oesophageal 
(n=19) 
Prostate 
(n=104) 
Total 
(n=500) 
Length of initial run-in period (days)      
    n 248 123 19 103 493 
    Median (IQR) 56 (53-59) 56 (54-60) 56 (52-58) 56 (52-60) 56 (53-59) 
    Range 0 - 79 14 - 79 10 - 63 1 - 97 0 - 97 
    Missing 4 2 0 1 7 
   <40 days 13     5% 4     3% 1     5% 6     6% 24     5% 
   40-49 days 16     6% 4     3% 1     5% 7     7% 28     6% 
   50-59 days 159    63% 84    67% 15    79% 64    62% 322    64% 
   60-69 days 54     21% 28    22% 2    11% 23    22% 107    21% 
   70+ days 6     2% 3     2% 0     0% 3     3% 12     2% 
   Missing 4     2% 2     2% 0     0% 1    <1% 7     1% 
RUN-IN PERIOD EXTENSIONS      
   Run-in extension approved   0           4          0           2           6        
Extension length                                       
   4 week   0           4          0           1           5        
   8 week   0           0          0           1           1        
 
The median duration of the run-in period was 56 days for all cohorts, which was exactly equal 
to the recommended duration. Some flexibility was permitted (+/-14 days) to fit with patient 
and appointment availability, and 91% of run-in period durations fell within that +/-14 day 
window. The duration fell short of 40 days in 5% (n=24) of participants. This was due to the 
run-in period being discontinued early for 23 participants, and data on the remaining 
participant is incomplete. For 2% (n=12) of participants, the duration of the run-in period was 
70 days or over. Restricting eligibility for randomisation to a run-in duration of 56 +/-14 days 
would make the way adherence and tolerance is assessed more consistent.  
A run-in period extension was only awarded six times (1.2% of participants). Two four week 
extensions were awarded so that aspirin could be withheld to allow for stoma reversal (both 
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participants were subsequently randomised). Two four week extensions were awarded to 
allow optimisation of blood pressure control in participants identified as hypertensive (one 
participant was randomised, the other was not). One four week extension was awarded to 
allow temporary NSAID treatment for pain (with subsequent randomisation). One eight week 
run-in period extension was awarded because the participant developed bleeding from 
haemorrhoids (who subsequently developed grade 2 tinnitus and was not randomised). 
Overall 67% of run-in extensions led to randomisation. 
 
4.3.2.2 Adherence during the run-in period  
Three sources of adherence data were available for 55.8% of participants (n=279), with two 
sources available for 22.0% (n=110), one source for 11.2%. No adherence data was available 
for 11% (n=55), none of whom were randomised. Adherence during the run-in period from 
each of the three available sources (participant interview, blister packs and participant diary 
card) is summarised in figure 4.6. This data is based on the initial run-in attempt, rather than 
any extension.  
Table 4.6 Adherence during the run-in period 
 Breast 
(n=252) 
Colorectal 
(n=125) 
Gastro-
oesophageal 
(n=19) 
Prostate 
(n=104) 
Total 
(n=500) 
Availability of adherence data                                                             
  n  252         125          19         104         500        
  Participant reported  217    86%  115    92%   15    79%   90    87%  437    87% 
  Blister packs  156    62%   81    65%    9    47%   57    55%  303    61% 
  Diary card  184    73%  102    82%   13    68%   74    71%  373    75% 
Run-in adherence based on                                                         
participant interview      
   n  217         115          15          90         437        
   100%  138    64%   78    68%   10    67%   66    73%  292    67% 
   90% to <100%   54    25%   29    25%    3    20%   17    19%  103    24% 
   80% to <90%   12     6%    5     4%    1     7%    1     1%   19     4% 
   <80%   13     6%    3     3%    1     7%    6     7%   23     5% 
Run-in adherence based on blister packs                                                        
   n  156          81           9          57         303        
   100%   98    63%   49    60%    7    78%   43    75%  197    65% 
   90% to <100%   34    22%   23    28%    1    11%   10    18%   68    22% 
   80% to <90%   10     6%    4     5%    1    11%    1     2%   16     5% 
   <80%   14     9%    5     6%    0     0%    3     5%   22     7% 
Run-in adherence based on diary card                                                        
   n  184         102          13          74         373        
   100%  117    64%   69    68%   10    77%   52    70%  248    66% 
   90% to <100%   44    24%   23    23%    2    15%   19    26%   88    24% 
   80% to <90%   10     5%    5     5%    1     8%    1     1%   17     5% 
   <80%   13     7%    5     5%    0     0%    2     3%   20     5% 
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Participant interview, diary card and blister pack based adherence data was available for 87%, 
75% and 61% of participants respectively. Overall, only 5% of participants had less than 80% 
adherence, (the cut-off for acceptable adherence in the run-in period) and this was similar 
across the three sources of adherence data. There were no notable differences in adherence 
data return between the breast, colorectal and prostate cohorts, and meaningful comparison 
with the gastro-oesophageal cohort was limited by small numbers. Tables 4.7 to 4.9 show a 
comparison of adherence sources. 
Table 4.7 Comparison of adherence sources across cohorts 
 Breast 
(n=252) 
Colorectal 
(n=125) 
Gastro-
oesophageal 
(n=19) 
Prostate 
(n=104) 
Total 
(n=500) 
Comparison of adherence from                                                        
participant interview and blister packs      
   n  155          81           9          55         300        
   Identical adherence from both sources  128    83%   71    88%    7    78%   50    91%  256    85% 
   Different but within +/-5%   14     9%    8    10%    2    22%    3     5%   27     9% 
   Different but within +/-10%    6      4%    0     0%    0     0%    1     2%    7      2% 
   Different by +/-10% or more    7      5%    2     2%    0     0%    1     2%   10     3% 
Comparison of adherence from                                                        
participant interview and diary card      
   n  181         101          11          72         365        
   Identical adherence from both sources  168    93%   90    89%   11   100%   67    93%  336    92% 
   Different but within +/-5%    7      4%    6     6%    0     0%    2     3%   15     4% 
   Different but within +/-10%    4      2%    2     2%    0     0%    3     4%    9      2% 
   Different by +/-10% or more    2      1%    3     3%    0     0%    0     0%    5      1% 
Comparison of adherence from                                                        
blister packs and diary card      
   n  143          78           8          53         282        
   Identical adherence from both sources  120    84%   64    82%    7    88%   45    85%  236    84% 
   Different but within +/-5%    9      6%    8    10%    1    13%    4     8%   22     8% 
   Different but within +/-10%    7      5%    1     1%    0     0%    3     6%   11     4% 
   Different by +/-10% or more    7      5%    5     6%    0     0%    1     2%   13     5% 
Footnote: Based on those participants for whom percentage adherence was calculable. 
 
Table 4.8 Statistical comparison of adherence sources 
Adherence comparison Participants Correlation coefficient p-value 
Participant interview vs. blister packs 300 0.75 <0.0001 
Participant interview vs. diary card 365 0.91 <0.0001 
Blister packs vs. diary card 282 0.67 <0.0001 
Footnotes: The correlation coefficient is a value between -1 and 1 which represents the strength of 
association between two variables, with 1 representing perfect “agreement”, -1 representing perfect 
“disagreement” and 0 representing no correlation at all. The p-values given are a test of the hypothesis 
that there is no correlation. 
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Table 4.9 Comparison of level of reported adherence between sources  
   n      % 
Adherence based on participant interview vs blister packs            
   n  300        
   Identical adherence  256    85% 
   Blisters better than participant reported   18     6% 
   Participant reported better than blisters   26     9% 
Adherence based on participant interview vs diary card            
   n  365        
   Identical adherence  336    92% 
   Diary card better than participant reported    6     2% 
   Participant reported better than diary card   23     6% 
Adherence based on blister packs vs diary card            
   n  282        
   Identical adherence  236    84% 
   Diary card better than blisters   23     8% 
   Blisters better than diary card   23     8% 
TOTAL  500        
 
To investigate consistency between the three adherence data sources, a correlation 
coefficient between each was calculated and the results are available in table 4.8. This shows 
a significant correlation between each of the adherence sources. The highest level of 
correlation in adherence data was found between the participant interview and diary card, 
suggesting participants may be using the diary card to inform verbally reported adherence at 
interview, rather than their used blister packs. There is no evidence of any systematic over, or 
under-reporting of adherence between sources (table 4.9). Given these findings, to simply the 
run-in period process, the blister pack assessment of adherence could be removed which 
would reduce the burden to participants and site staff. 
4.3.2.3 Patient reported reasons for missed doses 
At the end of run-in assessment, 32% of participants reported missing doses. The most 
frequent reason given was forgetting doses (57%) followed by toxicity (19%). The explanations 
given were similar for each tumour cohort, with the exception of the gastro-oesophageal 
cohort, where toxicity was given as a reason more frequently (43%), however the number of 
participants was too small for meaningful interpretation (n=3). The reasons reported for 
missing doses are shown in table 4.10. 
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Table 4.10 Patient reported reasons for missed doses 
 Breast 
(n=252) 
Colorectal 
(n=125) 
Gastro-
oesophageal 
(n=19) 
Prostate 
(n=104) 
Total 
(n=500) 
Any doses missed                                                        
   No  161    64%   86    69%   12    63%   72    69%  331    66% 
   Yes   87     35%   35    28%    7    37%   30    29%  159    32% 
   Missing    4      2%    4     3%    0     0%    2     2%   10     2% 
Reasons for missed doses                                                             
(more than one reason allowed)      
   n   87   35    7   30  159 
   Due to toxicity   18    21%         5     14%    3      43%     4     13%     30      19%       
   Due to other reasons   76    87%       34    97%     6      86%     27    90%     143     90%     
Main other reason for missed doses                                                             
(one reason per participant)      
   Forgotten doses of aspirin   47    54%     24     69%     2       29%   18    60%     91     57%     
   Patient choice not to take aspirin    3      3%    1       3%    0       0%    3     10%     7       4% 
   Lost aspirin tablets    1      1%    0       0%    0       0%    0     0%    1      <1% 
   Other reason for missed doses    25    53%      9      26%    4       57%    6     20%   44      28%  
 
4.3.2.4 Toxicity reported during the run-in period  
In order to fully illustrate patient safety during the run-in period, any toxicity reported during 
the run-in period or any extension was included in the analysis. Table 4.11 shows all toxicities 
reported during the run-in period. 
Table 4.11 Toxicity reported during the run-in period 
Toxicity 
CTCAE v4 
grade 
Breast 
(n=252) 
Colorectal 
(n=125) 
Gastro-
oesophageal 
(n=19) 
Prostate 
(n=104) 
Total 
(n=500) 
Allergic reaction to aspirin Grade 1-2 0   (0%)    1   (<1%) 0    (0%) 0   (0%) 1   (<1%) 
Anaemia Grade 1-2 4   (2%) 5     (4%) 1    (5%) 7   (7%) 17    (3%) 
Bleeding gums Grade 1-2 8   (3%) 5     (4%) 0    (0%) 1  (<1%) 14    (3%) 
Bruising Grade 1-2 31 (12%) 7     (6%) 1    (5%) 6   (5%) 45    (9%) 
Dyspepsia Grade 1-2 31 (12%) 14  (11%) 2   (11%) 15 (14%) 62  (12%) 
 Grade 3-4 0    (0%) 1   (<1%) 0     (0%) 0   (0%) 1   (<1%) 
Haematuria Grade 1-2 1  (<1%) 0    (0%) 0     (0%) 0   (0%) 1   (<1%) 
Lower gastrointestinal bleeding Grade 1-2 0   (0%) 1   (<1%) 1     (5%) 0   (0%) 2   (<1%) 
Nose bleed (epistaxis) Grade 1-2 10   (4%) 10    (8%) 0     (0%) 4   (4%) 24    (5%) 
Tinnitus Grade 1-2 5   (2%) 4     (3%) 3   (16%) 2   (2%) 14    (3%) 
 
The majority of toxicities reported were grade 1 or 2, with only a single grade 3 toxicity 
(dyspepsia in a colorectal cohort participant). Only six participants (1.2%) experienced 
toxicities that mandated permanent discontinuation of the run-in period. These included grade 
3 dyspepsia (n=1), grade 2 allergic reaction to aspirin (n=1), grade 2 tinnitus (n=3), and grade 
1 lower gastrointestinal bleeding (n=1). Randomisation was permitted for one participant 
96 
 
reporting grade 1 lower gastrointestinal bleeding after a central review of clinical information 
establishing that the bleeding had been from the mucocutaneous junction of a stoma which 
had subsequently healed and was therefore low risk. Nine participants reported grade 1 
tinnitus, however it was unestablished whether the onset of the tinnitus pre-dated the run-in 
period, and randomisation went ahead. A protocol amendment was subsequently made to 
only mandate permanent discontinuation in new cases or worsening tinnitus (grade 2 or 
above), and grade 3 or 4 lower gastrointestinal bleeding.  
In the breast cohort, bruising (12%) was more frequent than in the other cohorts (5-6%). There 
is data to suggest that bruising is more common in women taking aspirin than men (146) which 
could account for this observation. In the colorectal cohort, epistaxis (8%, n=10) was reported 
more frequently than in the other cohorts (0-4%). Chemotherapy is also a common cause for 
epistaxis, and all 10 participants developing nose-bleeds had adjuvant chemotherapy, five of 
whom had ongoing chemotherapy at the time, which may explain this finding. In the gastro-
oesophageal cohort, tinnitus (16%) was reported more frequently than in the other cohorts (2-
5%). Whilst small numbers (n=3) limit interpretation, this finding does advocate further 
monitoring, as this is the only cohort who receive a cisplatin containing chemotherapy regimen, 
which is commonly associated with the development of tinnitus. In the prostate cohort, 
anaemia (7%, n=7) was reported more frequently than in the other cohorts (2-5%). Subclinical 
rectal and urinary blood loss are a known complication of radical prostate cancer treatment 
(147), and the contribution of aspirin requires further investigation in the randomised phase. 
4.3.2.5 Run-in period outcomes 
The outcomes of the run-in period are based on all participants registered up to and including 
the 500th participant for whom end of run-in data has been received, including those registered 
during that time where an end of run-in form has not been received, but are expected to have 
completed the run-in period (an extra 104 participants). This is to avoid biasing results based 
on data return, which is expected to be lower for non-randomised participants.  
88% (n=534/604), of the participants registered, were randomised at the time of data 
extraction. There were 18 participants without CRF data confirming non-randomisation, 
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however sufficient time had passed to make randomisation impossible, and as such, those 
participants were included in the analysis as non-randomised. The proportion of participants 
going on to be randomised following the run-in period is similar in all four cohorts, and slightly 
below the 90% that was anticipated at the start of the trial (88%, 91%, 74%, and 89% in the 
breast, colorectal, gastro-oesophageal and prostate cohorts respectively). Table 4.12 
summarises the run-in period outcomes and the reasons reported for non-randomisation. 
Table 4.12 Run-in period outcomes 
 Breast 
(n=304) 
Colorectal 
(n=145) 
Gastro-
oesophageal 
(n=23) 
Prostate 
(n=132) 
Total 
(n=604) 
Run-in outcome                                                        
n  304         145          23         132         604        
Not-randomised   36     12%    13     9%    6     26%   15     11%   70     12% 
Randomised  268    88%  132    91%   17    74%  117    89%  534    88% 
Reason for non-randomisation                                                             
(more than one reason may apply)      
n   36           13           6          15          70        
Participant choice   19           4           1           4          28        
Toxicity or adverse event   15           2           3           6          26        
Inadequate adherence to protocol   
treatment 
   4           2          0           0           6        
Usage of non-permitted medication    1           1          0           2           4        
Other reason    4           4          3           4          15        
No reason given    1           1          0           0           2        
Missing     9    4   1    4   18 
Combinations of reasons given 
for non-randomisation: 
                                                       
n   25           5           4           6          40        
Toxicity only    3    12%    1    20%    2    50%    2    33%    8     20% 
Participant choice only    8    32%    3    60%    0     0%    0     0%   11    28% 
Toxicity and participant choice    9    36%    1    20%    0     0%    4    67%   14    35% 
Other combination of reasons    5    20%    0     0%    2    50%    0     0%    7     18% 
 
Toxicity was given as the reason for non-randomisation for 26 participants. The nature of the 
toxicity experienced only mandated non-randomisation for six participants (table 4.11), 
therefore for the remainder (n=20), it is assumed that the toxicity experienced made it 
unacceptable to them to continue. This is consistent with the finding that both toxicity and 
participant choice were given as the reason for non-randomisation jointly (n=14), more 
frequently than they were given individually (toxicity alone n=8, participant choice alone n=11). 
Overall, the most frequent reason for non-randomisation was participant choice (n=28). It 
seems likely that this group would be at highest risk of discontinuing the trial prematurely, and 
as such, their non-randomisation prevents this happening during the main trial and fulfils one 
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of the main objectives of the run-in period. This CRF question has now been re-written to ask 
the main reason for non-randomisation, as the ability to select more than one reason doesn’t 
reveal which is most important. 
4.3.3 Timing of trial registration  
4.3.3.1 Treatment pathway and early and late registrations by cohort 
An analysis of the treatment pathway taken by participants, in relation to the timing of their 
registration, was conducted for the first 500 participants for whom end of run-in data had been 
received. The treatment pathway taken, and the number or registrations occurring outside the 
timing of entry window are shown in table 4.13. 
Table 4.13 Timing of trial registration according to cohort and pathway 
Cohort Pathway* N Timing of entry criteria 
Early registrations Late registrations 
   N (%) 
Min—max 
days early 
N (%) 
Min—max 
days late 
Breast 
(n=252) 
 
   Surgery 
 
4 
(2%) 
6-12 weeks after surgery 0 (0%) - 
1 
(25%) 
1 
   Surgery  
+ adjuvant CT 
21 
(8%) 
After completion of CT  
And ≤6 weeks after CT 
0 (0%) - 
2 
(10%) 
5-9 
   Surgery  
+ adjuvant RT 
66 
(26%) 
≥6 weeks after surgery  
And ≤6 weeks after RT 
2 (3%) 1-9 3 (5%) 1-7 
   Surgery  
+ adjuvant CT  
+ adjuvant RT 
161 
(64%) 
After completion of CT  
And  
≤6 weeks after RT 
0 (0%) - 5 (3%) 2-13 
Colorectal 
(n=125) 
   Surgery  
12 
(10%) 
6-12 weeks after surgery 0 (0%) - 0 (0%) - 
   Surgery  
+ adjuvant CT 
113 
(90%) 
≥6 weeks of CT and ≤6 
weeks after CT ends 
3 (3%) 1 
14 
(12%) 
3-22 
Gastro-
oesophageal 
(n=19) 
   Primary CRT 
 
5 
(26%) 
After completion of CRT  
and ≤12 weeks after CRT 
0 (0%) - 0 (0%) - 
   Surgery   
 
10 
(53%) 
6-12 weeks after surgery 0 (0%) - 
3 
(30%) 
36-102*** 
   Surgery  
+ adjuvant CT 
 
4 
(21%) 
≥6 weeks of adjuvant CT 
and  
≤6 weeks from end of CT 
1 
(25%) 
22 0 (0%) - 
Prostate† 
(n=90**) 
   Radical RT 
51** 
(57%) 
After last fraction of RT  
and ≤12 weeks after RT 
0 (0%) - 2 (4%) 2-6 
   Prostatectomy 
 
34 
(38%) 
6-12 weeks after surgery 0 (0%) - 1 (3%) 10 
   Prostatectomy  
+ adjuvant RT 
0 
6 weeks after surgery  
and ≤6 weeks after RT 
- - - - 
   Prostatectomy  
+ salvage RT 
5 
(6%) 
6 weeks after surgery  
and ≤12 weeks after RT 
0 (0%) - 0 (0%) - 
Footnotes: *+/- neo-adjuvant therapy, ** an additional 9 patients have a missing radiotherapy end date 
and are therefore not included. *** possible data error. † an additional two patients were not included 
as the primary therapy was unclear. CT=chemotherapy, RT=radiotherapy, CRT=chemoradiotherapy. 
 
Across all tumour cohorts, there were very few participants registered before the timing of 
entry window (1.2%, n=6), however there were a more late registrations (6%, n=31). The Add-
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Aspirin protocol was written to be pragmatic, recognising that not all clinical scenarios can be 
covered, and sites were directed to contact the trial team directly for discussion. 
For patients undergoing surgery alone (in any tumour cohort), the last permitted point of 
registration was normally 12 weeks after completion of surgery. Late registrations for patients 
undergoing surgery alone in the breast and gastro-oesophageal cohorts were higher than 
anticipated (25% and 30% respectively), however this was not common in the prostate and 
colorectal cohorts (3% and 0% respectively). Interpretation is limited due to small numbers, 
but it is possible that the timing of entry window aligns poorly with the follow-up schedule for 
visits in breast and gastro-oesophageal cancer in some trusts, and thus requires further 
monitoring as the trial progresses.  
For patients undergoing adjuvant chemotherapy without radiotherapy, the latest point of 
registration is six weeks after the final day of the final cycle of chemotherapy given. In the 
breast and colorectal cohorts, 10%, 12% were registered late respectively. It is possible that 
late registrations occur because additional time is required to recover from chemotherapy 
related toxicity in some patients. 
The latest point of registration for pathways involving radiotherapy was 12 weeks after radical 
radiotherapy, and six weeks after adjuvant radiotherapy. There were very few late registrations 
in these pathways, suggesting the current window of trial entry is feasible.  
 
4.3.3.2 Timing of registration for participants receiving adjuvant therapies 
For some cohorts there is flexibility around which point in the treatment pathway patients 
register and start the run-in period. The timing of registration for participants receiving adjuvant 
therapies is summarised below in table 4.14. 
 
 
 
100 
 
Table 4.14 Timing of registration for participants receiving adjuvant therapies 
Cohort Pathway* 
N 
 
Adjuvant CT Adjuvant RT Salvage RT 
Unclear 
Before* During After Before During After Before During After 
Breast 
(n=248) 
   Surgery  
+ adjuvant CT 
21 
 
 
21 
(100%) 
      0 
   Surgery  
+ adjuvant RT 
66 
 
  
  9 
(14%) 
  15 
(23%) 
41 
(62%) 
   
1 
(2%) 
   Surgery  
+ adjuvant CT  
+ adjuvant RT 
161 
 
 
 160 
(99%) 
15 
(9%) 
27 
(17%) 
119 
(74%) 
   
1 (CT) 
(<1%) 
Colorectal 
(n=113) 
   Surgery  
+ adjuvant CT 
113 
2* 
(2%) 
35 
(31%) 
75 
(66%) 
      
1 
(<1%) 
Gastro-
oesophageal 
(n=4) 
   Surgery  
+ adjuvant CT 
4 
 
2 
(50%) 
2 
(50%) 
      0 
Prostate 
(n=5) 
  
Prostatectomy  
+ adjuvant RT 
0 
 
  - - -    - 
  
Prostatectomy  
+ salvage RT 
5 
 
      
4 
(80%) 
1 
(20%) 
0 
*Early registrations, CT=chemotherapy, RT=radiotherapy, CRT=chemoradiotherapy 
 
In the breast cohort, there was flexibility around the timing of registration with respect to 
delivery of adjuvant radiotherapy. The options to register before, during or after radiotherapy 
were all utilised, suggesting this approach was acceptable to participants and investigators.  
In the colorectal cohort, participants were able to register whilst chemotherapy was ongoing 
(after two cycles with acceptable blood platelet counts), or once it had finished (and up to six 
weeks later). 31% of participants registered whilst chemotherapy was ongoing, 66% once 
chemotherapy was finished (2% registered early). There were initial concerns about the risk 
of chemotherapy induced dyspepsia when aspirin was given concomitantly. 14 participants 
developed dyspepsia in the colorectal cohort during the run-in period. The proportion 
developing dyspepsia who registered during chemotherapy (14%, 5/5 grade 1) was similar to 
the proportion who developed dyspepsia registering once chemotherapy had finished (12%, 
8/9 grade 1, 1/9 grade 3). These findings could be used to reassure investigators of the risks 
of chemotherapy induced dyspepsia. 
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4.3.4 Metformin use at registration 
There was a high level of data return on metformin use at trial registration (96%). At the time 
of registration, 4% of participants were using metformin overall, and the median total daily 
metformin dose reported was 1,000mg (IQR 625-1,650mg). Metformin use was twice as 
prevalent in the prostate compared to the breast cohort. This is likely to be a reflection of the 
increasing prevalence of DM with age, and the greater average age of those with prostate 
compared to breast cancer. Data on concomitant metformin use at the time of registration is 
summarised in table 4.15.  
Table 4.15 Metformin use at registration 
 
 Breast Colorectal 
Gastro-
oesophageal 
Prostate Total 
Participants in main analysis  252  125   19  104  500 
Participants with metformin data  241  120   19  101  481     
Current or previous metformin 
use at registration 
                                                       
   No  233    97%  115    96%   18    95%   95    94%  461    96% 
   Yes    8     3%    5     4%    1     5%    6     6%   20     4% 
When was Metformin last taken?                                                        
   n    8           5           1           6          20        
   Within last week    8   100%    5   100%    1   100%    6   100%   20   100% 
Frequency of use                                                        
   n    8           5           1           6          20        
   Daily    8   100%    5   100%    1   100%    6   100%   20   100% 
Duration of use                                                        
   n    8           5           1           6          20        
   Less than or equal to 6 months    1    13%    1    20%    0     0%    2    33%    4    20% 
   Greater than 6 months    7    88%    4    80%    1   100%    4    67%   16    80% 
Total daily dose (mg)      
   n  7 5 1 5 18 
   Median 1000 2000 2000 500 1000 
   IQR 500 - 1500 1000 - 2000 2000 - 2000 500 - 1000 500 - 1700 
   Range 500 - 1700 1000 - 2500 2000 - 2000 500 - 1500 500 - 2500 
Total daily dose (mg)                                                        
   n    8           5           1           6          20        
   500    2    25%    0     0%    0     0%    3    50%    5    25% 
   1000    3    38%    2    40%    0     0%    1    17%    6    30% 
   1500    1    13%    0     0%    0     0%    1    17%    2    10% 
   1700    1    13%    0     0%    0     0%    0     0%    1     5% 
   2000    0     0%    2    40%    1   100%    0     0%    3    15% 
   2500    0     0%    1    20%    0     0%    0     0%    1     5% 
   Missing    1    13%    0     0%    0     0%    1    17%    2    10% 
TOTAL  241         120          19         101         481        
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4.4 Discussion 
4.4.1 Baseline characteristics 
Overall the characteristics of patients registering for the Add-Aspirin trial were similar to 
population data from national audits, and trials with similar eligibility criteria, however there 
were some notable differences, including a lower proportion, in the colorectal cohort, of 
participants with resection of liver metastases, and in the prostate cohort, of participants who 
had undergone a prostatectomy. This information can be used to direct recruitment strategies 
toward these under-represented groups, with the aim of making the trial representative of the 
wider population, and to ensure expected event rates are met to ensure the trial is powered 
as anticipated. 
4.4.2 Design and utility of the run-in period 
Overall, 88% of participants registered for the run-in period were randomised. The run-in 
period was effective in identifying 5% of participants who had less than 80% adherence, and 
1.2% of participants who developed severe aspirin related toxicities, thus preventing their 
randomisation. Participants were also identified who choose not to be randomised, and who 
developed toxicities that were unacceptable to them, but where discontinuation was not 
mandated. This, along with the acceptability of a run-in period design, as demonstrated in 
chapter two, recommends continuation of the run-in period as the trial progresses.  
The use of a run-in period extension was only used by 1.2% of participants, was useful in 
identifying a number of participants as suitable, who would otherwise had missed out 
unnecessarily. The duration of the run-in period was effective but restricting eligibility for 
randomisation to a run-in duration of 56 +/-14 days would make the way adherence and 
tolerance is assessed more consistent. Establishing accurate adherence rates is challenging, 
however the methods used showed a high level of concordance. The interview and diary card 
have the potential to be more prone to reporting and/or recall bias, which would favour the use 
of blister packs as a more objective measure of adherence, however there was no systematic 
over, or under-reporting of adherence between sources identified. The collection of used 
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blister packs didn’t appear to provide any additional adherence information, and the data 
return rate was lower than the other two adherence sources, therefore discontinuing data 
collection from used blister packs is advocated.  
A number of early signals suggest there may be patterns of toxicity for individual cohorts, 
including, epistaxis in those who have had chemotherapy, tinnitus in the gastro-oesophageal 
cohort (possibly related to cisplatin use), anaemia in the prostate cohort and bruising in the 
breast cohort. Further monitoring of these toxicities as the trial progresses is recommended. 
4.4.3 Timing of registration 
For most treatment pathways, there were very few early or late registrations suggesting that 
registering patients within the current timing of entry criteria was feasible. Exceptions include 
those who undergo surgery alone, and those having adjuvant chemotherapy (without 
radiotherapy), where a notable proportion of patients register late. For those undergoing 
surgery alone, a survey of cohort leads who are surgeons could help identify the underlying 
reasons, and potential corrective strategies. For those undergoing adjuvant chemotherapy 
(without radiotherapy), directing sites to contact the central trial team to discuss the clinical 
circumstances or reason underlying the request for late registration could help identify the 
underlying reasons, and potential corrective strategies. This is preferable to extending the 
registration window, which will reduce the alignment with other treatment pathways.  
Around a third of the colorectal cohort participants started the active run-in period whilst 
chemotherapy was ongoing, demonstrating the acceptability of this approach. No significant 
increase in the risk of chemotherapy induced dyspepsia when aspirin was given concomitantly 
with chemotherapy was demonstrated. In the breast cohort, it is currently mandated that the 
run-in period is initiated once chemotherapy is complete. Giving the option of starting the run-
in period whilst chemotherapy is ongoing would align the cohorts more closely, and help with 
treatment/timing recommendations in the future should the use of aspirin in this setting be 
shown to be beneficial, and should be considered. 
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4.4.4 Metformin use in Add-Aspirin trial participants 
Metformin use in participants in the Add-Aspirin trial was only 4% overall, and there was only 
slight variation in its use between tumour cohorts. This is useful in estimating the number of 
patients with these tumour types that would not be eligible for a metformin trial (because of 
existing metformin use). It also shows the feasibility and utility of collecting detailed data on 
key concomitant medications, however, given the time consuming nature of collecting such 
data, the number of concomitant medications needs to be as selective as possible. The 
evidence supporting the adjuvant use of metformin, and how it may inform the design of such 
a trial is explored in the next chapter. 
 
4.5 Conclusion 
Overall, 88% of participants were randomised which is in-keeping with the expected non-
randomisation rate of 10%.The rate of serious bleeding complications is low, but the number 
of patient-years examined in this analysis is too small to make inferences on bleeding risk. 
This data confirms the viability of the trial but suggests some minor protocol amendments that 
may increase recruitment further and facilitate the conduct of the trial. 
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Chapter 5. A systematic review and meta-analysis of 
Metformin as an adjuvant treatment for cancer 
 
5.1 Introduction 
The oral drug metformin is the current first-line choice for the treatment of DM (148), and with 
an estimated 420 million diagnoses globally (149), metformin is now one of the most frequently 
prescribed generic medicines worldwide (150). Biguanides (a group of compounds of which 
metformin is one) were originally developed from Galegine, one of the active ingredients of 
the plant Galega Officinalis, also known as French Lilac, which is a traditional medicine used 
since the medieval era as a treatment of polyuria associated with DM (151). Metformin was 
first synthesised by chemists in 1922 (152), and discovered to induce hypoglycaemia in 
animals in 1929, but was overlooked as a potential treatment for DM until the 1950’s (153) 
because of the greater glucose lowering properties of other biguanides like phenformin and 
buformin. It became available as a therapy for DM in the UK in 1958, but was not commonly 
used until the 1990’s, initially due to the preference for insulin and other biguanides, and later, 
due to concerns about biguanide associated lactic acidosis (153), however further research 
established that metformin has a superior safety profile (153). It wasn’t until 1995 that 
metformin was approved in the US by the FDA for the treatment of DM.  
5.1.1 Mechanism of action of metformin in type II Diabetes Mellitus 
In those with DM, metformin is thought to act mainly by addressing insulin resistance in the 
liver, through suppression of hepatic glucose production (gluconeogenesis) and opposing the 
hyperglycaemic effects of the hormone, glucagon. Metformin enters hepatocytes through 
solute transporters in the cell membrane (mostly organic cation transporter-1 (OCT1) (154)). 
Metformin then transiently inhibits the enzyme, Mitochondrial Complex I, which disrupts the 
electron transport chain (155) and reduces the availability of cellular energy by reducing levels 
of adenosine triphosphate (ATP) and increasing levels of its counterpart, adenosine 
monophosphate (AMP). The rise in levels of AMP promotes the activity of the adenosine 
monophosphate activated protein kinase (AMPK) pathway (156), which inhibit the cellular 
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mechanisms that perform gluconeogenesis and fatty acid synthesis (157). A additional 
consequence of the rise in AMP levels is disruption glucagon signalling. Under normal 
conditions, when the glucagon receptor is bound by glucagon, adenylate cyclase converts 
ATP to cyclic AMP (cAMP), which, in turn, increases protein kinase A (PKA) activity, resulting 
in increased glycolysis and gluconeogenesis. By increasing AMP levels, metformin inhibits 
glucagon induced formation of cAMP and thus reduces glycolysis and gluconeogenesis. 
Figure 5.1 describes the molecular pathway in hepatocytes by which metformin reduces 
circulatory blood glucose, increases insulin sensitivity, and improves DM associated 
dyslipidaemia. 
 
Figure 5.1 The molecular pathway by which metformin lowers glucose production by 
hepatocytes 
 
ATP= adenosine triphosphate, AMP= adenosine monophosphate , AMPK= AMP activated protein 
kinase, PKA= protein kinase A, cAMP= cyclic AMP. 
 
Metformin is also proposed to have a number of additional mechanisms by which it 
counteracts the metabolic dysregulation seen in DM. In skeletal muscle, in-vivo studies show 
that increased AMPK signalling increases activity and translocation of glucose transporters to 
the cell membrane, particularly GLUT4, resulting in increased glucose uptake (158, 159). In 
adipocytes, in-vivo studies show that raised AMPK activity increases glucagon-like peptide-1 
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(GLP1) and leptin levels (160), leading to reduced appetite (161). In studies in people without 
DM, metformin has been shown to reduce leptin levels, and as a consequence reduce 
centripetal adiposity, cholesterol levels and body weight (162). In the gastrointestinal tract, 
both animal and human studies have also shown that metformin increases lactate production 
in gastrointestinal cells suggesting an increase in anaerobic glucose metabolism (163, 164), 
however, this could also be a consequence of increased gastro-intestinal glucose uptake, 
which can be seen on Positron Emission Tomography (PET) imaging, where gastro-intestinal 
uptake of a 18-F-fluoro-deoxy glucose (a radiolabelled glucose analogue) is increased by 
metformin (165). Figure 5.2 describes the effects of metformin on glucose, insulin and lipid 
metabolism in different organ systems.  
 
Figure 5.2 The effects of metformin on glucose, insulin and lipid metabolism 
 
It has also been suggested that metformin may have beneficial effects for individuals with 
metabolic syndrome, a set of disorders which include raised fasting glucose, dyslipidaemia, 
high blood pressure, and central obesity (166). Metformin has also been investigated as a 
treatment for cardiovascular disease, non-alcoholic fatty liver disease and infertility in women 
with polycystic ovarian syndrome, (which are all associated with metabolic syndrome) 
however its use in these conditions remains controversial (167-169).  
In 2004, the discovery that the tumour suppressor gene, liver kidney B1 (LKB1), is an 
upstream regulator of AMPK (170) inspired the first observational study investigating the anti-
cancer effects of metformin. A large case-control study in Tayside, Scotland (n=11,876), 
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metformin was associated 23% reduction in the risk of developing cancer (OR 0.77, 95% CI 
0.64-0.92), and a greater protective effect was observed with increasing duration of exposure 
to metformin and the number of prescriptions dispensed (171). This prompted an increase in 
research into the anti-cancer effects of metformin over the next decade. 
5.1.2 Anti-cancer mechanistic hypothesis and in-vitro and in-vivo evidence 
It has been proposed that that the anti-cancer properties of metformin result from both direct 
effects on cancer cells, and indirect systemic effects on the host (172). Many of the proposed 
indirect anti-cancer effects are a consequence of the metformin-induced metabolic changes, 
such as lower circulating glucose levels and increased insulin sensitivity, as described in the 
previous section. For example, mouse models have shown that high energy diets increase 
tumour growth (173), and metformin reduces glucose consumption in breast cancer 
xenographs (174). Metformin, by virtue of its glucose-lowering properties, could indirectly 
reduce the availability of energy to cancer cells thus reducing cancer proliferation and growth. 
However, contrary to this hypothesis, there is currently no evidence that other DM treatments, 
which also lower circulating glucose levels, have anti-cancer effects, in-fact a limited number 
of studies have suggested that sulphonylurea based DM therapies increase cancer incidence 
(175), and an observational study has also suggested that pioglitazone (one of the  
thiazolidinedione class of DM therapies), could increase the risk of bladder cancer (176), 
although this has not been substantiated in other studies (177, 178). 
Unlike other treatments for DM, metformin is associated with a reduction in insulin levels. The 
ability of metformin to lower circulating insulin has also been proposed to underlie the anti-
cancer effects of metformin, and while treatment with exogenous insulin is not known to 
adversely affect cancer outcomes (179), high levels of serum c-peptide (a marker of increased 
endogenous insulin secretion) have been shown to be associated with poor breast and 
prostate cancer outcomes (180, 181), suggesting endogenous insulin reduction may have a 
role in the anti-cancer effects of metformin. Another potential mechanism is the anti-
inflammatory effects of metformin, where human studies have shown that it reduces tumour 
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necrosis factor (TNF-α) and interleukin 6 (IL-6) levels (182), Inflammatory cytokines including 
TNF-α and IL-6 are promoters of tumourogenesis (183). Metformin-induced systemic 
metabolic changes are a plausible anti-cancer mechanism, however translational studies 
aligned with phase III trials are needed if the contribution of indirect mechanisms are to be 
better understood. 
Metformin may also have direct effects on cancer cells, though inhibition mediators in 
phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) signalling, and 
LKB1 signalling, which are key oncogenic pathways. Both pathways are inhibited through 
activation of the AMPK pathway (184, 185), and also through direct inhibition of mTOR 
complex 1 (mTORC1) by metformin (186). Components of the PI3K/mTOR signalling pathway 
are mutated, amplified or translocated more than those in any other oncogenic pathway (187). 
LKB1 is a tumour suppressor gene, loss of which is associated with a number of epithelial 
malignancies, most commonly colorectal cancer as part of Peutz-Jeghers syndrome (a 
condition where there is significantly increased risk of intestinal polyp formation leading to 
colorectal cancer), but also breast, ovarian, liver and lung cancer (188). Figure 5.3 describes 
the proposed mechanism for the direct effects of metformin on cancer cells. 
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Figure 5.3 Direct anti-cancer effects of metformin 
 
 
PI3K= phosphatidylinositol-3-kinase, TSC2= tuberous sclerosis complex 2, Rheb= RAS homologue 
enriched in brain, mTORC1= mammalian target of rapamycin complex 1, ATP= adenosine triphosphate, 
AMP= adenosine monophosphate, AMPK= AMP activated protein kinase, LKB1= liver kinase B1. 
 
There is evidence that metformin has anti-cancer activity in-vitro. Metformin inhibits the growth 
and survival of cancer in a number of different cancer cell-lines (184, 189-193), however the 
metformin concentrations used (5-20mmol/L) are not achievable in humans (where serum 
concentrations are usually ≤0.5mmol/L (194)). It has been hypothesised that the requirement 
for supra-physiological concentrations of metformin to show that anti-cancer effects could be 
a consequence of the supra-physiological glucose concentrations used in cell cultures (189).  
In-vivo models have studied the effect of metformin in HER-2 transgenic mice with mammary 
tumours (195) and prostate cancer xenograft mice (195), and found reductions in tumour 
growth in both. Evidence has also emerged in humans from window of opportunity studies, 
where the tissue is examined before and after metformin exposure. Pre-operative metformin 
use has been shown to reduce Ki-67 protein expression (a marker of tumour proliferation) in 
breast cancer (196, 197), and to reduce the precancerous changes (aberrant crypt foci) which 
are thought to precede the development of colorectal cancer (198). Most recently, a 
randomised phase III trial of non-DM patients showed that 250mg of metformin daily (a low 
dose compared to standard dose range of 1-2g daily in those with DM) was effective in the 
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chemoprevention of metachronous colorectal adenomas or polyps when compared with 
placebo (199). 
5.1.3 Objectives 
Objectives: 
1. To conduct a systematic review and meta-analysis of randomised and non-randomised 
studies to investigate the effect of metformin use compared with non-use on 
recurrence-free survival (RFS), overall survival (OS) and cancer-specific survival 
(CSS) for individual tumour types in the adjuvant setting. 
2. To assess whether there is sufficient evidence to undertake a phase III trial of 
metformin in the adjuvant setting, and possibly as an additional intervention to the Add-
Aspirin trial.  
 
5.2 Methods 
All methods for this systematic review and meta-analysis were outlined in a protocol 
prospectively registered with PROSPERO, an International prospective register of systematic 
reviews and meta-analyses (identifier CRD42015020519, also available in appendix E). A 
freely available permanent record of the study protocol reduces the opportunity for reporting 
bias by enabling comparison of the completed review with what was planned in the protocol. 
Reporting follows PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines(200). PRISMA guidelines aim to improve the quality of reporting for 
systematic reviews and meta-analyses by describing the minimum set of information that 
should be reported.  
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5.2.1 Eligibility criteria  
Eligible studies were those that met the following criteria: 
• Participants over 16 years old 
• Data was available for participants with a potentially curable solid tumour  
(defined as those either undergoing radical therapy with curative intent, or 
those with an early stage cancer where cure is normally the objective of 
standard treatment) 
• Data was available for individual tumour types 
• Intervention was metformin use and the comparator individuals who were not using 
metformin  
• Data is reported on at least one of RFS, CSS or OS for individual tumour types 
• HR and CI are reported or could be calculated 
• Randomised controlled trials or non-randomised studies (including observational, 
cohort and case-control studies) were eligible 
5.2.2 Search strategy  
Electronic searches of databases (MEDLINE, EMBASE, Cochrane Central Register of 
Controlled Trials), clinical trial registries (clinicaltrials.gov, ISRCTN and EU Clinical Trials 
Register) and conference proceedings (American Society of Clinical Oncology, and European 
Society of Medical Oncology) were conducted. All sources were searched from inception until 
the 31st May 2015 (conference abstracts 2005-2015). Bibliographies of the reports of all 
identified studies and review articles were hand-searched for further potentially eligible 
studies. A search strategy was designed to identify all randomised and non-randomised 
studies (including case-control, cohort, cross-sectional, longitudinal, retrospective and 
prospective observational studies) where a biguanide was the intervention investigated. 
Further details of the search strategy are available in appendix E. 
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5.2.3 Study selection 
All retrieved studies were assessed for eligibility and, when sufficient information was not 
available from the title and/or abstract, the full-text publication or (for conference abstracts) 
the associated poster or presentation was acquired and where this was not available, the 
study author was contacted. For studies with multiple publications, or where there was overlap 
in the patients studied, the most recent publication was chosen. No study was excluded for 
weakness of study design or quality.  For the purpose of analysis, studies presenting data 
separately by tumour type were treated as separate studies. Articles were grouped by cancer 
type according to the site of origin and histology.  
5.2.4 Data items and collection  
Data on patient characteristics, interventions and outcomes were extracted for all studies into 
a pre-designed table. These were cross-checked by a second independent reviewer (Fay 
Cafferty) and any disagreements were resolved by consensus. Where the necessary data was 
not available in published material, missing information was requested from the study author. 
A list of data extracted is available in appendix E. Studies were evaluated to determine 
whether they accounted for potential confounding factors [body mass index (BMI), age, 
gender, cancer-specific prognostic factors and the use of other anti-DM medications], either 
by demonstrating that there was no significant difference in their distribution between 
treatment groups or by inclusion in multivariable analyses. In order to minimise the potential 
for confounding by DM status, where the comparator included both non-DM patients and DM 
non-metformin users, data based on a DM non-metformin comparator was extracted in 
preference. Where a time-varying covariate was used to model treatment effect, the most 
conservative HR was selected. Where reported, the HR after adjustment for potential 
confounding factors was extracted in preference to an unadjusted value.  
The Newcastle-Ottawa quality assessment scale for cohort studies (NOS) (201) was used to 
evaluate methodological quality. The NOS is a scoring system developed to assess the quality 
of non-randomised studies for use in systematic reviews. It judges studies from three 
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perspectives; the selection of the study groups, the comparability of the groups, and the 
ascertainment of the outcome of interest. Since all eligible studies were of cohort design, this 
scoring system was used for all studies (study scoring is presented in appendix F). 
5.2.5 Statistical Analysis 
The primary outcome of the study was RFS and secondary outcomes were OS and CSS. 
These are all time-to-event outcomes are most appropriately analysed using HRs, which take 
into account of the number and timing of events, and the time until last follow-up for each 
patient who has not experienced an event. Odds ratios (ORs) or relative risks (RRs) do not 
take account of when outcome events occur, only the total number of events, and therefore 
do not account for the maturity of data, or the length of follow-up. Combining OR and/or RR 
from different studies would therefore provide a summary statistic that is both unreliable and 
difficult to interpret. HRs and associated statistics were either extracted directly from the study 
reports, or estimated from the Kaplan-Meier curves by dividing up the curve into a number of 
time intervals to give a representation of event rates over time and calculating a HR using a 
computational spreadsheet using published methods (202-204).  
Where sufficient data were available on outcomes for individual cancer types, a meta-analysis 
was conducted with a primary outcome of RFS and secondary outcomes of OS and CSS. HRs 
were combined across trials using a fixed-effect model. A fixed-effect model was chosen over 
a random-effects model because the former weights trials by their size and allows statistical 
heterogeneity to be tested, whereas the latter weights trials by both size and heterogeneity 
which, with small numbers of studies, can mean small trials have the same weight as large 
trials. With the fixed-effect model, where heterogenity is detected, this can be explored, or the 
reasons for it investigated. Heterogeneity was assessed using the chi-squared (χ2) test and 
the I2 statistic. A random-effects model (DerSimonian and Laird) (205) was used to assess 
whether the results were robust to the choice of model. Probability values were two-sided with 
p<0.05 considered of statistical significance.  
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Analyses were pre-planned to explore whether the size or the direction of the effect of 
metformin therapy varied according to specific study or patient characteristics, including: DM 
status of the comparator group (with and without non-DM patients in the comparator group); 
prostate cancer primary treatment type (prostatectomy or radical radiotherapy) and study 
design. The resulting HR estimates from study group analyses were compared using the χ2 
test for interaction.  
We also planned to explore the impact of metformin dose/exposure on the outcomes 
described above but insufficient data was available. Sensitivity analyses were conducted for 
the primary outcome of RFS. This was carried out according to study quality (restricted to 
studies with a NOS score greater than, or equal to the median); publication type (restricted to 
studies where a full publication was available); setting (restricted to hospital based studies); 
follow-up (restriction of follow-up less than three years); and by the potential confounding 
factors accounted for (restricted to studies that adjusted for BMI, age, gender, cancer-specific 
prognostic factors and other DM medications).  
An additional unplanned exploratory analysis was also conducted according to whether the 
study was from a western (North America or Europe) or non-western population after a wide 
geographical distribution of studies was noted. Study group and sensitivity analyses were only 
conducted where study numbers were sufficient to be meaningful (at least two studies were 
available in each group). Statistical analyses were carried out using STATA version 14. 
 
 
5.3 Results 
Using the search terms described 7,670 reports and conference abstracts were identified and 
screened. 23 full publications and four conference abstracts were identified that met the 
eligibility criteria, comprising of 24,178 participants (206-231). In-order to identify all relevant 
studies investigating metformin, the search strategy also identified studies using the term 
“biguanide”, “neoplasm” or a related term, and included cancer prevention studies, which 
sometimes contain RFS, OS and CSS as secondary outcomes. This identified a large number 
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of articles (6,210) the majority of which were excluded based on their title and/or abstract 
alone. Following full text review, a further 80 articles were excluded, and after qualitative 
synthesis (data extraction), a further nine studies were excluded. The PRISMA study selection 
diagram is shown in figure 5.4.   
All studies identified were retrospective cohort studies except for one prospective cohort study 
embedded in a clinical trial (209). The majority of identified studies examined the effect of 
metformin in one of four tumour types; prostate, colorectal, breast and urothelial cancer 
(transitional cell carcinoma of bladder, kidney or urinary tract) which, therefore, represent the 
main focus of this analysis. 17 studies were based in North America, four in Asia, two in Europe 
and four included patients from more than one continent. 23 studies were hospital based and 
four were population based. A summary of the main characteristics for studies of breast, 
colorectal and prostate cancer is presented in table 5.1, and a table of study characteristics 
for other cancer types is presented in table 5.2.  
Figure 5.4 PRISMA study selection diagram 
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Table 5.1 Main study characteristics: Colorectal, prostate and breast cancer 
Tumour group 
 
Study author 
Patient characteristics Study characteristics 
Comparator   
DM status 
Outcomes 
Definition of 
metformin 
exposure 
Median 
follow-up 
(months) 
Potential confounders 
(R=reported & not significant, M=included in multivariate 
model, x=not assessed, or significant but not adjusted for) 
NOS 
score 
Treatment 
Tumour stage / 
other 
restrictions 
Sample size 
(met/total) 
Article 
type 
Study 
location 
Setting 
(H=Hospital, 
P=Population) 
DM 
Non-
DM 
RFS OS CSS BMI Age Sex 
Cancer 
specific 
variables 
Other DM 
meds 
Colorectal 
adenocarcinoma 
Spillane (206) Not specified I-III 207/315 Full Ireland P ✓ X X ✓ ✓ 
In year before 
diagnosis 
46 X M M M M 7 
Lee, GE (207) Not specified II-III 223/356 Abstract Singapore H ✓ X ✓ ✓ X At diagnosis 78 X M X M X 5 
Lee, JH (208) Not specified III(b) 96/220 Full Korea H ✓ X X ✓ ✓ >6m exposure 41 M(c) M(c) M(c) M(c) M(c) 8 
Singh (209) Not specified 
III 
/colon only 
115/267 Abstract 
USA & 
Canada 
H ✓ X ✓ ✓ X 
Before 
randomisation 
Not 
given 
X M M M X 5 
Zanders (210) Not specified I-III 512/778 Full 
The  
Netherlands 
P ✓ X X ✓ X 
Cumulative 
exposure 
41 X M M M M 7 
Prostate 
Adenocarcinoma 
Allott (211) Prostatectomy Localised 155/369 Full USA H ✓ X ✓ X ✓ At surgery 59/73(a) M M n/a M X 8 
Kaushik (212) Prostatectomy Localised 323/885 Full USA H ✓ X ✓ ✓ X 
In 3months      
before surgery 
61 M M n/a M R 7 
Rieken WJU (232) Prostatectomy Localised 287/6486 Full 
USA & 
Europe 
H X ✓ ✓ X X At surgery 25 X M n/a M n/a 6 
Spratt (214) 
Radical 
radiotherapy 
Localised 157/319 Full USA H ✓ X ✓ ✓ ✓ 
At diagnosis or  
after radiotherapy 
104 R M n/a M R 8 
Margel (215) 
Prostatectomy or 
radical 
radiotherapy 
Localised(b)/  
≥66 years 
old 
Total 955 Full Canada P ✓ X X ✓ ✓ 
Cumulative 
exposure 
56 X M n/a M M 8 
Zannella (216) 
Radical 
radiotherapy 
Localised 114/504 Full Canada H ✓ ✓ ✓ X X 
At time of 
radiotherapy 
82 X R n/a M X 5 
Danzig (217) Prostatectomy Localised 98/767 Full USA H ✓ X ✓ X X At surgery 27 X M n/a M X 6 
Taira (218) Brachytherapy Localised 126/2298 Full USA H ✓ ✓ X ✓ X 
Diagnosis to 
3months after 
brachytherapy 
100 M M n/a M X 7 
Breast 
adenocarcinoma 
Oppong (219) Adjuvant chemo I-III 76/141 Full USA H ✓ X ✓ ✓ X 
Diagnosis to 6 
months after 
87 R M n/a M M 8 
Bayraktar (220) Adjuvant chemo 
I-III / 
triple negative 
63/130 Full USA H ✓ X ✓ ✓ X 
During adjuvant 
chemo 
62 M(d) M n/a M R 8 
Lega (221) 
Breast cancer 
surgery 
Infer I-III 
/ ≥66 years 
868/1774 Full Canada P ✓ X X ✓ ✓ 
Cumulative 
exposure 
54 X M n/a M M 6 
Abbreviations: NOS= Newcastle-Ottawa Quality Assessment Scale for Cohort Studies, BMI= body mass index, met= metformin, N/A= not applicable, 
(a)=metformin/non-metformin, (b)=data from sub-analysis, (c)=main analysis only, (d)= adjustment for body weight, RFS=recurrence-free survival, OS=overall 
survival, CSS=cancer-specific survival 
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Table 5.2. Main study characteristics: Other cancer types 
Tumour group 
Study 
author 
Patient characteristics Study characteristics 
Comparator 
DM status 
Outcomes 
Definition of 
metformin 
exposure 
Median 
follow-up 
(months) 
Potential confounders 
(R=reported & not significant, M=included in 
multivariate model X=not assessed, or significant 
but not adjusted for) NOS 
Score 
Treatment 
Tumour stage 
/ other 
restriction 
Sample 
size 
(met/total) 
Article 
type 
Study 
location 
Setting 
(H=hospital, 
P=population) 
DM 
Non-
DM 
RFS OS CSS BMI Age Sex 
Cancer 
specifi
c 
Other DM 
meds 
Urothelial carcinoma 
Rieken BJU 
(222) 
TURBT 
pTa-pT1 N0 M0 
/urothelial carcinoma 
of bladder (NMI) 
43/1035 Full 
USA & 
Europe 
H X ✓ ✓ ✓ X At surgery 64 X M R M n/a 8 
Rieken UO 
(223) 
Radical surgery 
M0 
/invasive urothelial 
carcinoma of 
bladder 
80/1382 Full 
USA & 
Europe 
H X ✓ ✓ ✓ ✓ At diagnosis 34 M M M M n/a 8 
Rieken EJS 
(213) 
Radical surgery 
M0 / Upper tract 
urothelial carcinoma 
194/2330 Full 
USA, 
Europe   & 
Japan 
H X ✓ ✓ ✓ ✓ At surgery 36 X M M M n/a 6 
Head &neck 
(squamous cell 
carcinoma) 
Kwon (224) 
curative surgery    
or radiotherapy 
No distant   
metastases 
99/1072 Full Korea H X ✓ ✓ ✓ ✓ Ever exposure 65 M M R M n/a 8 
Thompson 
(225) 
Not specified 
Disease free at 3m       
/ oral-oropharynx 
33/78 Full USA H ✓ X ✓ X X Diagnosis  to relapse 44 X R R R X 5 
Renal cell carcinoma 
Hakimi (226) 
partial/radical 
nephrectomy 
T2-T3 N0 M0 55/784 Full USA H ✓ ✓ ✓ X ✓ At surgery 41 M M R M X 6 
Psutka (227) 
partial/radical 
nephrectomy 
Localised 83/200 Full USA H ✓ X ✓ ✓ ✓ 
In 90 days before   
surgery 
97 R M R M X 8 
Pancreatic 
adenocarcinoma 
Ambe (228) Radical surgery Resectable 19/44 Abstract USA H ✓ X X ✓ X At surgery 
Not 
given 
R R R R X 7 
Non-small cell lung 
carcinoma 
Fortune-
Greeley (229) 
Not specified data on stage I-II Not given Abstract USA H ✓ X X ✓ X Not given 
Not 
given 
M M X M X 6 
Endometrial cancer Ko (230) Not specified 
I-IV  (RFS data  
extracted) 
200/363 Full USA H ✓ X ✓ X X At diagnosis 33 R M n/a M R 8 
Gastric cancer Lee, CK (231) Gastrectomy I-III 132/326 Full Korea H ✓ X ✓ ✓ ✓ Cumulative exposure 74 M M M M M 9 
Abbreviations: NOS= Newcastle-Ottawa Quality Assessment Scale for Cohort Studies, BMI= body mass index, met= metformin, N/A= not applicable, NMI=Non-
muscle invasive, TURBT=Transurethral resection of bladder tumour, RFS=recurrence-free survival, OS=overall survival, CSS=cancer-specific survival 
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5.3.1 Colorectal cancer 
Five eligible studies were identified, with a total of 1,936 colorectal cancer patients. RFS was 
assessed in two studies (623 patients), OS in all five studies (1,936 patients), and CSS in two 
studies (535 patients). Overall, metformin use appeared to demonstrate significant 
improvements in RFS (HR 0.63, CI 0.47-0.85), OS (HR 0.69, CI 0.58-0.83) and CSS (HR 0.58, 
CI 0.39-0.86) (figure 5.5), although there was variation between the results of the individual 
studies for RFS (I2=83.1%, p=0.015) and OS (I2=82.3 p<0.001). When the random effects 
model was applied, the benefits seen for both OS (HR 0.62, CI 0.40-0.97) and CSS (HR 0.58, 
CI 0.39-0.86) remained but there was no longer a significant benefit of metformin on RFS (HR 
0.62, CI 0.30-1.29). In an unplanned exploratory analysis that grouped studies with western 
and non-western populations separately we found there was a significant interaction between 
the effect of metformin on OS and the population studied (χ2 = 14.31, p<0.001). In studies in 
non-western populations, there was a highly significant benefit of metformin on OS (HR 0.36, 
CI 0.25-0.53) however there was evidence of heterogeneity (I2=85.8% p=0.013). In studies 
with western populations, only a trend towards a significant effect was identified (OS HR 0.84, 
CI 0.68-1.03) with no clear evidence of heterogeneity (I2=4.6% p=0.350). In planned sensitivity 
analyses, there appeared to be a larger relative benefit of metformin on OS when analyses 
were restricted to studies that had follow-up of greater than three years (HR 0.64, CI 0.52-
0.78). Insufficient data were available to explore the impact of dose or duration on the effect 
of metformin. Details of study group and sensitivity analyses for all tumour types are available 
in table 5.4. 
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Figure 5.5 Meta-analysis of early stage colorectal cancer outcomes according to 
metformin use 
 
5.3.2 Prostate cancer 
Eight eligible studies were identified, with a total of 12,583 prostate cancer patients. RFS was 
assessed in six studies (9,330 patients), OS in four studies (4,457 patients), and CSS in three 
studies (1,643 patients). Metformin use demonstrated a borderline significant improvement in 
RFS (HR 0.83, CI 0.69-1.00), and significant improvements in OS (HR 0.82, CI 0.73-0.93) and 
CSS (HR 0.58, CI 0.37-0.93) (figure 4.6), however the relationship was inconsistent across 
studies (RFS I2=64.8%, p=0.014; OS I2=87.3% p<0.001; CSS I2=75.3% p=0.017), which was 
reflected when the random effects model was applied (RFS HR 0.80, CI 0.57-1.13; OS 0.69, 
CI 0.44-1.10; CSS 0.64, CI 0.19-2.12). In a pre-specified analysis, there was significant 
interaction between the effect of metformin and the primary treatment type on RFS (χ2 test for 
interaction 9.03, p=0.003). For patients receiving radical radiotherapy (214, 216) there was a 
Cancer-specific survival
Overall survival
Recurrence
study
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Subtotal (I-squared = 0.0%, p = 0.757)
Spillane(206)
Lee, Jin Ha(208)
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Singh(209)
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Lee, Jin Ha(208)
Lee, Guek Eng(207)
Subtotal (I-squared = 83.1%, p = 0.015)
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Hazard ratio
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Figure 2: Colorectal cancer outcomes according to metformin use
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significant benefit from metformin (HR 0.45, CI 0.29-0.70), whereas no significant benefit was 
seen for patients who underwent radical prostatectomy (HR 0.94, CI 0.77-1.15) (figure 5.7). 
Only a single study was able to provide data on OS and CSS in those having radical 
radiotherapy, however significant improvements were seen in both (OS 0.44, CI 0.27-0.72; 
CSS 0.19, CI 0.06-0.63) (214). There was no evidence of an interaction between the effect of 
metformin on RFS and the presence or absence of non-DM patients in the comparator group 
(χ2 = 0.49, p=0.48). In planned sensitivity analyses, there appeared to be a larger relative 
benefit of metformin on RFS when analyses were restricted to studies that had a follow-up of 
greater than three years (HR 0.77 CI 0.62-0.96) or considered other DM medications in their 
analysis (HR 0.79 CI 0.64-0.98), however, insufficient data were available to explore the 
impact of dose or duration on the effect of metformin. 
 
Figure 5.6 Meta-analysis of early stage prostate outcomes according to metformin use 
 
 
Footnotes: (a) Hazard ratios for Taira et.al. (218) were estimated from Kaplan Meier curves and 
summary statistics using published methods (202-204). 
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Figure 3: Prostate cancer outcomes according to metformin use
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Figure 5.7 Meta-analysis of prostate cancer recurrence-free survival according to 
metformin use by primary treatment  
 
 
5.3.3 Breast cancer 
Three eligible studies were identified, with a total of 2,045 breast cancer patients. RFS was 
assessed in two studies containing 271 patients and OS in all three studies (2,045 patients). 
Metformin demonstrated a trend towards improvement in RFS (HR 0.77, CI 0.49-1.22) (figure 
5.8), however no effect was seen in OS (HR 0.99, CI 0.92-1.05). There was no evidence of 
variation between the results of the studies either for RFS (I2=0.0% p=0.74) or OS (I2=0.0% 
p=0.75). As CSS was only available for one study containing 1,774 patients, no meta-analysis 
was possible for this outcome, however in this study, metformin did not appear to have an 
impact on CSS (HR 1.01, CI 0.86-1.19). There were insufficient study numbers for any 
meaningful study group or sensitivity analyses. 
  
Heterogeneity between groups: p = 0.003
Radical radiotherapy
Radical prostatectomy
study
Treatment and
Overall (I-squared = 64.8%, p = 0.014)
Subtotal (I-squared = 32.1%, p = 0.225)
Spratt(214)
Zannella(216)
Subtotal (I-squared = 19.1%, p = 0.295)
Danzig(217)
Allott(211)
Kaushik(212)
Rieken WJU(232)
(95% CI)
Hazard ratio
0.83 (0.69, 1.00)
0.45 (0.29, 0.70)
0.50 (0.31, 0.81)
0.23 (0.07, 0.73)
0.94 (0.77, 1.15)
1.90 (0.89, 4.06)
0.93 (0.61, 1.41)
0.91 (0.67, 1.24)
0.84 (0.58, 1.22)
Favours metformin  Favours no metformin
.125 .25 .5 1 2 4 8
 Figure 4: Prostate cancer recurrence-free survival according to metformin use
 for different treatment groups
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Figure 5.8 Meta-analysis of early stage breast cancer outcomes according to 
metformin use 
 
 
 
5.3.4 Urothelial Cancer 
Three studies were identified and included patients with upper tract urothelial carcinoma, and 
urothelial carcinoma of the bladder. RFS and OS was assessed in all three studies including 
4,747 patients. Two studies assessed CSS including 3,712 patients. There was no clear 
evidence that metformin improved either RFS (HR 0.91, CI 0.73-1.14), OS (HR 0.94, CI 0.76-
1.16) or CSS (HR 0.88, CI 0.66-1.17) (figure 5.9). Although there was some evidence of 
inconsistency between the results of studies for both RFS (I2=59.0% p=0.087) and OS (I2-
51.5% p=0.127), the results did not change significantly when the random-effects model was 
applied (RFS HR 0.84, CI 0.57-1.24; OS HR 1.00, CI 0.72-1.39; CSS HR 0.88 CI 0.66-1.17). 
There were insufficient study numbers for any meaningful study group or sensitivity analyses. 
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Figure 5: Breast cancer outcomes according to metformin use
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Figure 5.9 Meta-analysis of early stage urothelial cancer outcomes according to 
metformin use 
 
5.3.5 Other cancer types 
There were insufficient studies identified to warrant meta-analyses for other cancer types, the 
findings of which are presented in table 5.3. In head and neck cancer, a positive trend towards 
improved RFS and CSS was seen in one study (224), but there was no effect on OS. However, 
the second study identified showed a potential detriment of metformin use on RFS(225). In 
renal cell carcinoma, two studies were identified, both showing a non-significant inverse 
relationship with metformin use and RFS, and no significant benefit in OS or CSS. Single 
studies were identified showing a significant improvement in OS in lung cancer, RFS and OS 
in endometrial cancer and RFS, OS and CSS in gastric cancer. A small single study in 
pancreatic cancer did not suggest any effect of metformin, however this study had a very small 
sample size. 
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Figure 6: Urothelial cancer outcomes according to metformin use
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Table 5.3 Early stage cancer outcomes by metformin use for tumour types with limited 
numbers of studies 
 
Tumour 
group 
Study author Sample size Recurrence-free 
survival 
 HR (95% CI) 
Overall survival 
HR (95% CI) 
Cancer-specific 
survival 
HR (95% CI) 
Head and 
neck  
Kwon (224)  1072 0.76 (0.49-1.21) 0.95 (0.59-1.50) 0.79 (0.42-1.50) 
Thompson 
(225)  
78 1.26 (0.62-2.56) - - 
Renal cell 
carcinoma 
Hakimi (226) 784 1.22 (0.66-2.27) - 0.76 (0.21-2.70) 
Psutka (227) 200 1.07 (0.61-1.88) 0.74 (0.48-1.15) 0.83 (0.41-1.67) 
Pancreas Ambe (228) 44 - 0.54 (0.16-1.68) - 
Lung Fortune (229) Not given by stage - 0.85 (0.77-0.93) - 
Endometrial Ko (230)  363 0.56 (0.34-0.91) 0.43 (0.24-0.77) - 
Gastric 
Lee, CK (231) 
(a) 
326 0.86 (0.80-0.94) 0.87 (0.80-0.95) 0.87 (0.78-0.96) 
Footnote: (a)HR for each 6 months of metformin use 
 
5.3.6 Duration and dose 
 The impact of different exposures to metformin on early-stage cancer outcomes is examined 
in some of the identified studies, however limited data, and differences in the methods used 
to investigate exposure, preclude any study-group analyses.  In colorectal cancer, Spillane et 
al. (206) conducted additional analyses on dose intensity and found survival benefits for high-
intensity metformin users not using other diabetic therapies (CSS HR 0.44, CI 0.20-0.95; OS 
HR 0.41, CI 0.24-0.70), but no significant benefits were identified in other sub-groups. In 
gastric cancer, Lee et al. (231) found that increased cumulative duration of metformin use 
improved cancer-specific and all-cause mortality. Single studies in colorectal (210) and 
prostate cancer (211) also investigated the impact of different exposures to metformin but 
found no significant associations. 
  
126 
 
Table 5.4 Sub group and sensitivity analyses 
  
Restriction Study group RFS OS CSS 
Colorectal cancer 
All HR Lee GE, Singh 
HR=0.63 (0.47, 0.85), p=0.002 
Lee GE, Lee GH, Spillane, Singh, Zanders 
HR=0.69 (0.58, 0.83), p<0.001 
Lee JH, Spillane 
HR=0.58 (0.39, 0.86), p=0.006 
NOS<7 (median) HR x Lee GH, Spillane, Zanders 
HR=0.75 (0.61, 0.94), p=0.011 (hetero p=0.301) 
x 
Without abstracts HR x Lee GH, Spillane, Zanders 
HR=0.75 (0.61, 0.94), p=0.011 (hetero p=0.301) 
x 
Without western 
patients  
(not North America, 
Europe) 
Western 
population 
x Western (Spillane, Singh, Zanders): 
HR=0.839 (0.682, 1.033), p=0.097 (hetero p=0.350) 
x 
Non-western 
population 
x Non-West (Lee GE, Lee GH): 
HR=0.362 (0.247, 0.531), p<0.001 (hetero p=0.013) 
x 
Interaction x Chi-squared=14.31, p<0.001 x 
Without population 
setting 
HR x Lee GE, Lee GH, Singh 
Hr=0.58 (0.43, 0.76), p<0.001 (hetero p<0.001 
x 
<36 months HR x Lee GE, Lee GH, Spillane, Zanders 
HR=0.64 (0.52, 0.78), p<0.001 (hetero  p<0.001) 
x 
Sex HR x Lee GH, Spillane, Singh, Zanders 
HR=0.80 (0.66, 0.97), p=0.023 (hetero p=0.295) 
x 
Other DM Meds HR x Lee GH, Spillane, Zanders 
HR=0.75 (0.61, 0.94), p=0.011 (hetero p=0.301) 
x 
Prostate cancer 
All HR Spratt, Zannella, Rieken WJU, Kaushik, Allott, Danzig 
HR=0.83 (0.69, 1.00), p=0.044 
Spratt, Taira, Margel, Kaushik 
HR=0.82 (0.73, 0.94), p=0.003 
Spratt, Margel, Allott 
HR=0.58 (0.37, 0.93), p=0.023 
Comparator group DM only control Spratt, Kaushik, Allott, Danzig 
HR=0.863 (0.698, 1.066), p=0.171 (hetero p=0.025) 
x x 
 Mixed or 
 non-DM control 
(Zannella, Rieken WJU) 
HR=0.744 (0.522, 1.060), p=0.102 (hetero p=0.037) 
 
x 
x 
 Interaction Chi-squared = 0.49, p=0.483 x x 
NOS<7 (median) HR Spratt, Kaushik, Allott  
HR=0.807 (0.647, 1.006), p=0.057  (hetero p=0.089) 
x x 
Without population 
setting 
HR x Spratt, Taira, Kaushik 
HR=0.577 (0.455, 0.731), p<0.001 (hetero p=0.003) 
Spratt, Allott 
HR=0.570 (0.227, 1.431), p=0.231 (hetero p=0.004) 
<36 months HR Spratt, Zannella, Kaushik, Allott 
HR=0.772 (0.622, 0.959), p=0.019 (hetero p=0.027) 
x x 
BMI HR Spratt, Kaushik, Allott, 
HR=0.807 (0.647, 1.006), p=0,057 (hetero p=0.089) 
Spratt, Taira, Kaushik 
HR=0.577 (0.455, 0.731), p<0.001 (hetero p=0.003) 
Spratt, Allott 
HR=0.570 (0.227, 1.431), p=0.231 (hetero p=0.004) 
Other DM Meds HR Spratt, Rieken WJU, Kaushik 
HR=0.788 (0.637, 0.975), p=0.028 (hetero p=0.111)  
Spratt, Margel, Kaushik 
HR=0.910 (0.793, 1.044), p=0.178 (hetero p=0.008) 
Spratt, Margel 
HR=0.487 (0.299, 0.795) (hetero p=0.089) 
Footnotes: Study group analyses are only presented where there are two or more studies in each group. X= insufficient study numbers for study group 
analysis. Sensitivity analyses are only presented where there are two or more studies after restriction. The fixed effect model is used for all analyses. 
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Table 5.4 continued. 
 
Restriction Study group RFS OS CSS 
Breast cancer 
All HR Bayraktar, Oppong 
HR=0.77 (0.49, 1.22), p=0.263 
Bayraktar, Oppong, Lega 
HR=0.99 (0.93, 1.05) 
Lega 
HR=1.01 (0.86, 1.19), p=0.907 
NOS<7 (median) HR x Bayraktar, Oppong 
HR=0.81 (0.49, 1.35), p=0.426 (hetero p=0.964 
x 
Without population 
setting 
HR x Bayraktar, Oppong 
HR=0.81 (0.49, 1.35), p=0.426 (hetero p=0.964 
x 
BMI HR x Bayraktar, Oppong 
HR=0.81 (0.49, 1.35), p=0.426 (hetero p=0.964 
x 
Urothelial cancer 
All HR Reiken BJU, Reiken EJS, Reiken UO 
HR=0.91 (0.73, 1.14), p=0.414 
Reiken BJU, Reiken EJS, Reiken UO 
HR=0.94 (0.76, 1.16), p=0.549 
Reiken EJS, Reiken UO 
HR=0.88 (0.66, 1.17), p=0.361 
NOS<7 (median) HR Reiken BJU, Reiken UO 
HR=0.77 (0.54, 1.09), p=0.140 (hetero p=0.068) 
Reiken BJU, Reiken UO 
HR=1.16 (0.84, 1.61), p=0.378 (hetero p=0.234) 
x 
<36 months HR Reiken BJU, Reiken EJS 
HR=0.89 (0.68, 1.17), p=0.397 (hetero  p=0.029) 
Reiken BJU, Reiken EJS 
HR=0.92 (0.72, 1.17), p=0.506 (hetero p=0.044) 
x 
Footnotes: Study group analyses are only presented where there are two or more studies in each group. X= insufficient study numbers for study group 
analysis. Sensitivity analyses are only presented where there are two or more studies after restriction. The fixed effect model is used for all analyses. 
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5.4 Discussion 
This analysis suggests that metformin could be a useful adjuvant agent, particularly in 
colorectal and prostate cancer. The number of studies identified for each tumour type is likely 
to reflect the incidence and demographics of the disease, particularly the likelihood of 
presentation with early stage disease and a diagnosis of DM, for example, a large proportion 
of patents colorectal and prostate cancer present at an early stage of disease, this is also the 
case for breast cancer patients, but presentation is often a younger age where DM is less 
prevalent. 
 The variation in the adjuvant effects of metformin according to tumour type could be explained 
by differences in both patient characteristics and tumour biology. As outlined in the introduction 
to this chapter, the effect of metformin on AMPK signalling has been hypothesised to be a 
major pathway through which metformin exerts its anti-cancer effects (185). AMPK signalling 
dysregulation is also associated with metabolic syndrome (156). Metabolic syndrome is also 
known to increase the risk of developing some cancers, particularly colorectal cancer (233), 
where it is also associated with poorer recurrence and survival outcomes (234). In addition 
metabolic syndrome is known to develop as a consequence of androgen deprivation therapy 
in men with prostate cancer (235). Metformin may improve OS by reducing the number of 
cardiovascular deaths associated with metabolic syndrome, however the improvements in 
RFS and CSS identified suggest an anti-cancer effect. In prostate cancer the study group 
analysis suggests that the beneficial effects of metformin use could be limited to those 
undergoing radical radiotherapy. The AMPK pathway is known to play a role in regulating 
cellular responses to radiotherapy (236) and studies in xenograft mice models suggest that 
metformin can improve tumour oxygenation and therefore radiation response (216).   
The limitations of this meta-analysis include the inherent weaknesses of observational data, 
particularly potential measurement errors in the exposure to metformin, and variation in the 
definition of metformin use, and the risk of time related biases (237). For example, if metformin 
was started at a time after diagnosis of cancer, there will not be any deaths during that period 
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(otherwise they would not have been recorded as starting metformin), which prevents early 
deaths being recorded in metformin users who started after cancer diagnosis. This could bias 
results and underestimate the risk of death in metformin users (representing immortal time 
bias). A high degree of variation between the results of studies was observed for a number of 
the outcomes investigated in most of the cancer types. Sensitivity analyses were designed to 
explore possible reasons for this to inform future observational and clinical trial design, 
however only a small number of analyses were possible due to insufficient study numbers.  
For both prostate and colorectal cancer, the relative effect size appeared to increase for 
studies with follow-up of three years or greater, highlighting the importance of ensuring 
adequate duration of follow-up in future studies. Similarities have been seen in studies of 
aspirin, where greater benefits have been seen with longer follow-up (90, 92, 93). A limited 
number of studies investigated the relation with frequency, dose and duration of metformin in 
early stage cancer, however findings are inconsistent and further research is required to better 
understand this relationship. 
Previous studies have suggested that a diagnosis of DM has a negative impact on cancer 
outcomes (238, 239), in an analysis of 97 prospective cohort studies, patients with DM had a 
25% increased risk of death from cancer, HR 1.25 (95% CI, 1.19-1.31), compared to those 
without (240). Therefore, inclusion of non-DM patients in comparator groups could 
underestimate the beneficial effect of metformin. Owing to insufficient study numbers, it was 
only possible to analyse the effect of the presence or absence of non-DM patients in the 
comparator group for RFS in prostate cancer, where no evidence for an effect was found.  
5.4.1 Observational data in the cancer primary prevention and treatment setting 
Previous meta-analyses have examined the role of metformin in the primary prevention of 
cancer, where it was found to significantly reduce overall cancer incidence, however findings 
were inconsistent when individual tumour types were considered (241-245) again suggesting 
analyses are best conduced for individual tumour types separately. Benefits in the primary 
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prevention, or advanced setting do not necessarily translate to utility in the adjuvant setting as 
the mechanism of action may be different. A systematic search using MEDLINE identified a 
number of meta-analyses which have investigated the effect of metformin use across all 
stages in a number of individual tumour types (246-253). Table 5.5 describes the results of 
previous meta-analyses on the effect of metformin on cancer outcomes across all stages for 
individual tumour types. 
Table 5.5 Results from other meta-analyses of the effect of metformin across all stages 
for individual tumour types 
 
Tumour 
type 
Overall Survival 
Effect size  (95% confidence interval) 
Zhang 
(246) 
(relative risk) 
Lega 
(247) 
Yin  
(248) 
Mei 
(249) 
Raval 
(250) 
Stopsack 
(251) 
Yu 
(252) 
Xu 
(253) 
Breast RR 0.70,  
(0.55-0.88) 
HR 0.81, 
(0.64-1.04) 
HR 0.94,  
(0.90-0.99) 
x x x x HR 0.53, 
(0.39-0.71) 
Colorectal RR 0.70,  
(0.59-0.84) 
HR 0.65, 
(0.56-0.76) 
HR 0.65, 
(0.56-0.77) 
HR 0.56, 
(0.41-0.77) 
x x x x 
Prostate x HR 0.73, 
(0.51-1.06) 
HR 0.68,  
(0.51-0.90) 
x HR 0.86, 
(0.67-1.10) 
HR 0.88, 
(0.86-0.90) 
HR 0.86, 
(0.64-1.14) 
x 
Tumour 
type 
Cancer-specific survival 
Effect size (95% confidence interval) 
Breast x x HR 0.88,  
(0.79-0.99) 
x x x x  HR 0.89, 
(0.79-1.00) 
Colorectal x x HR 0.66, 
(0.50-0.87) 
HR 0.66, 
(0.50-0.87) 
x x x x 
Prostate x x x x HR 0.76, 
(0.43-1.33) 
HR 0.76,  
(0.44-1.31) 
x x 
        Statistically significant benefit                         No statisticially signficiant benefit found 
 
In colorectal cancer, four meta-analyses have examined the effect on OS (246-249), two of 
which also investigated colorectal CSS (248, 249). All meta-analyses identified significant 
improvements in these outcomes which is consistent with the findings of this study. For 
prostate cancer, findings are less consistent. Five meta-analyses have examined the effect of 
metformin on OS (247, 248, 250-252), two of which also investigated prostate CSS (250, 251). 
Only two meta-analyses identified a significant benefit in OS (248, 251), with no benefit 
identified in prostate CSS. This differs from the findings of this study where significant benefits 
in OS and prostate CSS were identified, which could suggest that metformin is better suited 
to the adjuvant setting for prostate cancer. 
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In breast cancer four meta-analyses examined OS (246-248, 253), two of which investigated 
breast CSS. Two meta-analyses identified a significant benefit in OS (246, 248, 253), the other 
approached significance (HR 0.81, CI 0.64-1.04) (247), and the two meta-analyses 
investigating breast CSS also showed significant improvements (248, 253). This differs from 
the findings of this study where no significant benefit in OS and breast CSS was identified. 
This could suggest that metformin may be effective in those with established breast cancer 
which is consistent with the findings of breast cancer window studies where direct anti-tumour 
effects have been identified (196, 197). 
5.4.2 Randomised evidence 
We systematically searched the clinicaltrials.gov database for phase III trials investigating the 
effect of metformin on cancer, and while no phase III trials have reported to date, a number 
were ongoing. In colorectal cancer, a phase III trial of metformin versus standard care 
assessing recurrence and survival in stage III disease is now in set-up in South Korea 
(NCT02614339). In prostate cancer, the Metformin Active Surveillance Trial (NCT01864096), 
an ongoing randomised, phase III trial of metformin versus placebo given before primary 
therapy is assessing time to progression in men with low risk prostate cancer. The 
STAMPEDE trial (NCT00268476), a multi-arm multi-stage randomised controlled trial 
investigating a number of agents in the treatment of hormone-naïve, high risk, localised and 
metastatic prostate cancer, is investigating whether the addition of metformin improves 
survival in this group.  
In breast cancer, the results did not identify any meaningful benefit of metformin use in the 
adjuvant setting, however this could be due to the limited number of studies identified. 
Additional supporting data are available in the primary prevention and treatment setting 
(across all stages), where meta-analyses have shown a beneficial effect (246, 248, 253, 254). 
A randomised phase III trial of metformin versus placebo assessing recurrence and survival 
in early stage breast cancer has recently completed recruitment (MA-32, NCT01101438), and 
interim biomarker analysis has reported a small reduction in fasting insulin levels, C-reactive 
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protein (a marker of inflammation) and weight in the metformin arm (255), and the main results 
are awaited. 
5.4.3 Safety data 
Metformin has been in continuous clinical use for five decades, consequently, it has a well-
defined safety profile and has been administered alongside most cancer treatments without 
the emergence of any important interactions. Common adverse effects associated with 
metformin in those with DM are almost entirely related to the gastrointestinal tract and include 
nausea, abdominal discomfort, and diarrhoea, but these side-effects are usually mild, transient 
and self-limiting. Animal studies suggest the gastrointestinal tract accumulates higher 
concentrations of metformin than any other tissue (256), which may account for this toxicity 
profile, (and may also explain the activity seen in those with colorectal cancer). These side-
effects are not thought to compromise safety and are minimised by starting a low dose and 
slowly increasing.  
Historically there have been concerns about the association between metformin and lactic 
acidosis, (build-up of lactate which is a life-threatening medical emergency). Recent meta-
analyses have shown that the risk of lactic acidosis is very low when metformin is prescribed 
according to its contraindications, particularly renal dysfunction (creatinine clearance greater 
than 60 mL/min), or any acute conditions with the potential to alter renal function. The 
incidence of lactic acidosis with metformin use is approximately 9/100,000 patient years of 
metformin treatment (257).  
The glucose lowering properties of metformin do not occur as a result of increased insulin 
levels, but rather, metformin is associated with a reduction in insulin levels, and consequently 
does not cause overt hypoglycaemia in patients without DM. Data on the toxicity profile of 
metformin in those without DM is already available from clinical trials investigating its role as 
a treatment for polycystic ovarian syndrome, metabolic syndrome, weight-loss and DM 
prevention and is thought to be similar to those with DM (181, 258, 259). A key consideration 
of metformin use in the adjuvant cancer setting is that metformin is generally discontinued 
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prior to, or at the time of CT (computed tomography) scans and restarted 48 hours later as 
iodinated contrast can cause renal failure, could cause lactic acidosis (260).  
 
5.5 Incorporating metformin as an intervention in the Add-Aspirin trial 
The Add-Aspirin trial has the potential to investigate additional agent(s) within the same 
platform, thus maximising the utilisation of participant and operational resources to evaluate 
further potential adjuvant anti-cancer treatment(s). Any potential additional intervention would 
need to have sufficient supporting evidence to justify its inclusion, and not impact on the safety 
or integrity of the original trial. The design of Add-Aspirin would need to be adapted such that 
its ability to answer its original research questions would not be compromised.  
Of the four Add-Aspirin tumour cohorts, this meta-analysis suggests that metformin may be a 
useful adjuvant therapy in colorectal and prostate cancer. A treatment effect in breast and 
gastro-oesophageal cancer in the adjuvant setting has not been excluded, however the 
availability of supporting evidence at this time is limited. In the adjuvant breast cancer setting 
the findings of the MA-32 trial will provide further insight. The addition of a second intervention 
in some, but not all cohorts, or even different second interventions in individual cohorts, could 
be possible, provided impact on existing outcomes that span cohorts, (for example 
cardiovascular outcomes or combined OS at 15 years) are considered carefully.  
5.5.1 Metformin dose and formulation 
Data on the relationship between metformin dose and its anti-cancer effect is limited, however, 
when used as a treatment for DM, the dose of metformin is increased gradually over several 
weeks to minimise the risk of gastro-intestinal side effects and titrated according to glycaemic 
control up to 2000mg per day (148). The optimal schedule to maximise tolerability and 
minimise gastro-intestinal side-effects, where the treatment aim is not glycaemic control, is 
unknown, however, a common regimen used in a number of other trials of patients without 
DM (STAMPEDE trial, NCT00268476 and MA-32 trial NCT01101438) is 850mg once daily, 
increasing to 850mg twice daily if tolerated after 4-6 weeks, and reducing to 750mg then 
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500mg once daily where side-effects develop. Metformin is also available in an extended 
release formulation which would be advantageous in a randomised controlled trial as it allows 
once daily dosing, is thought to reduce gastro-intestinal toxicity (261, 262), and as such, could 
improve adherence. A major drawback is the price difference between extended release 
tablets and the immediate release formulation, at twelve pence compared to two pence per 
tablet (500mg) respectively (current NHS listing price) (112), which could be problematic 
without pharmaceutical industry support.  
5.5.2 Eligibility and DM status 
The Add-Aspirin trial includes patients both with and without DM. While some window studies 
have suggested an anti-cancer effect in individuals without DM, existing observational 
evidence (including this meta-analysis) is only available in those with DM. There is no 
evidence to suggest that metformin is not efficacious as an adjuvant cancer therapy in those 
without DM, however this remains an unproven assumption. Investigating metformin in a 
phase III trial in those with DM only is not feasible because randomising a patient with DM to 
not receive metformin, where it is currently indicated, or may become indicated, would be 
unethical. One approach could be to have a second randomisation to metformin for patients 
without DM only.  
5.5.3 Safety considerations 
Following prescribing information and current National Institute for Health and Care 
Excellence (NICE) guidelines, metformin would need to be interrupted for the following 
reasons: 
• Deterioration of renal function below 30 ml/min/1.73m2 (with an estimated glomerular 
filtration rate (eGFR) below 45 ml/min/1.73m2, the dose of metformin should be 
reviewed) 
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• Any risk of tissue hypoxia, such as severe infection, shock, sepsis, acute heart failure, 
respiratory failure or hepatic impairment, or those who have recently had a myocardial 
infarction  
• 48 hours before a scheduled surveillance CT scan or colonoscopies in the colorectal 
cohort, and CT scans investigating recurrence in both colorectal and prostate cohorts, 
and until renal function is confirmed as within normal limits afterwards 
5.5.4 Potential biomarkers  
High BMI at the time of diagnosis of many cancer types is associated with increased all-cause 
mortality (263). The influence of obesity on the anti-cancer effects of metformin are unknown, 
however, obesity is associated with chronic inflammation (264), and is one of the potential 
mechanisms for its anti-cancer effects and could represent an important biomarker.  
The metabolic effects of metformin could differ in patients with an underlying impaired glucose 
tolerance. By performing a glucose tolerance test at baseline, as well as a glycosylated 
haemoglobin level (HbA1c) level, would allow this potential biomarker to be investigated. 
Stratification by BMI, glucose tolerance, and HbA1c would also ensure that this potential 
confounding factor is evenly distributed between arms.  
5.5.5 Trial conduct methodology for incorporating metformin into the Add-Aspirin trial 
Applying a run-in period to metformin could help select a population that is able to tolerate and 
adhere to metformin, particularly as both aspirin and metformin cause gastrointestinal side-
effects. A run-in period would also allow the dose of metformin to be titrated to a tolerated 
dose. If a placebo-control for metformin was used, this would also need to be titrated up, 
making the use of a placebo-control impractical. There are no known interactions between 
aspirin and metformin and their mechanisms are thought to be independent, so metformin 
could be added as a three by two factorial design, with the following arms (table 5.6): 
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Table 5.6 Potential factorial design for the incorporation of metformin into the Add-
Aspirin trial 
 
  Aspirin 300mg  +  metformin 
    Aspirin 300mg  +  Placebo 
(metformin) 
   Aspirin 100mg  +  
metformin 
    Aspirin 100mg  +  Placebo 
(metformin) 
Placebo (aspirin)  +  
metformin 
Placebo (aspirin)  +  Placebo 
(metformin) 
 
 
The aim of this design would aim to answer the following questions: 
1) The efficacy of aspirin 
2) The efficacy of aspirin according to dose 
3) The efficacy of metformin 
4) The efficacy of metformin and aspirin together 
There is a precedent for trials investigating aspirin alongside other interventions using a 
factorial design. In the Canadian transient ischaemic attack study aspirin with sulfinpyrazone 
were examined individually, together and with placebo (265) and the Physicians’ Health Study 
compared aspirin and beta carotene individually, together and with placebo (266).  
 
5.6 Conclusions  
The findings of this meta-analysis support the concept of randomised clinical trials using 
metformin in the adjuvant setting, with the strongest supporting evidence in colorectal and 
prostate cancer, particularly those treated with radical radiotherapy. Such trials could also 
further the understanding of the relationships between cancer outcomes and the dose and 
duration of metformin. There are no ongoing adjuvant phase III trials of metformin in prostate 
cancer, or colorectal cancer in western populations. The addition of metformin as a second 
randomisation in the Add-Aspirin colorectal and prostate cancer cohorts has the potential to 
evaluate a second established medicine as an adjuvant cancer therapy.  
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A systematic review and meta-analysis found that adjuvant metformin use was associated 
with significant improvements in cancer outcomes for early stage colorectal and prostate 
cancer and phase III trials of metformin in these tumour types are advocated. Research into 
the design and conduct of the Add-Aspirin trial showed that opening a large phase III basket 
trial with an active run-in period is feasible, and identifies key challenges, as well as potential 
solutions which are now adopted into the design and delivery of the trial.  
This chapter summarises the lessons learnt about both the early and later stages of the 
repurposing process from metformin and aspirin, which could be applied to overcome similar 
challenges in evaluating other established drugs as cancer therapies in the future. The 
potential barriers to implementing repurposed medicines into standard practice and future 
research directions are also discussed. 
 
6.1 The early stages of the repurposing process 
6.1.1 Pre-clinical data 
For aspirin and metformin, some of the preliminary steps of the drug development pathway 
such as target identification, compound discovery and chemical optimisation (ADMET) 
(section 1.3) were not undertaken because their development pre-dated the molecular era of 
drug discovery. The absence of these steps has resulted in uncertainty surrounding 
mechanisms of action for both drugs (sections 1.5.1 and 5.1.2), and therefore optimal dosing. 
For example, the dose of aspirin required for an anti-platelet mechanism is likely to be less 
than that required for one based on direct tissue effects (51).  
An unknown mechanism of action also results in difficulty identifying biomarkers for response 
and toxicity. For aspirin, proposed biomarkers involving a direct tissue effect include tumour 
COX-2 expression (71) and PIK3CA mutation status (102), and for an anti-platelet mechanism, 
Chapter 6: Conclusions and future work 
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potential biomarkers such as urinary 11-dehydro-thromboxane B2 (TBX2) levels are proposed 
(51). For metformin, there are several potential biomarkers that are dependent on a 
mechanism involving alterations in glucose metabolism (172), such as BMI, baseline glucose 
tolerance, HbA1c, and c-peptide levels, whereas others such as TNF-α and IL-6 (inflammatory 
cytokines) rely on an anti-inflammatory mechanism (182). 
In-vitro and in-vivo studies on aspirin and metformin provide evidence supporting potential 
mechanisms of action, biomarkers, and possible resistance mechanisms, however many of 
the pre-clinical studies identified failed to appraise whether biologically relevant concentrations 
of the drug were used, and therefore if the effect could be tenable in humans. Mechanistic 
understanding from the early steps of de-novo drug development are likely to be more robust, 
than for older established medicines. Additional pre-clinical research, with a programme of 
mechanistic studies conducted in parallel to phase III trials will be an essential part of the 
repurposing process for other established medicines with potential anti-cancer effects. 
6.1.2 Observational data 
A large number of observational studies investigating the anti-cancer effects of aspirin and 
metformin were identified, with a greater number for aspirin. This is likely to reflect that aspirin 
use is more common than metformin use and that the anti-cancer effects of aspirin were 
proposed a longer time ago. It is very possible that other established medicines in non-cancer 
indications have anti-cancer activity. For newly emerging candidates for repurposing, 
particularly those in less common use, it will take longer for a sufficient number of adequately 
powered observational studies to accumulate for a robust systematic review and meta-
analysis. Collaborative working by research groups across different populations, could be 
used to generate sufficient power to investigate the anti-cancer effects of less commonly used 
medications, particularly if common data collection fields and methods could be agreed.  
Data on concomitant medication use collected within randomised clinical trials can provide an 
alternative source of observational evidence, providing reliable data on cancer outcomes 
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linked to prospective data on medication exposure. Collection of concomitant medication data 
was shown to be feasible for a limited number of medications in the Add-Aspirin trial (section 
4.1.4 and 4.3.4). By establishing collaborations to standardise the way concomitant 
medication data is collected in clinical trials, this form of observational data could allow 
research into the anti-cancer properties of less commonly used medicines. 
In this thesis the observational evidence supporting the anti-cancer effects of aspirin was 
analysed separately for the cancer prevention, adjuvant and advanced setting as the 
underlying mechanism, and therefore treatment effect, could differ between them. This 
principle was also applied in the methods of the systematic review and meta-analysis of 
metformin. In reality, there is overlap between treatment settings for each individual patient. 
For example, for an adjuvant cancer patient, there would be an adjuvant treatment effect, the 
potential to prevent second primary cancers and, in the event of cancer recurrence, the 
opportunity to delay disease progression. Outcomes such as OS and CSS have the potential 
to be influenced by drug activity in all three settings and therefore it is difficult to evaluate these 
separately in observational data. Phase III trials are needed to provide this information by 
incorporating trial outcomes in all treatment settings, for example, second primary cancer 
rates, RFS, and PFS (in the event of recurrence) can be examined in an adjuvant trial. 
6.1.3 Randomised data 
Conducting a systematic review and meta-analysis of metformin in the adjuvant cancer setting 
highlighted the inherent weakness of observational data, particularly the potential for 
measurement errors in treatment exposure. Randomised data on an established medicine in 
another indication can minimise the risk of these biases and was found to be the cornerstone 
of the evidence supporting the anti-cancer effects of aspirin (90, 95, 96). All the evidence 
supporting metformin use as an adjuvant therapy is based on observational rather than 
randomised data, and only in patients with DM. Unlike aspirin, data on cancer incidence and 
survival from randomised trials in other indications is unlikely to emerge because phase III 
trials evaluating metformin in DM involve short-term administration (often between twelve 
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weeks and one year). Trials of metformin in other indications like polycystic ovarian syndrome 
and infertility also involve short-term administration and are conducted in a young adult 
population where cancer incidence is low. Trialists working in disease areas other than cancer 
have the opportunity to incorporate the collection of cancer outcome data which could 
maximise the research opportunities each trial can offer. The creation of generic protocols for 
collecting such data could encourage this practice.  
6.1.4 Selecting a dose 
The modern drug development process provides data on the pharmacokinetics and tolerability 
of a new medicine and allows the optimal dose for investigation in late phase trials to be 
established. These data are not available for older drugs. For established medicines, existing 
data are based on doses selected for other indications, and as such data in the dose range 
needed to infer efficacy in the cancer setting may not exist. Additionally, the most favourable 
dose may be unestablished when there is mechanistic uncertainty. For aspirin, observational 
data can sometimes provide information on efficacy and tolerability, and its relation to dose 
and duration. However, for medications like metformin, the dose taken often varies for 
individual patients according to diabetic control and tolerability, therefore information on the 
relationships between dose, effect and toxicity is often unavailable. The approach taken by 
the Add-Aspirin trial was to randomise patients between two different doses of aspirin (100mg 
and 300mg) and placebo in a platform design. Dosing based randomisations within similar 
trials could be used to provide this information. 
 
6.2 Later stages of the repurposing process  
The Add-Aspirin trial provides an example of how an established medicine can be evaluated 
as an adjuvant cancer therapy in a phase III trial. During the set-up of the trial there were 
several barriers which were overcome. In the absence of commercial interest from the 
pharmaceutical industry, all financial support for the trial was obtained from governmental 
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(NIHR Health Technology Assessment Programme and the Medical Research Council) and 
charity sources (Cancer Research UK). Furthermore, significant cost-efficiencies were made 
by directly commissioning and managing many operational procedures normally dependent 
on industry support, for example drug packaging, labelling, blinding, distribution, supply 
management and unblinding provision. Cost and practical efficiencies were also incorporated 
into the trial through the use of a multi-tumour type (basket) design, each incorporating multiple 
dose randomisations. 
This research finds that opening and conducting a phase III trial of an established medicine is 
achievable and provides recommendations for minor conduct modifications and protocol 
amendments summarised below.  
6.2.1 Basket design   
It was shown to be possible to successfully open and recruit to a trial with four tumour types 
in one protocol, with 66.7% of NHS trusts and boards in the UK having at least one recruiting 
site, and 81% of those recruiting in at least three out the four tumour cohorts at one year. 
Research sites recognised the efficiencies offered from a basket trial design particularly in 
terms of gaining approvals, staffing and data entry. A basket design could therefore help 
overcome the financial barriers of the later stages of the repurposing process for other similar 
agents by ensuring a broad evaluation in all suitable tumour types where sufficient evidence 
exists.   
At sites, the main challenges from a basket design were identified as understaffing, and the 
unequal division of labour between tumour cohorts at sites. To overcome understaffing in 
future similar trials, a system created to share NIHR credit for research activity and support 
costs between hospital sites when patients change site for primary treatment, adjuvant 
therapy, and follow-up could be considered.  Ensuring staff-time is divided evenly between 
tumour types could reduce the opening times and improve recruitment for individual cohorts. 
Future trials employing a basket design could consider contracts between sites and a sponsor 
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which include an agreement to ring-fence staff for each cohort and to reallocate staff-time to 
poorly recruiting cohorts where necessary. 
6.2.2 Run-in period design 
The design of the run-in period was well received by site staff and successfully implemented 
with 88% of the first 500 participants registered being successfully randomised after its 
completion. The run-in period was found to be successful in its objective to prevent 
randomisation of patients identified to have poor adherence or tolerance with short term aspirin 
use. These patients are unlikely to take regular aspirin long-term. Run-in period methodology 
could be a useful strategy for any trial of an agent that requires long-term adherence in-order 
for an anti-cancer effect to be identified.  
The three methods employed to assess adherence exhibited high levels of concordance, 
however given the poor return of blister packs, adherence assessments could be limited to 
the use of a diary card and direct questioning of participants. 
The existing evidence suggested that an eight-week period of aspirin use was unlikely to have 
a detectable treatment effect. Trials considering a run-in period would need to evaluate 
whether the drug under investigation had any short-term treatment effects before using this 
methodology. A change in side-effect profile when moving from the active run-in period to the 
randomised phase was not anticipated to result in unblinding treatment allocation to 
participants because aspirin is generally well tolerated, however the potential for unblinding 
needs to be considered for other agents.  
6.2.3 Optimising recruitment  
For a trial to be successful, recruitment milestones must be met, and for trials with a basket 
design, this needs to be achieved across all trial cohorts. To achieve this, anticipated 
recruitment projections must be as accurate as possible. This research explored how site 
recruitment predictions compare to actual recruitment rates and discovered that sites 
overestimate how many patients they can recruit per month by a median of 220-350% 
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depending on tumour type (section 3.3.3.1), and site recruitment predictions more accurately 
reflect their best month of recruitment (section 3.3.3.2). It is proposed that selecting an 
anticipated recruitment rate by asking for a lowest and highest monthly recruitment prediction 
and using the mean value may be a more accurate method. 
The Add-Aspirin trial has adopted a strategy where participants who are already taking part in 
other trials are encouraged to co-enrol, as long as both trial teams agree, and no negative 
impact on safety or the results of either trial is anticipated. This approach was successfully 
implemented, with a total of forty trials agreeing co-enrolment in the first year. A trial conduct 
survey found that site staff believed co-enrolment improved recruitment to clinical trials and 
maximised participant choice, but identified concerns about the potential for confounding, 
additional patient burden and toxicity (section 2.3.12). This approach could be utilised in phase 
III trials of repurposed medicines to attract participants who might normally favour a trial of a 
new cancer therapy over an established drug, thus maximising the pool of potential 
participants. Co-enrolment is well suited to trials investigating established medicines which 
are proposed as adjuncts to other treatments as it allows them to be examined alongside new 
and future therapies. To promote co-enrolment amongst site-staff and patients, a frequently 
asked questions document is recommended to provide reassurance about the chance of any 
negative impact on trial results and any additional burden or risk of toxicity. Patient 
representative involvement was also found to be key to successfully negotiating co-enrolment 
agreements between trial teams. 
This research proposes several strategies to increase recruitment of certain groups identified 
as under-represented in the trial. The gastro-oesophageal cohort failed to meet recruitment 
targets and the eligibility criteria have now been adjusted to include patients with positive 
resection margins and the timing of entry criteria for patients undergoing radical 
chemoradiotherapy from twelve to fourteen weeks. Other under-represented groups included 
patients in the colorectal cohort who underwent resection of liver metastases, and patients in 
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the prostate cohort who underwent a prostatectomy. The eligibility of these groups has now 
been highlighted to Investigators. 
6.2.4 Future implementation of repurposed drugs 
Once an established medicine has been shown to be efficacious in a phase III trial, there are 
likely to be barriers to adoption as part standard therapy. With late phase trials being 
conducted by several separate academic groups rather than a single pharmaceutical 
company, it is unclear who will take responsibility for taking licencing applications forward. 
Without the financial drive of industry, the source of funding for regulatory approvals is also 
uncertain. Governmental support and regulatory change may be needed to complete the final 
steps of the repurposing process.  
Another potential barrier to implementation is patient perceptions about the efficacy of older 
medicines compared to newly developed therapies. In an era where treatments have become 
targeted to particular tumour subtypes, a therapy indicated in multiple tumour types could be 
seen as outmoded and be less trusted. Patient and public involvement in the creation of 
promotional material to increase awareness and highlight any potential benefits will be 
essential. 
 
6.3 Future research directions 
6.3.1 Metformin 
Whilst this thesis provides evidence supporting a phase III trial of metformin in the adjuvant 
treatment of colorectal cancer and prostate cancer, there are no trials running in these tumour 
types at the present time. One major phase III trial (MA-32, NCT01101438) investigating 
metformin for the adjuvant treatment of breast cancer has completed recruitment, and another 
(IBIS 3, ISRCTN93764730)) has completed its feasibility phase. The findings of these trials 
will provide a randomised evaluation of the anti-cancer effects of metformin in patients without 
DM, and irrespective of tumour type investigated, will allow a fuller evaluation.  
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This research found that in prostate cancer, patients undergoing radical radiotherapy had a 
greater improvement in RFS (section 5.3.2). Any phase III trial in this setting should use 
randomisation by minimisation to ensure that primary treatment modalities are evenly 
distributed between arms, and sub-analyses are conducted to investigate these differences. 
Phase III trials in both western and non-western populations are also needed to investigate 
the potential differences in response to metformin identified in these populations (section 
5.3.1). 
Observational studies investigating the adjuvant effects of metformin have mostly been 
conducted in patients with breast, colorectal and prostate cancer. To examine the efficacy of 
metformin in less common tumour types, collaboration between research groups is needed to 
combine the observational data available from different populations. 
6.3.2 Aspirin 
The Add-Aspirin trial is currently recruiting and the last of the four cohorts is expected to 
complete recruitment in 2021. Sub-studies conducted in parallel to the main study have the 
potential to maximise the research value of the trial. Aspirin resistance is said to affect 25% of 
the population (267), and if the anti-cancer mechanism of aspirin relies on anti-platelet activity, 
then this has the potential to affect the power of the study. TBX2 is a product of platelet 
aggregation and is a marker of platelet activity (268). Urinary measurement of TBX2 in a sub-
population at baseline and at different timepoints throughout the trial could investigate this as 
a potential biomarker, provide mechanistic insights and investigate the role of aspirin 
resistance. A collection of tumour and blood samples from trial participants has been created 
which will allow the investigation of several of the biomarkers proposed, for example tumour 
expression of COX-2 and HLA, and also PIK3CA and BRAF mutation status.  
6.3.3 Trial methodology 
Further research into the accuracy of anticipated recruitment rates is needed, particularly the 
proposal to investigate differences between the accuracy of predictions from different types of 
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cancer centres. The proposal to improve the accuracy of recruitment projections by collecting 
minimum and maximum monthly site recruitment predictions and using the mean value, needs 
prospective validation.  
It is possible that adherence may diminish as participants continue to take trial treatment for 
up to 5 years. Investigation of adherence annually in a sub-group using the adherence 
methods used in the run-in period could be considered. Given the potential for placebo arm 
contamination, an assessment of participant blinding could also be considered at the 
completion of the trial. An analysis of the correlation between treatment adherence in the run-
in period and trial visit attendance later in the trial is also proposed. 
If sufficient evidence from phase III trials emerges to support the use of both aspirin and 
metformin in the adjuvant cancer setting, a poly-pill containing both aspirin and metformin 
could be considered. This could improve long-term adherence thought the use of a single pill 
and could be seen as a more innovative cancer therapy by patients. If developed in 
collaboration with the pharmaceutical industry it could also attract the financial and operational 
support necessary for further research and regulatory approval. 
 
6.4 Summary 
The repurposing of medicines for use in another treatment setting is very attractive, particularly 
because of its potential to generate low-cost and globally available therapies. Whilst this 
research highlights several advantages of repurposing, there will always be a need for new 
drug development, as all medicines must be discovered before they can be repurposed, and 
drug resistance means that new medicines will always be needed. This thesis provides a 
significant addition to the literature on the potential anti-cancer activity of metformin and how 
phase III trial methodology could be adapted for repurposing.    
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 We would be grateful if you could complete this short survey on the experiences that you have
had of the Add-Aspirin trial at your site. This will allow us improve the conduct of this, and
similar trials.
Please seek input from colleagues at your site as necessary. You can go back and edit your
answers up until the survey is complete.
 
Answering all questions should take less than 10 minutes.
 
We thank you in advance for participating in this survey.
Add-Aspirin Trial Conduct Survey
Add-Aspirin Trial Conduct Survey
1. Please select your job title/role
(please select the single option which most closely applies or select "other")
*
Clinical trials nurse
Clinical trials sister
Clinical trials coordinator
Clinical trials practitioner
Clinical trials assistant
Other (please specify)
 
2. Is your site open to the Add-Aspirin trial?*
Yes No
Add-Aspirin Trial Conduct Survey
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3. Please select the reason(s) that your site has not opened to Add-Aspirin. 
This will help us to identify any barriers we may be able to assist with in future. 
(Select all that apply).
*
Insufficient staff
Lack of interest in study
concerns about excess trial costs
Unable to identify principal investigator(s)
Competing trials
Lack of familiarity with a platform design
Lack of familiarity with a run-in period design
Concerns about differences in follow-up schedules
Delay in sponsor opening site
Other (please specify)
Add-Aspirin Trial Conduct Survey
Site number (four digits)
Additional site number (optional)
Additional site number (optional)
4. Please enter your four digit site number. 
If you work at multiple sites please add additional site numbers below
*
   
5. How many cohorts (tumour types) are open at your site?*
One Two Three Four
6. Please select the cohorts that are open at your site 
(select all that apply).
*
Breast cohort
Colorectal cohort
Gastro-oesophageal cohort
Prostate cohort
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7. If the breast cohort is not open at your site, please select the reason(s).
(If the breast cohort is open at your site, please select "N/A" only).
*
N/A (breast cohort is open)
Breast cancer patients are not seen at this site
Insufficient staffing
Unable to identify a Principal Investigator
Concerns about differences in follow-up schedules
Competing trials
Intention to open soon
Other (please specify)
8. If the colorectal cohort is not open at your site, please select the reason(s).
(If the colorectal cohort is open, please select "N/A" only.)
*
N/A (colorectal cohort is open)
Colorectal cancer patients are not seen at this site
Insufficient staffing
Unable to identify a Principal Investigator
Concerns about differences in follow-up schedules
Competing trials
Intention to open soon
Other (please specify)
9. If the gastro-oesophageal cohort is not open at your site, please select the
reason(s).
(If the gastro-oesophageal cohort is open, please select "N/A" only.)
*
N/A (gastro-oesophageal cohort is open)
Gastro-oesophageal cancer patients are not seen at this
site
Insufficient staffing
Unable to identify a Principal Investigator
Concerns about differences in follow-up schedules
Competing trials
Intention to open soon
Other (please specify)
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10. If the prostate cohort is not open at your site, please select the reason(s).
(If the prostate cohort is open, please select "N/A" only.)
*
N/A (prostate cohort is open)
prostate cancer patients are not seen at this site
Insufficient staffing
Unable to identify a Principal Investigator
Concerns about differences in follow-up schedules
Competing trials
Intention to open soon
Other (please specify)
Add-Aspirin has a platform design that spans four tumour types (cohorts) in one trial
Add-Aspirin Trial Conduct Survey
 
11. Were there any efficiencies in opening Add-Aspirin as one trial in multiple tumour types
(cohorts) compared to opening the same number of separate trials? 
*
Yes No
Strongly agree agree neither agree or disagree disagree strongly disagree
12. Please indicate how strongly you agree or disagree with the following statement.
"Opening Add-Aspirin as one trial in multiple tumour types (cohorts) was more efficient than opening
the same number of separate trials"
*
Add-Aspirin Trial Conduct Survey
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13. Please indicate where efficiencies in opening Add-Aspirin as one trial in multiple tumour
types (cohorts) occur (compared to opening the same number of separate trials).
(Select all that apply) 
*
Staffing
Training
Pharmacy set-up
Radiology departmental approval
Pathology departmental approval
Regulatory approval
Other (please specify)
Add-Aspirin Trial Conduct Survey
14. Please provide details of any reasons why it was less efficient to open Add-Aspirin as one trial in
multiple tumour types, compared to opening the same number of separate trials (enter "N/A" if there
were no inefficiencies identified).
*
Copy of page: Add-Aspirin has a platform design that spans four tumour types (cohorts) in
one trial
Add-Aspirin Trial Conduct Survey
 
15. Were there any efficiencies in running Add-Aspirin as one trial in multiple tumour types, compared
to running the same number of separate trials?
*
Yes No
Strongly agree agree neither agree or disagree disagree strongly disagree
16. Please indicate how strongly you agree or disagree with the following statement.
"Running Add-Aspirin as one trial in multiple tumour types (cohorts) was more efficient than running the
same number of separate trials"
*
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17. Please indicate where efficiencies in running Add-Aspirin as one trial in multiple tumour
types (cohorts) occur (compared to running the same number of separate trials). 
(Select all that apply)
*
Staffing
Data entry
Drug dispensing
One overarching protocol
Familiarity with common trial processes
Other (please specify)
Add-Aspirin Trial Conduct Survey
18. Please provide details of any reasons why it was less efficient to run Add-Aspirin as one trial in
multiple tumour types, rather than running the same number of separate trials. 
(Please enter "N/A" if there were no inefficiencies identified).
*
Add-Aspirin incorporates a run-in period design where all participants take
100mg of aspirin for eight weeks to select participants that are more likely to
tolerate and adhere to trial treatment during the rest of the trial.
Add-Aspirin Trial Conduct Survey
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Strongly
agree Agree
Neither
agree or
disagree Disagree
Strongly
disagree
"Treatment adherence in the Add-Aspirin run-in period is likely
to be a good predictor of treatment adherence in the rest of the
trial (randomised phase)"
"Treatment tolerance in the Add-Aspirin run-in period is likely to
be a good predictor of treatment tolerance in the main trial
(randomised phase)"
"The Add-Aspirin run-in period is likely to reduce the number of
participants who do not tolerate treatment during the main trial
(randomised phase)"
"The Add-Aspirin run-in period is likely to reduce number of
participants who do not adhere to treatment in the main trial
(randomised phase)"
"The Add-Aspirin run-in period is likely to reduce number of
participants who miss scheduled follow-up visits in the
main trial (randomised phase)"
19. Please indicate how strongly you agree or disagree with the following statements.*
20. Please help us to understand why you selected the answers above (optional question):
Add-Aspirin Trial Conduct Survey
21. The following are potential reasons that patients might give for not registering for Add-Aspirin.
Based on your experiences (or that of your colleagues), please rank them in order of how frequently
each reason has been given, (with the most common reason at number 1 etc). Please select "N/A" if a
particular reason has not been expressed.
*
Over the counter availability of aspirin (without a prescription)  N/A
Number of follow-up visits  N/A
Reluctance to be randomised to placebo  N/A
Need to take trial treatment for at least 5 years  N/A
Concerns about toxicity  N/A
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22. Is your site open to the gastro-oesophageal cohort?*
Yes No
Add-Aspirin Trial Conduct Survey
Other (please specify)
23. Please select from the following list, the reason(s) which reduce(s) recruitment to the gastro-
oesophageal cohort of Add-Aspirin at your site.
(Select all that apply)
*
Gastro-oesophageal MDT is at a different site
Workload from other Add-Aspirin tumour types
Few patients meet eligibility criteria
Trial registration timelines
It is easier to recruit patients in other tumour types (cohorts) in Add-Aspirin
Concerns about toxicity
Individuals who are participating in other approved trials may also register (co-
enrol) for the Add-Aspirin trial (providing they are otherwise eligible). By including
individuals who are registered in other trials, we will be able to assess how well
aspirin works when given in addition to both current and potentially future
standard treatments.
Add-Aspirin Trial Conduct Survey
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 Strongly agree agree
neither agree or
disagree disagree strongly disagree
"Allowing co-enrolment
with other trials
maximises participant
choice."
"Allowing co-enrolment
with other trials
improves recruitment to
clinical trials."
24. Please indicate how strongly you agree or disagree with the following statements.*
25. If you have any concerns you have about co-enrolment please describe them below (optional
question).
Add-Aspirin includes a short cognitive assessment called the MoCA blind. This is
to investigate the hypothesis that aspirin protects against cognitive decline. It can
be administered by any member of the trial team where the task is delegated by
the local Principal Investigator.
Add-Aspirin Trial Conduct Survey
26. Have you, or a colleague at your site (other than a clinician) administered the cognitive assessment
(MoCA blind) questionnaire?
*
Yes
No
Add-Aspirin Trial Conduct Survey
27. How long, on average, did the MoCA blind questionnaire take to deliver?
(Drag the slider to the preferred position)
*
0 minutes 15 minutes 30 minutes
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Very easy Easy Average Hard Very hard
28. Please indicate how difficult the survey was to deliver (Select one)*
29. Were you aware of the audio recording and video example of the questionnaire
being administered on Add-Aspirin website?
*
Yes
No
Add-Aspirin Trial Conduct Survey
 
Once you click "done" below, the survey will finish and no further changes will be
possible.
If you want to go back and make changes please click "prev" to edit any responses.
Thank-you for completing this survey.
275
Appendix C:  
Add-Aspirin site initiation form 
  
276
ADD-ASPIRIN 
 
Add-Aspirin Initial Site Evaluation Form_v2.0_29th October 2014  Page 1 of 3 
 
Initial Site Evaluation Form 
 
Please complete this questionnaire and keep the original at the front of your site file. 
Please send a signed and dated copy by email as an attachment to: mrcctu.add-aspirin@ucl.ac.uk. 
Please return only 1 form from your site. 
 
 
Site name and address: Principal Investigator name: 
Email: Phone: 
Clinical Research Network: Please list all other clinical sites where your patients might also 
be seen/followed up: 
 
In order to facilitate the R&D approval process, each clinical site should name a Principal Investigator 
(PI) to take overall responsibility for the trial at site, as well as responsibility for their own tumour 
site-specific cohort(s). There should also be named co-PIs, responsible for each of the other tumour 
site-specific cohorts that a site will recruit to. PIs and co-PIs will be acknowledged in the relevant 
publications. 
 
Which cohort(s) do you anticipate that you will recruit to? 
It is hoped that the vast majority of sites will recruit to all four cohorts. If you are unable to identify 
co-PIs within your site, please contact the trial team (mrcctu.add-aspirin@ucl.ac.uk) who may be 
able to assist.  
 
 
Yes No 
If yes, please indicate which cohort(s) the PI is responsible for 
and provide co-PI name and email for the other cohorts 
Name Email 
Breast □ □   
Gastro-oesophageal □ □   
Colorectal □ □   
Prostate □ □   
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Please provide the following contact details in order to facilitate the set-up process: 
 
 Name Email Phone 
First point of contact    
Main contact for 
agreement between 
Trust and UCL  
   
Contact to transfer SSI 
form to on IRAS 
   
Main pharmacy 
contact 
   
 
Patient population: approximately how many eligible patients do you expect to recruit at your 
site per month (broken down by cohort)? 
 
Approximately how many eligible 
patients do you see? 
Approximately how many patients 
would you expect to recruit? 
Breast   
Gastro-oesophageal   
Colorectal   
Prostate   
 
Investigator and Staff experience 
Please note that PI and co-PIs for the trial must send a copy of their CV to MRC CTU before site 
activation. Please send the copies to the Add-Aspirin trial team either by fax (020 7670 4818) or 
email (mrcctu.add-aspirin@ucl.ac.uk). All staff who will be working on the trial are required to have 
up-to-date GCP training. It is the responsibility of the PI to ensure that this is the case. 
 Yes No Details 
Has your site participated in 
other MRC CTU studies? If yes, 
please provide brief details. 
□ □ 
 
Has your site participated in 
other academic studies? If yes, 
please provide brief details. 
□ □ 
 
Has your site participated in 
pharmaceutical company 
studies? If yes, please provide 
brief details. 
□ □ 
 
Has your site ever had any 
serious protocol breaches? If 
yes, provide details. 
□ □ 
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Has your site ever had an audit 
or MHRA inspection? If yes, 
please give details of any major 
or critical findings that might be 
relevant to the Add-Aspirin trial. 
□ □ 
 
 
Pharmacy 
Default initial drug delivery at set-up will be 70 boxes (approx. total size 495cm x 585cm x 135cm). 
Please contact the trial team (mrcctu.add-aspirin@ucl.ac.uk) if you anticipate any problems with 
receiving this quantity of trial drugs. 
 Yes No Comments 
Drug destruction policy: can 
your pharmacy routinely 
destroy returned drug? Please 
note that we are only 
collecting returned drug for 
the run-in period, and not for 
the blinded part of the trial. 
□ □ 
  
Do you accept IMP deliveries on 
Saturdays? □ □ 
 
Please provide the contact 
name, exact address and 
telephone number for IMP 
deliveries 
 
Please provide instructions for 
delivery including what to do if 
named contact is not available 
to receive delivery 
 
 
Signature: Date: 
Printed name: Role: 
 
  
Thank you very much for completing this form.  
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 PROSPERO International prospective register of systematic reviews
 
A systematic review and meta-analysis of metformin as an adjuvant treatment for
cancer
Christopher Coyle, Fay Cafferty, Claire Vale, Ruth Langley
 
 Citation
Christopher Coyle, Fay Cafferty, Claire Vale, Ruth Langley. A systematic review and meta-analysis of metformin as
an adjuvant treatment for cancer. PROSPERO 2015:CRD42015020519 Available from  
http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42015020519  
Review question(s)
Aim: To systematically review the available evidence on cancer outcomes in patients receiving, compared to those
not receiving, metformin.
Primary objective: To assess the effects of metformin on recurrence-free survival in the adjuvant setting by tumour
group.
Secondary objective: To assess the effects of metformin for the treatment of cancer in terms of cancer specific and
overall survival by tumour group.
Searches
Identification of studies
Electronic Databases:
• MEDLINE 1966-2015 will be searched to retrieve any RCT or non-RCT examining the effects of metformin cancer
mortality or primary or secondary prevention of cancer
• EMBASE 1982-2015 will be searched to retrieve any RCT or non-RCT examining the effects of metformin on the
primary or secondary prevention of cancer or cancer mortality. 
• Cochrane Central Register of Controlled Trials (CENTRAL) will be searched for any meta-analysis or systematic
review examining the effects of metformin on the primary or secondary prevention of cancer or cancer mortality.
Trial Registers:
ClinicalTrials.gov
Conference Proceedings:
Conference proceedings searched electronically: 
Proceedings of the American Society of Clinical Oncology (ASCO) 2004-2015
Proceedings of the European Society of Medical Oncology (ESMO) 1990-2015
Proceedings of the European Cancer Conference Organization (ECCO) 1990-2015
Additional hand searches:
Bibliographies of the reports of all identified studies and review articles will be screened for further studies.
                               Page: 1 / 6
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Types of study to be included
Inclusion criteria
Any randomised controlled trials (RCTs), non- RCTs (including epidemiologic studies, case control studies, cohort
studies, cross-sectional studies and longitudinal studies).
Studies must include data on individual tumour groups.
Condition or domain being studied
The oral anti-diabetic medication Metformin.
Cancer and cancer outcomes, in the adjuvant settting
Participants/ population
Inclusion criteria
Adults with a diagnosis of any solid cancer type
Exclusion criteria
Age less than 16 years old
Intervention(s), exposure(s)
Inclusion criteria: metformin use
Comparator(s)/ control
Treatment comparisons:
• Metformin users compared to non-metformin users with a diagnosis of type II diabetes
• Metformin users with type II diabetes compared to non-metformin users without type II diabetes
Outcome(s)
Primary outcomes
Recurrence-free survival
Secondary outcomes
Overall survival 
Cancer specific survival
Data extraction, (selection and coding)
Selection of studies
All relevant abstracts will be assessed for eligibility, and when search results cannot be rejected from the title and/or
abstract, the full text publication will be obtained, where available. Any queries will be checked by a second
independent reviewer and resolved by consensus.  
Data extraction and management
Data on patient characteristics, interventions and outcomes will be extracted from publications and presentations into
predesigned forms (appendix C) and cross-checked by a second independent reviewer. Any disagreements will be
resolved by consensus.
Patient characteristics
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Age
Sex
Diabetic status (intervention and control arm)
Treatment setting (e.g. adjuvant)
Clinical Stage
Patient ethnicity
Study Characteristics
country
Type of study (e.g. rct, case-control, retrospective cohort study)
Publication type (e.g. full, conference abstract)
Method of participant selection
Source data
Number of inclusions/exclusions
Median follow-up
Study statistical methods- confounding factors examined (age, stage, sex, BMI, smoking status, other anti-diabetic
therapy use) and whether adjustment performed or multivariate analysis used
Risk of bias (e.g. time- related biases, adjustment for confounders)
Treatment characteristics
Control arm details (e.g. any additional agents)
Time-point of metformin exposure assessment 
Outcomes
(Primary)
Recurrence-free survival 
(Secondary)
Overall survival 
Cancer specific survival 
Other outcomes of interest
We also hope to explore the impact of metformin dose/exposure and clinicopathological characteristics on the
outcomes described above and also examine data on metastasis free survival where data is available
Risk of bias (quality) assessment
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Data will be extracted on the type of study and for potential sources of bias, for example whether particular potential
confounding factors are accounted for (see trial group analysis plan). All studies will be individually assessed for
bias.
Strategy for data synthesis
The primary analysis of recurrence free survival will be undertaken for patients who have undergone potentially
curative treatment. Studies will be grouped by tumour type for analysis, and a meta-analysis will be performed where
sufficient data exists for each tumour type. All eligible studies will be included in the analyses for secondary
outcomes (overall survival and cancer specific survival) and meta-analysis performed as described above for each
tumour type where possible.
For meta-analyses of time-to-event outcomes, such as recurrence-free survival and overall survival, the hazard ratio
(HR) is the most appropriate statistic. Where available, the HR and associated statistics will be extracted directly from
the trial reports. Where not reported, they will be estimated from Kaplan Meier curves or summary statistics using
published methods (Parmar 1998, Tierney 2007, Williamson 2002). Where insufficient data are available,
supplementary data may be sought directly from the trial investigators.
Analysis of subgroups or subsets
Trial group analyses
To explore whether any trial or patient characteristics have any impact on the size or the direction of the effect of
metformin therapy, for the primary outcome of recurrence free survival, we also aim calculate HRs for groups of
trials, providing sufficient data are available. The resulting HR estimates from the trial groups will be compared using
the test for interaction. If no difference in the effect of treatment between groups of trials is found, interpretation will
be based on results from all trials together, otherwise they will be based results from groups of trials.
Studies will be therefore be grouped according to:
•Treatment comparison (studies with diabetic compared to non-diabetic control groups)
•Study type (RCT, case-control study, retrospective cohort study).
•Secondary outcomes in patients who have undergone potentially curative treatment only 
And for studies in prostate cancer only:
•Primary treatment type (prostatectomy or radical radiotherapy)
Heterogeneity will be assessed using the chi-square test for heterogeneity and the I-squared statistic. The random
effects model will be used to establish the robustness of all results to the choice of model.
Contact details for further information
Dr Coyle
c.coyle@ucl.ac.uk
Organisational affiliation of the review
Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL)
http://www.ctu.mrc.ac.uk
Review team
Dr Christopher Coyle, MRC CTU at UCL
Dr Fay Cafferty, MRC CTU at UCL
Dr Claire Vale, MRC CTU at UCL
Dr Ruth Langley, MRC CTU at UCL
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Anticipated or actual start date
15 May 2015
Anticipated completion date
31 July 2015
Funding sources/sponsors
MRC CTU at UCL
Conflicts of interest
None known
Language
English
Country
England
Subject index terms status
Subject indexing assigned by CRD
Subject index terms
Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Humans; Metformin; Neoplasms
Stage of review
Completed and published
Date of registration in PROSPERO
15 May 2015
Date of publication of this revision
13 December 2016
Details of final report/publication(s)
Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and
meta-analysis. Annals of Oncology. 2016 Sep 28.
http://annonc.oxfordjournals.org/content/early/2016/09/27/annonc.mdw410.full.pdf+html
DOI
10.15124/CRD42015020519
Stage of review at time of this submission Started Completed
Preliminary searches Yes   Yes 
Piloting of the study selection process   Yes   Yes 
Formal screening of search results against eligibility criteria   Yes   Yes 
Data extraction   Yes   Yes 
Risk of bias (quality) assessment   Yes   Yes 
Data analysis   Yes   Yes 
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faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record,
any associated files or external websites.
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Search Strategies  
 
MEDLINE Search strategy  
Interventions:  
1. exp Biguanides/  
2. exp Metformin/  
3. Metformin.tw,ot.  
4. Biguanide$.tw,ot.  
5. or/1-4 (Combines all of the intervention hits)  
 
Outcomes (+ disease setting)  
6. exp Mortality/  
7. mortality.tw,ot.  
8. mortaliti$.tw,ot.  
9. or/6-8 (combines all mortality studies)  
10. exp Primary Prevention/  
11. exp Secondary Prevention/  
12. (prevention$ or prevent$).tw,ot.  
13. exp Neoplasm/  
14. (cancer$ or neoplasm$ or tumo?r$).tw,ot.  
15. or/10-14 (combines all primary and secondary prevention studies)  
 
Standard RCT search  
16. exp Randomized Controlled Trials as topic/  
17. Randomized Controlled Trial.pt.  
18. exp Controlled Clinical Trials as topic/  
19. Controlled Clinical Trial.pt.  
20. exp Random Allocation/  
21. exp Double-Blind Method/  
22. exp Single-Blind Method/  
23. or/16-22  
 
Other Study types  
24. Epidemiologic Studies/  
25. exp Case-Control Studies/  
26. exp Cohort Studies/  
27. Cross-Sectional Studies/  
28. (epidemiologic adj (study or studies)).ab,ti.  
29. case control.ab,ti.  
30. (cohort adj (study or studies)).ab,ti.  
31. cross sectional.ab,ti.  
32. cohort analy$.ab,ti.  
33. (follow up adj (study or studies)).ab,ti.  
34. longitudinal.ab,ti.  
35. retrospective$.ab,ti.  
36. prospective$.ab,ti.  
37. (observ$ adj3 (study or studies)).ab,ti.  
38. adverse effect?.ab,ti.  
39. Or/24-38 (Non-RCTs)  
40. exp "Review Literature as topic"/  
41. exp Technology Assessment, Biomedical/  
42. exp Meta-analysis as topic/  
43. Meta-analysis.pt.  
44. hta.tw,ot.  
45. (health technology adj6 assessment$).tw,ot.  
46. (meta analy$ or metaanaly$ or meta?analy$).tw,ot.  
47. ((review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or 
psycinfo or psyclit or healthstar or biosis or current content$ or systemat$)).tw,ot.  
48. or/40-47 (Combines all reviews)  
49. 23 or 39 (RCTs or non-RCTs)  
50. 48 or 49 (RCTs or non-RCTs or reviews)  
51. 5 and 15 and 50 (Interventions + prevention studies + RCTs and non-RCTs and reviews)  
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52. 5 and 9 and 50 (Interventions and mortality + RCTs and non-RCTs and reviews)  
53. 51 or 52 (Combines prevention and mortality)  
54. limit 53 to animals  
55. limit 53 to humans  
56. 54 not 55 (Animals not humans)  
57. 53 not 56 (Prevention and mortality – all studies excluding animal studies)  
 
EMBASE Search strategy  
Interventions:  
1. exp Biguanides/  
2. exp Metformin/  
3. Metformin.tw,ot.  
4. Biguanide$.tw,ot.  
5. or/1-4 (Combines all of the intervention hits)  
 
Outcomes (+ disease setting)  
6. exp Mortality/  
7. mortality.tw,ot.  
8. mortaliti$.tw,ot.  
9. or/6-8 (combines all mortality studies)  
10. exp Primary Prevention/  
11. exp Secondary Prevention/  
12. (prevention$ or prevent$).tw,ot.  
13. exp Neoplasm/  
14. (cancer$ or neoplasm$ or tumo?r$).tw,ot.  
15. or/10-14 (combines all primary and secondary prevention studies)  
 
Standard RCT search  
16. randomi$.tw  
17. placebo.mp  
18. double-blind.tw  
19. or/16-18  
 
Other Study types  
20. epidemiology/  
21. exp case control study/  
22. exp cohort analysis/  
23. cross sectional study/  
24. (epidemiologic adj (study or studies)).ab,ti.  
25. case control.ab,ti.  
26. (cohort adj (study or studies)).ab,ti.  
27. cross sectional.ab,ti.  
28. cohort analy$.ab,ti.  
29. (follow up adj (study or studies)).ab,ti.  
30. longitudinal.ab,ti.  
31. retrospective$.ab,ti.  
32. prospective$.ab,ti.  
33. (observ$ adj3 (study or studies)).ab,ti.  
34. adverse effect?.ab,ti.  
35. Or/20-34 (Non-RCTs)  
36. exp literature/  
37. exp biomedical technology assessment/  
38. exp meta-analysis/  
39. meta-analysis.kw  
40. hta.tw,ot.  
41. (health technology adj6 assessment$).tw,ot.  
42. (meta analy$ or metaanaly$ or meta?analy$).tw,ot.  
43. ((review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or embase or cochrane or cinahl or 
psycinfo or psyclit or healthstar or biosis or current content$ or systemat$)).tw,ot.  
44. or/36-43 (Combines all reviews)  
45. 19 or 35 (RCTs or non-RCTs)  
46. 44 or 45 (RCTs or non-RCTs or reviews)  
47. 5 and 15 and 46 (Interventions + prevention studies + RCTs and non-RCTs and reviews)  
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48. 5 and 9 and 46 (Interventions and mortality + RCTs and non-RCTs and reviews)  
49. 47 or 48 (Combines prevention and mortality)  
50. limit 49 to animals  
51. limit 49 to humans  
52. 50 not 51 (Animals not humans)  
53. 49 not 52 (Prevention and mortality – all studies excluding animal studies)  
 
Cochrane search strategy  
#1 “metformin”  
#2 “neoplasm”  
#1 and#2  
 
ASCO and ESMO search strategy  
Keyword search for “metformin”  
Clinicaltrials.gov, ISRCTN and EU Clinical Trials Register search strategy  
Search term “metformin” AND “cancer”  
Restricted to trials with published results 
 
 
Data extraction fields  
Study characteristics  
 Tumour group  
 Tumour subtype/histopathology  
 Treatment  
 Other eligibility restrictions  
 Stage  
 Comparator diabetic status  
 Study design  
 Cancer outcomes reported  
 Publication type  
 Study time period  
 Countries  
 Clinical setting (population level, hospital, number of centres)  
 Metformin exposure definition  
 Data source  
 
Participant characteristics  
 Mean/median age of participants  
 Median follow-up  
 Gender (%male)  
 Median BMI  
 Proportion of metformin users (%)  
 Number of metformin users (intervention group)  
 Number of non-metformin users (comparator group)  
 
Cancer outcome data  
 End-point terminology used  
 Hazard ratio  
 95% confidence interval  
 p-value  
 
Study confounding factors/biases  
 Covariates adjusted for  
 Assessment of specific potential confounders  
 (BMI, age, gender,  
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 NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 CASE CONTROL STUDIES  
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Exposure categories. A maximum of two stars can be given for Comparability. 
 
Selection 
1) Is the case definition adequate? 
a) yes, with independent validation ¯ 
b) yes, eg record linkage or based on self reports 
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases  ¯ 
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls ¯ 
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint) ¯ 
b) no description of source 
Comparability 
1) Comparability of cases and controls on the basis of the design or analysis 
a) study controls for _______________  (Select the most important factor.)  ¯ 
b) study controls for any additional factor ¯  (This criteria could be modified to indicate specific             
      control for a second important factor.) 
 
Exposure  
1) Ascertainment of exposure 
a) secure record (eg surgical records) ¯ 
b) structured interview where blind to case/control status ¯ 
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls 
a) yes ¯ 
b) no 
3) Non-Response rate 
a) same rate for both groups ¯ 
b) non respondents described 
c) rate different and no designation 
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 NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 COHORT STUDIES  
 
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and 
Outcome categories. A maximum of two stars can be given for Comparability 
 
Selection 
1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) in the community ¯  
b) somewhat representative of the average ______________ in the community ¯ 
c) selected group of users eg nurses, volunteers 
d) no description of the derivation of the cohort 
2) Selection of the non exposed cohort 
a) drawn from the same community as the exposed cohort ¯ 
b) drawn from a different source 
c) no description of the derivation of the non exposed cohort  
3) Ascertainment of exposure 
a) secure record (eg surgical records) ¯ 
b) structured interview ¯ 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of study 
a) yes ¯ 
b) no 
Comparability 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important factor) ¯ 
b) study controls for any additional factor ¯  (This criteria could be modified to indicate specific             
      control for a second important factor.)  
Outcome  
1) Assessment of outcome  
a) independent blind assessment ¯  
b) record linkage ¯ 
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 
a) yes (select an adequate follow up period for outcome of interest) ¯ 
b) no 
3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for ¯  
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % (select an               
      adequate %) follow up, or description provided of those lost) ¯ 
c) follow up rate < ____% (select an adequate %) and no description of those lost 
d) no statement 
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Background: There is a considerable body of pre-clinical, epidemiological and randomised data to support the hy-
pothesis that aspirin has the potential to be an effective adjuvant cancer therapy.
Methods: Add-Aspirin is a phase III, multi-centre, double-blind, placebo-controlled randomised trial with four
parallel cohorts. Patients who have undergone potentially curative treatment for breast (n= 3100), colorectal
(n=2600), gastro-oesophageal (n=2100) or prostate cancer (n=2120) are registered into four tumour spe-
ciﬁc cohorts. All cohorts recruit in the United Kingdom, with the breast and gastro-oesophageal cohort also
recruiting in India. Eligible participants ﬁrst undertake an active run-in period where 100 mg aspirin is taken
daily for approximately eight weeks. Participants who are able to adhere and tolerate aspirin then undergo a
double-blind randomisation and are allocated in a 1:1:1 ratio to either 100 mg aspirin, 300 mg aspirin or a
matched placebo to be taken daily for at least ﬁve years. Those participants ≥75 years old are only randomised
to 100 mg aspirin or placebo due to increased toxicity risk.
Results: Theprimaryoutcomemeasures are invasivedisease-free survival for thebreast cohort, disease-free survival for
the colorectal cohort, overall survival for the gastro-oesophageal cohort, and biochemical recurrence-free survival for
the prostate cohort, with a co-primary outcome of overall survival across all cohorts. Secondary outcomes include ad-
herence, toxicity including serious haemorrhage, cardiovascular events and some cohort speciﬁc measures.
Conclusions: The Add-Aspirin trial investigates whether regular aspirin use after standard therapy prevents recurrence
and prolongs survival in participants with four non-metastatic common solid tumours.
© 2016 Published by Elsevier Inc.
Keywords:
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Randomised controlled trial
1. Background and introduction
1.1. Rationale
The Add-Aspirin trial includes participants with breast, colorectal,
gastro-oesophageal and prostate tumours which, together, accounts
for approximately one third of all cancer cases and cancer deaths [1].
The selected disease sites are those for which (i) the evidence relating
to potential beneﬁt of aspirin is strongest; (ii) the potential impact is
large (common cancers with large numbers of cases diagnosed at an
early stage, or where outcomes of curative treatment are particularly
poor); and (iii) recruitment is feasible. As a low-cost pharmaceutical,
feasible to administer in both resource poor and rich countries, aspirin
has the potential to signiﬁcantly impact on cancer outcomesworldwide.
This, combined with other possible health beneﬁts (such as cardiovas-
cular effects), means that aspirin warrants further investigation as an
anti-cancer agent.
Contemporary Clinical Trials 51 (2016) 56–64
⁎ Corresponding author.
E-mail address: ruth.langley@ucl.ac.uk (R.E. Langley).
1 The Add-Aspirin investigators are detailed in Appendix A.
http://dx.doi.org/10.1016/j.cct.2016.10.004
1551-7144/© 2016 Published by Elsevier Inc.
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1.2. Supporting evidence
There have been well over 100 case-control and cohort studies in-
vestigating the use of aspirin and cancer risk [2]. A meta-analysis of
such studies showed that aspirin use resulted in signiﬁcant reductions
in the risk of developing cancer, most notably in colorectal (relative
risk (RR) 0.73, 95% conﬁdence-interval (CI) 0.67–0.79), gastric (RR
0.67, CI 0.54–0.83), adenocarcinoma of the oesophagus/cardia (RR
0.67, CI 0.54–0.83), squamous cell carcinoma of the oesophagus (RR
0.64, CI 0.52–0.78), breast (RR 0.90, CI 0.85–0.95), and prostate cancer
(RR 0.90, CI 0.85–0.98) [2]. Observational studies have also shown im-
provements in survival with aspirin use after a diagnosis of breast
[3–5], colorectal [6–11], gastro-oesophageal [12,13] and prostate cancer
[14–16].
Randomised data is available to indirectly substantiate these obser-
vations. A meta-analysis of individual participant data on cancer inci-
dence in randomised trials (designed to investigate the effect of
aspirin on vascular disease) show marked reductions in cancer inci-
dence and cancer mortality associated with regular aspirin use (greater
than three years) in both the short and long-term [17–20]. Similarly,
long-term follow-up from the Women's Health Study, a randomised
placebo-controlled trial designed to assess the effects of aspirin
(100 mg on alternate days) in the primary prevention of cardiovascular
disease and cancer, showed that allocation to aspirin reduced the inci-
dence of colorectal cancer with ten years of follow-up (hazard ratio
(HR) 0.80, CI 0.67–0.97) [21]. A recentmeta-analysis of studies examin-
ing aspirin use after a cancer diagnosis has shown a signiﬁcant reduc-
tion in cancer-speciﬁc mortality in colon cancer, but not in breast and
prostate cancer, however signiﬁcant heterogeneity between studies
was identiﬁed [22].
Furthermore, the ﬁrst randomised trial speciﬁcally designed to dem-
onstrate that aspirin can prevent the development of cancer has shown
that 600 mg of aspirin daily for up to four years prevents colorectal and
other cancers associated with Lynch syndrome (a hereditary condition
which predisposes to cancer development) HR 0.45, CI 0.26–0.79 [23].
The potential beneﬁts of aspirin have to be weighed against the risk
of adverse effects. A number of systematic reviews and meta-analyses
have examined the potential risks of adverse events [24,25]. A recent re-
view estimates that, depending on age and sex, regular aspirin use over
a 15-year period would lead to an absolute increase in major bleeding
events of between 0.16% and 0.81%. The authors conclude that prophy-
lactic aspirin use for aminimum of ﬁve years at a dose of 75mg–325mg
daily has a favourable beneﬁt-harm proﬁle [26]. For individuals treated
for cancer, with a high risk of recurrent disease, the balance could be
even more favourable.
2. Methods
2.1. Aims
The Add-Aspirin trial aims to assess whether regular aspirin use after
standard potentially curative primary therapy can prevent recurrence and
prolong survival in individuals with four common early stage solid tu-
mours. Avoiding recurrent disease, subsequent treatment and the associat-
ed morbidity and mortality in these individuals is an important goal.
Multicentre and international recruitment will allow assessment of the in-
tervention in a range of settings, with the aimof demonstrating that imple-
mentation is both feasible and cost-effective across varying health care
systems and in both the developing and developed world. A secondary
aim is to assess the potential overall health beneﬁts of aspirin for these in-
dividuals including cardiovascular outcomes.
2.2. Overview of design
The Add-Aspirin trial investigates the use of both 100 mg daily and
300 mg daily aspirin compared with matched placebo (double-blind)
in each of four different tumour types, utilising an overarching protocol.
Further details of the rationale for this design are provided in the discus-
sion section of this article. Fig. 1 shows a summary schema for the trial.
2.3. Participants
Participants entering the Add-Aspirin trial have undergone poten-
tially curative treatment (surgery or other radical treatment) for breast,
colorectal, gastro-oesophageal or prostate cancer with standard neoad-
juvant and/or adjuvant therapy if indicated, and may also have partici-
pated in any pre-approved trials and satisfy the eligibility criteria,
summarised in Fig. 2.
2.4. Registration
The Add-Aspirin trial is open to centres in every Cancer Research
Network (CRN) throughout the four devolved nations of the United
Kingdom (UK) and will also recruit participants in India (other coun-
tries may join subsequently). Eligible participants who have provided
consent and meet the timing of entry criteria are registered online
(through the trial website, www.addaspirintrial.org). The timing of
entry window has been designed so that aspirin can be started at the
earliest opportunity to maximise the potential beneﬁts, whilst starting
at a timewhen it is considered safe to do so and unlikely to compromise
the curative intent of standard primary treatment. Figures describing
the timing of entry criteria for each cohort are available in Appendix B.
2.5. Run-in period
The Add-Aspirin trial incorporates a feasibility phase lasting approx-
imately 2 1/2 years during which recruitment feasibility, treatment ad-
herence and safety will be assessed. During the feasibility phase of the
study, all participants are required to complete an active run-in period
after registration but prior to randomisationwhere they take 100mgas-
pirin daily (one tablet per day) in an open-label manner for a period of
approximately eight weeks.
2.6. End of run-in period assessment
At the end of the run-in period, the participant's tolerance of aspirin
and adherence to daily treatmentwill be assessed. This approach allows
those individuals who are unlikely to be able to tolerate aspirin, as well
as thosewho are unlikely to be able to adhere to the protocol treatment
schedule, to be identiﬁed. Adherence will be assessed using a combina-
tion of a participant diary card, used blister packs and patient reported
adherence. Participants will be suitable for randomisation if they have
taken at least 80% of their run-in treatment and have not experienced
any aspirin-related severe toxicity (deﬁned as ≥grade 3 CTCAE v4),
nor any grade of gastrointestinal bleeding, active gastrointestinal ulcer-
ation, new or worsening tinnitus, macular degeneration, intracranial
bleeding or hypersensitivity to aspirin. If the investigator feels that the
reason for inadequate adherence is temporary (for example, due to tox-
icity resulting from concomitant adjuvant treatment which has subse-
quently ﬁnished or a non-recurrent unrelated event), the run-in
period may be extended by four or eight weeks to reassess adherence
and toxicity subject to agreement from the central trial team. Those par-
ticipants identiﬁed as suitable for further study participation, and who
remain eligible and are willing to continue in the trial then re-conﬁrm
their consent to participate before being randomised.
2.7. Randomisation
Following assessment at the end of the run-in period, eligible
participants in the UK are randomised by phone and, in India, via the
trial website. Participants undergo a double-blind randomisation.
Randomisation is performed separately within each tumour-speciﬁc
57C. Coyle et al. / Contemporary Clinical Trials 51 (2016) 56–64
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cohort and uses minimization algorithms based on key prognostic fac-
tors (dependent on tumour site), incorporating a random element.
Within each tumour-speciﬁc cohort, participants who are below
75 years old are allocated in a 1:1:1 ratio to either 100 mg aspirin,
300 mg aspirin or a matched placebo. Participants who are 75 years
old or over, are only allocated to either 100 mg aspirin or matched pla-
cebo as toxicity is thought to increasewith age but the allocation ratio of
2:1 remains so that they have the same chance of receiving active
FOUR PARALLEL 
PHASE III COHORTS
BREAST 
COHORT 
GASTRO-
OESOPHAGEAL 
COHORT 
PROSTATE 
COHORT
300mg 
ASPIRIN 
FOLLOW-UP
≥ 5 years, including active follow-up largely aligned with standard care, and long term passive follow-up in the UK
Primary Outcome:
DFS
2600 participants
Primary Outcome:
Invasive DFS
3100 participants
Primary Outcome:
OS
2100 participants
Primary Outcome:
Biochemical RFS
2120 participants
100mg 
ASPIRIN PLACEBO 
Run-in
(100mg Aspirin 
for 8 weeks )
300mg 
ASPIRIN 
100mg 
ASPIRIN PLACEBO 
Run-in
(100mg Aspirin 
for 8 weeks )
300mg 
ASPIRIN 
100mg 
ASPIRIN PLACEBO 
Run-in
(100mg Aspirin 
for 8 weeks )
300mg 
ASPIRIN 
100mg 
ASPIRIN PLACEBO 
COLORECTAL  
COHORT
Run-in
(100mg Aspirin 
for 8 weeks )
Fig. 1. Add-Aspirin trial schema. DFS = Disease free survival, OS = overall survival, RFS = recurrence free survival.
Breast cohort main inclusion criteria
Histologically confirmed invasive breast cancer.
Node positive or node negative with high risk features. 
Surgery (R0 resection) with standard. neoadjuvant 
and/or adjuvant therapy where indicated.
Known HER2 and ER status.
Gastro-oesophageal cohort main inclusion criteria
Oesophageal or gastric adenocarcinoma or squamous 
cell carcinoma.
Previous therapy with curative intent:
Either: Surgery (R0 resection) with standard      
neo-adjuvant +/- adjuvant therapy, 
or Primary chemoradiotherapy
Proton pump inhibitor is mandated for patients 
undergoing partial gastrectomy or oesophagectomy.
Colorectal cohort main inclusion criteria
Stage II or III colon or rectum adenocarcinoma. 
(Patients with resected liver metastases are eligible*).
Surgery (R0 resection) with standard neo-adjuvant 
/adjuvant therapy where indicated.
CEA ≤1.5 X upper limit of normal.
Prostate cohort main inclusion criteria
Histologically confirmed non-metastatic prostate 
adenocarcinoma (T1-3a, N0).
Intermediate or high risk as per D’Amico classification
Previous therapy with curative intent:
Either: Radical radiotherapy, 
or Radical prostatectomy (+/- adjuvant radiotherapy)
or Salvage radiotherapy after radical prostatectomy
Common exclusion criteria
No clinical or radiological evidence of residual or distant disease.                                                         
(*Patients with colorectal cancer who have undergone resection of liver metastases with clear margins are eligible).
No current, regular use of aspirin, NSAIDs or anti-coagulants. 
No pre-disposition to aspirin toxicity (e.g. active ulceration).
For the full eligibility criteria please see the protocol or  www.addaspirintrial.org.
Fig. 2. Summary of eligibility criteria.
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treatment as the other participants. The target randomisation ﬁgure is
9920 participants in the United Kingdom (UK) and India combined. As-
suming that approximately 10% of participants will not be randomised
following the run-in (for reasons relating either to toxicity or adher-
ence), it is expected that 11,000 participants will be registered to
begin the run-in period.
2.8. Follow-up
Patients are followed up at three-monthly intervals initially and then
six-monthly. Adherence to treatment is verbally assessed at every
follow-up visit. In the UK, trial treatment, and active follow-up, con-
tinues for at least ﬁve years after randomisation. Long-term passive
follow-up data will be obtained from routinely-collected healthcare da-
tabases for at least ten further years. Indian participants will be actively
followed-up for at least ten years after randomisation. For participants
that are registered but do not go on to be randomised, active participa-
tion in the trial will end at that time. However, passive follow-up will
continue via routinely-collected healthcare datasets where consent for
this has been obtained. The trial assessment schedule for each cohort
is aligned with standard practice where possible to ensure they can be
implemented easily. This is balanced with the need to ensure appropri-
ate monitoring of patients on trial treatment and assessment of out-
come measures. The trial follow-up schedules are available in
Appendix C.
2.9. Toxicity management
Participants that experience any aspirin-related severe toxicity (de-
ﬁned as ≥grade 3 Common Terminology Criteria for Adverse Events
(CTCAE v4)) or any grade of gastrointestinal bleeding, active gastroin-
testinal ulceration, tinnitus, macular degeneration, intracranial bleeding
or hypersensitivity to aspirin are required to permanently discontinue
aspirin immediately.
For those who are asymptomatic, prophylactic measures to reduce
the risk of gastrointestinal toxicity from aspirin (such as proton pump
inhibitor (PPI) prophylaxis and helicobacter pylori eradication) are not
routinely recommended in participants at low risk of gastrointestinal
complications and so are not mandated in the Add-Aspirin trial proto-
col. However, PPI use for the duration of aspirin treatment is recom-
mended for patients who have undergone oesophagectomy or partial
gastrectomy and should also be considered for older patients (≥75
years), or any other participant whomight be at increased risk of toxic-
ity. Intracranial bleeding is a rare toxicity of aspirin, and hypertension
can increase the risk. Those with poorly controlled hypertension have
trial treatmentwithheld until their blood pressure is controlled. Further
guidelines are available in the trial protocol.
Investigators are advised tomanage toxicities under the assumption
that the participant is receiving the highest possible dose of the active
product (300 mg aspirin), without the need for unblinding, however
where knowledge of treatment allocation would alter clinical manage-
ment, unblinding is possible. Unblinding can be performed via an
access-controlled system available through the trial website (www.
addaspirintrial.org).
2.10. Sub-studies
The size and diversity of the Add-Aspirin cohort provides opportuni-
ty to address other secondary research questions and evaluate novel
methodology. Aspirin has been proposed to have a number of health
beneﬁts beyond cancer, particularly in older people. To investigate the
overall health beneﬁts of aspirin, functional capacity is assessed using
theVulnerable Elders Survey (VES-13) [27]. This is performed for partic-
ipants that are 65 years old or over at trial registration, and ﬁve years
after randomisation and can be administered in person or over the tele-
phone. The hypothesis that aspirin protects against cognitive decline is
assessed using a short version of the Montreal Cognitive Assessment
(the MoCA-blind). The MoCA-blind takes approximately 7 to 10 min
to complete and is administered in all Add-Aspirin trial participants at
registration, then again at one and ﬁve years after randomisation. No
training is required to administer the questionnaire, which can be con-
ducted in person, or over the telephone. A methodological sub-study
will compare the quality and completeness of routinely-collected
healthcare data with data collected within the trial, with the aim of
assessing the suitability of passive follow-up data collection for investi-
gating long-term primary and secondary outcomemeasures within the
trial. This will be an early validation that will determine ongoing use of
routinely collecteddata in the trial. A sub-study is planned to investigate
methods ofmeasuring adherence, including the collection of urine sam-
ples to measure thromboxane B2 (a direct measure of the effects of as-
pirin). Methodological sub-studies to improve site initiation and
recruitment will also be undertaken.
2.11. Translational objectives
The Add-Aspirin trial incorporates a sample repository where a
baseline blood sample and tumour sample are stored for future transla-
tional projects. The sample repository is jointly hosted by two institu-
tions in the UK, Tayside Tissue Bank and the Wales Cancer Bank. In
India, a baseline blood sample and tumour sample from selected sites
will be stored at the TataMemorial Centre biobank. A number of studies
are expected to be initiated whilst the trial is ongoing (subject to
funding), including studies to identify groups that will beneﬁt most
from aspirin use (for example, investigation of the role of tumour
PIK3CAmutation status), and to investigate themechanisms underlying
the anti-cancer effects of aspirin, particularly effects on platelet function
and the pro-thrombotic tumour microenvironment.
3. Results
3.1. Outcomes
Tumour site-speciﬁc primary analyses will take place 5–6 years after
recruitment of the last participant for that cohort, with the exact timing
based on the observed numbers of events. Primary and secondary out-
come measures are available in Table 1. Overall survival is a secondary
outcome measure in all cohorts except the gastro-oesophageal cohort,
where it is the primary outcome. Overall survival will also be assessed
as a co-primary outcome measure in all participants after 15 years.
The longer follow-up and large sample size associatedwith this analysis
will enable any long-term beneﬁts of aspirin to be realised, including
those unrelated to the primary cancer, for example the potential for pre-
vention of deaths related to vascular events and second malignancies.
Consideration of rates of serious toxicity (andparticularly serious haem-
orrhage), as well as other secondary health outcomes, alongside the ef-
ﬁcacy results will be particularly important in these analyses in order to
provide an holistic assessment of the potential risks and beneﬁts associ-
ated with different doses.
3.2. Statistical considerations
Primary analyses will compare outcomes for participants allocated to
aspirin (100 mg and 300 mg arms combined) and participants allocated
to placebo, regardless of the treatment received (i.e. intention-to-treat).
The primary analyses will include both those participants b75 years
who underwent the full randomisation and those ≥75 years who
underwent randomisation between 100 mg aspirin or placebo only, but
the dose effects of aspirin will be investigated only on those randomised
between the two doses.
If an overall effect of aspirin vs. placebo is observed in the primary
treatment comparison for one or more cohorts, a further analysis will
be performed to investigate differences in efﬁcacy according to aspirin
59C. Coyle et al. / Contemporary Clinical Trials 51 (2016) 56–64
337
dose. This analysis will be performed only in the cohorts that show a
positive result for aspirin vs. placebo and will be stratiﬁed by cohort.
By making these analyses conditional on a beneﬁt of aspirin being ob-
served in the primary analysis, the likelihood of a false-positive result
is reduced. The rationale for combining the data across cohorts is to
maximise power, as we anticipate that any difference between doses
of aspirin will be smaller than the difference between aspirin and place-
bo. The trial has also established collaborative links with research
groups running other aspirin cancer trials internationally with a view
to future meta-analyses.
3.3. Sample size breast cohort
Based on data from recent trials, we expect that ﬁve-year invasive
disease-free survival (IDFS) in the control group will be approximately
80% [29–32]. 717 IDFS events will be required to achieve 90% power
to detect a 4% (HR = 0.78) improvement in this rate. Assuming that
the cohort takes 3 1/2 years to recruit, with analysis six years later, we
anticipate that 3100 participants will be required to observe this num-
ber of events.
3.4. Sample size colorectal cohort
Based on data from recent trials, we expect that ﬁve-year disease-
free survival (DFS) in this cohort will be approximately 70% [33,34].
899 DFS events will be required to achieve 90% power to detect a 5%
(HR = 0.80) improvement in this rate. Assuming that the cohort takes
3 1/2 years to recruit, with analysis six years later, we anticipate that
2600 participants will be required to observe this number of events.
3.5. Sample size gastro-oesophageal cohort
Based on data from recent trials, we expect thatﬁve-year overall sur-
vival in this cohort will be approximately 45% [35–39]. 1120 deathswill
be required to achieve 80% power to detect a 6% (HR = 0.84)
improvement in this rate. Assuming that the cohort takes six years to re-
cruit, with analysis ﬁve years later, we anticipate that 2100 participants
will be required to observe this number of events.
3.6. Sample size prostate cohort
The radical prostatectomy and radical radiotherapy groups are
powered to assess effects separately. In the radical prostatectomy
group, we anticipate that biochemical recurrence-free survival (bRFS)
atﬁve yearswill be approximately 75% [40]. For the radical radiotherapy
group, ﬁve year bRFS is estimated to be approximately 65% [41]. To
achieve 90% power to detect an 8% improvement in these rates, 673
bRFS events will be required. Assuming that the cohort takes ﬁve
years to recruit, with analysis ﬁve years later, we anticipate that 2120
participants will be required to observe this number of events.
Sample size calculations for all cohorts are based on a two-sided 5%
signiﬁcance level and account for a degree of loss to follow-up and
slower recruitment in the early stages of the trial. Target registrations
have been inﬂated to allow a 10% dropout after the run-in period.
3.7. Ethical considerations
The trial will be conducted in compliance with the approved proto-
col, the Declaration of Helsinki 2008, the principles of Good Clinical
Practice (GCP), Commission Directive 2005/28/EC with the implemen-
tation in national legislation in the UK by Statutory Instrument 2004/
1031 and subsequent amendments, the UK Data Protection Act (DPA
number: Z5886415), and the National Health Service (NHS) Research
Governance Framework for Health and Social Care (RGF). International
centres will comply with the principles of GCP as laid down by the ICH
topic E6 (Note for Guidance on GCP) and applicable national regula-
tions. The Add-Aspirin trial is registeredwith the International Standard
Randomised Controlled Trial Number ISRCTN74358648, and has also
been submitted for registration with the Clinical trials Registry of India
(REF/2016/06/011465). The Add-Aspirin trial was approved by the
South Central – Oxford C research ethics committee and is part of the
UK National Cancer Research Network (NCRN) portfolio. In India, the
trial has been approved by the Directorate of the National Cancer Grid
(NCG), and is part of the NCG trials portfolio. University College
London (UCL) and the Tata Memorial Centre (TMC) are co-sponsors of
the trial and have delegated responsibility for the overall management
of the Add-Aspirin trial to the MRC CTU at UCL and Tata Memorial Cen-
tre CTU for India.
4. Discussion
The Clinical Trials Authorisation for the Add-Aspirin trial was
granted by the Medicines and Healthcare products Regulatory Agency
(MHRA) on 25th November 2014, and ethics approval was given on
4th June 2014. The ﬁrst participant was recruited on 8th October
2015. At the time of writing on 1st May 2016, the Add-Aspirin trial is
recruiting across 120 centres in the UK, and is recruiting ahead of its
overall projected targets, with the breast cohort the fastest recruiter.
The last of the four cohorts is now expected to complete recruitment
in 2021. Current recruitment ﬁgures are available at www.
addaspirintrial.org.
4.1. Challenges and methodological solutions
There are a number of practical and operational challenges present-
ed by a large adjuvant trial of a generic and repurposed intervention.
These include the need for cost efﬁciencies due to a lack of industry ﬁ-
nancial support for a trial of a generic pharmaceutical; ensuring sufﬁ-
cient long-term adherence in a largely asymptomatic population; and
the potential for control arm contamination due to over the counter
Table 1
Outcome measures.
Cohort Primary outcome measures
Breast cancer Invasive disease-free survival (IDFS) [28]
Colorectal cancer Disease-free survival (DFS)
Gastro-oesophageal
cancer
Overall survival
Prostate cancer Biochemical recurrence-free survival (bRFS)
All cohorts combined Overall survival
Cohort Secondary outcome measures
All cohorts Overall survival (except for gastro-oesophageal cohort)
Adherence
Toxicity
Serious haemorrhage CTCAE (v4) grade 3 or greater
Serious vascular events
Thrombotic events
Diabetes and associated complications
Second malignancies
Age-related macular degeneration
Cognitive assessment (using the MOCA-blind
questionnaire)
Dementia
Comorbidities (using the Charlson Index)
Obesity (using the Body Mass Index)
Functional capacity (using the VES-13 questionnaire)
Breast Breast cancer-speciﬁc survival
Bone metastases-free survival
Invasive disease-free survival-ductal carcinoma insitu
(IDFS-DCIS)
Colorectal Colorectal cancer-speciﬁc survival
Gastro-oesophageal Disease-free survival
Prostate Prostate cancer-speciﬁc survival
Time to initiation of salvage treatment
Bone metastases-free survival
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(OTC) availability of aspirin. These have been addressed using a number
of contemporary methodological approaches.
4.2. Overarching protocol
A platform trial designwas chosen because there is evidence that as-
pirin is potentially effective inmultiple tumours. Investigating the use of
both 100 mg daily and 300 mg daily aspirin across cohorts addresses
uncertainty surrounding the optimal aspirin dose required to achieve
anti-cancer effects, potentially saving many years of research time.
Keeping all four cohorts within a single protocol ensures that the man-
agement of each cohort is as comparable as possible (with the exception
of some site speciﬁc procedures). This allows a combined analysis of
overall survival as a co-primary outcomemeasure and cross cohort sec-
ondary analyses of toxicity, cardiovascular and other health beneﬁts,
thus increasing the overall potential impact of the trial. In addition,
this design provides the capacity to add further tumour sites and also
provides a potential platform for evaluation of other repurposed agents.
An overarching protocol provides economies of scale both centrally and
site level, including site set-up, regulatory approval, central stafﬁng, co-
ordination, oversight and data management. The resulting cost efﬁcien-
cies improve the ﬁnancial viability of the trial given the lack of industry
support, and provide value for money for our charitable and govern-
mental funders.
4.3. Antecedent aspirin use
A proportion of individuals who are otherwise eligible for the trial
will already be taking aspirin regularly. It is conceivable that pre-
existing aspirin use could alter tumour biology [42], and that those al-
ready taking aspirin might be randomised to placebo which would be
unethical. Consequently a decision wasmade to exclude current or pre-
vious regular aspirin users.
4.4. Over the counter aspirin
Unlike most other cancer trials, the intervention in the Add-Aspirin
can be purchased without a prescription. There is a risk that some po-
tential participants might opt to not enter the trial and purchase aspirin
independently. OTC availability of aspirin also leads to the potential for
control arm contamination and an increased risk of toxicity if they are
randomised to 300 mg aspirin. To combat OTC aspirin use, site staff
are trained to re-enforce the key message that as yet, there is no clear
evidence from a randomised trial that adjuvant aspirin use improves
survival, and equipoise is emphasised in all information provided to po-
tential participants. For those already registered, site staff are trained to
regularly ask about and discourage OTC aspirin use. Randomisation to
two doses of aspirin or placebo also leads to a 2:1 chance of receiving
a potentially active agent.
4.5. Timing of entry considerations
The timing of trial registration has been aligned across all four co-
horts to make the treatment of each as similar as possible, however a
number of adjustments have been necessary to account for the variety
of treatment modalities and pathways, and differences in patient char-
acteristics between cohorts. The timing of entry around adjuvant che-
motherapy requires particular consideration. The risk of developing
dyspepsia during adjuvant chemotherapy varies according to the regi-
men used, the need for dexamethasone as a supportive therapy, and
the incidence of risk factors in that group. Dyspepsia is a common occur-
rence during adjuvant chemotherapy for breast cancer and as such, pa-
tients can only register once chemotherapy is complete. In the
colorectal and gastro-oesophageal cohorts dyspepsia developing as a
consequence of adjuvant chemotherapy is less common, and registra-
tion is permitted when six weeks of adjuvant chemotherapy has been
administered (without developing dyspepsia and subject to acceptable
platelet counts).
4.6. Run-in period
The run-in periodwas implemented after funders' concern about the
risk of poor adherence. Adherencewill be assessed during the run-in pe-
riod using three differentmethods to allow amore accurate assessment.
These include a participant diary card, return of used blister packs and
participant interview at an end of run-in assessment. The run-in period
provides an early opportunity to assess feasibility, in terms of early tox-
icity, recruitment and patient acceptability, and provides a population
for the randomised phase who are more likely to tolerate and adhere
to the trial treatment for the duration of the trial [43]. This strategy
has also been used successfully in other aspirin trials [44,45]. We do
not believe that eight weeks of aspirin will reduce the effect between
the aspirin and placebo comparison in the trial as data have consistently
shown that long-term treatment (a minimum of 2 years [1], and up to
5–10 years [2,3]) with aspirin is required for the anti-cancer effects of
aspirin to become identiﬁable [1–3]. The use of the run-in period is
beingmonitored carefully andwill be reviewed on completion of an ini-
tial feasibility phase. Other methods of encouraging adherence include
the use of blister packs labelled with days of the week, provision of
diary cards, participant newsletters and promotion of the trial website
which includes updates and reaction to stories related to aspirin in the
news media.
4.7. Drug supply
Aspirin is a generic drug, Bayer AG donated all doses of the blinded
active intervention and matched placebo, but not the packaging, label-
ling, blinding or distribution,which therefore represented amajor oper-
ational and funding challenge. These challenges have been met by
outsourcing some of these processes and development of an in-house
drug supply management system to track stock levels at sites and auto-
matically trigger re-orders based on projected demand. The system also
includes an unblinding capability.
4.8. Co-enrolment
Since aspirin is intended to be given following or alongside standard
primary therapy, rather than replacing any element of current treat-
ment, it will be appropriate to include participants who have already
taken part in trials of primary treatments wherever possible. This will
allow assessment of the efﬁcacy of aspirin in participants who have re-
ceived both current and potentially future standard of care treatments.
Including participants from other treatment trials will help to ensure
the future relevance of both trials, is important for recruitment feasibil-
ity, and maximises the opportunities for patients to participate in trials.
We have found that the acceptability of co-enrolment to researchers
varies by tumour group. This may be due to variation in the amount of
trial activity or even differences in patient group demographics. Our ap-
proach has been to consider co-enrolment on a trial-by-trial basis,
discussing this with the relevant trial teams, with a careful assessment
of any conﬂicts in eligibility criteria, scheduling and potential impact
on safety and the results of either trial.Where concerns exist, or reassur-
ance is required, statistical modelling is conducted to assess the poten-
tial impact on trial results (there is often limited overlap leading to
negligible impact). Co-enrolment has been agreed with 16 trials to-
date and is planned with other trials currently in development.
4.9. Recruitment in India
Since aspirin is easily available worldwide, demonstrating its imple-
mentation in different resource settings will increase the global impact
of the results. Recruitment in India is also important to ensure adequate
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recruitment in the gastro-oesophageal cohort and also allows the devel-
opment of new international collaborations. Academic multi-centre tri-
als are rare in India and the set-up of Add-Aspirin has helped with
development of a research infrastructure for this and future trials. Re-
cent changes in clinical regulations in India have delayed opening and
the trial is anticipated to open in India later in 2016.
4.10. Conclusions
Aspirin is a low-cost, generic drug that is easily available worldwide.
Consequently, if aspirin is shown to be beneﬁcial as an adjuvant treatment,
even with a modest effect, it would change practice globally. Compared
withmanynewagents or complex regimens, the intervention could be im-
plemented quickly and on a broad scale, including in lower resource set-
tings,with the potential to have a huge impact on the global cancer burden.
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Appendix A. The Add-Aspirin trial investigators
Gastro-oesophageal Cohort Trial Management Group
Professor Ruth Langley Chief Investigator and Lead Investigator, Gastro-oesophageal Cohort (UK) London, UK
Professor C S Pramesh Lead Investigator – India, Lead Investigator, Gastro-oesophageal Cohort (India) Mumbai, India
Dr Richard Hubner Medical Oncologist – Gastro-oesophageal Cohort Manchester, UK
Professor Janusz Jankowski Gastroenterologist – Gastro-oesophageal Cohort Warwick, UK
Mr Tim Underwood Surgeon – Gastro-oesophageal Cohort Southampton, UK
Professor Anne Thomas Medical Oncologist – Gastro-oesophageal Cohort Leicester, UK
Verity Henson Clinical Trials Ofﬁcer Bristol, UK
Professor John Bridgewater Medical Oncologist – Gastro-oesophageal Cohort London, UK
Breast Cohort Trial Management Group
Dr Alistair Ring Lead Investigator – Breast Cohort (UK) London, UK
Professor David Cameron Medical Oncologist – Breast Cohort. Lead Investigator, Translational Research Edinburgh, UK
Professor Sudeep Gupta Lead Investigator – Breast Cohort (India) Mumbai, India
Colorectal Cohort Trial Management Group
Professor Richard Wilson Lead Investigator – Colorectal Cohort Belfast, UK
Dr Tim Iveson Medical Oncologist – Colorectal Cohort Southampton, UK
Professor Robert Steele Surgeon – Colorectal Cohort Dundee, UK
Dr Daniel Swinson Medical Oncologist – Colorectal Cohort Leeds, UK
Ms Farhat Din Surgeon – Colorectal Cohort Edinburgh, UK
Prostate Cohort Trial Management Group
Professor Howard Kynaston Lead Investigator – Prostate Cohort Cardiff, UK
Dr Duncan Gilbert Clinical Oncologist – Prostate Cohort Brighton, UK
Mr Paul Cathcart Surgeon – Prostate Cohort London, UK
Cross-Study Collaborators
Professor Mahesh Parmar Director, MRC CTU London, UK
Professor Peter Rothwell Clinical Neurologist Oxford, UK
Professor Carlo Patrono Pharmacologist Rome, Italy
Professor Sir John Burn Clinical Geneticist Newcastle, UK
Dr David Adlam Cardiologist Leicester, UK
Dr Michael Peake Clinical Lead, National Cancer Intelligence Network London, UK
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Lindy Berkman Participant Representative, NCRI Consumer Forum UK
Mairead MacKenzie Participant Representative, Independent Cancer Patient Voices UK
Vandana Gupta Participant Representative, VCare India
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MRC CTU at UCL
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Ben Sydes Data Manager MRC CTU, UK
Shabinah Ali Data Manager MRC CTU, UK
Alex Robbins Data Manager MRC CTU, UK
Sam Rowley Statistician MRC CTU, UK
Dr Fay Cafferty Project Leader/Senior Statistician MRC CTU, UK
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Appendix B. Figures describing cohort speciﬁc timing of entry criteria
Appendix C. Trial schedules
Assessments Prior to registration Prior to randomisation
(end of run-in period)
Months since randomisation
3 6 9 12 18 24 30 36 42 48 54 60
All cohorts
Main assessments Registration assessmentsa ✓
End of run-in assessmentb ✓
Follow-up assessmentsc ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Intermittent assessments VES-13 questionnaire
(65 ≥ years at registration)
✓ ✓
Cognitive assessment ✓ ✓ ✓
Blood tests FBC, LFT, U&E & eGFR ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
C-Reactive Protein (CRP) ✓ ✓ ✓
Fasting lipid proﬁle ✓
Other tests Tumour and blood sample ✓
Breast cohort
Imaging Mammography ✓ ✓ ✓ ✓ ✓ ✓
Colorectal cohort
Imaging and procedures CT (chest/abdomen/pelvis) ✓ ✓ ✓ ✓
Colonoscopy ✓ ✓ ✓ ✓
Blood tests CEA test ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
(continued on next page)
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(continued)
(continued)
Assessments Prior to registration Prior to randomisation
(end of run-in period)
Months since randomisation
3 6 9 12 18 24 30 36 42 48 54 60
Prostate cohort
Blood tests PSA ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Gastro-oesophageal cohort
No cohort speciﬁc investigations
a Registration assessments include: eligibility, co-enrolment (if applicable), blood pressure, height, weight, blood results, concomitant medication and comorbidities.
b End of run-in assessments include: symptoms and toxicity, adherence, blood pressure.
c Follow-up assessments include: symptoms and toxicity, adherence, blood pressure, weight, concomitant medication.
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Abstract There is now a considerable body of data
supporting the hypothesis that aspirin could be effective in
the prevention and treatment of colorectal cancer, and a num-
ber of phase III randomised controlled trials designed to eval-
uate the role of aspirin in the treatment of colorectal cancer are
ongoing. Although generally well tolerated, aspirin can have
adverse effects, including dyspepsia and, infrequently, bleed-
ing. To ensure a favourable balance of benefits and risks from
aspirin, a more personalised assessment of the advantages and
disadvantages is required. Emerging data suggest that tumour
PIK3CA mutation status, expression of cyclo-oxygenase-2
and human leukocyte antigen class I, along with certain
germline polymorphisms, might all help to identify individ-
uals who stand to gain most. We review both the underpinning
evidence and current data, on clinical, molecular and genetic
biomarkers for aspirin use in the prevention and treatment of
colorectal cancer, and discuss the opportunities for further
biomarker research provided by ongoing trials.
Keywords Aspirin . Acetylsalicylic acid . NSAID .
Colorectalcancer .Chemoprevention .Secondaryprevention .
Primary prevention . Adjuvant therapy . Bleeding . PIK3CA .
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Introduction
Evidence for the anti-cancer effects of aspirin has emerged from
in vitro and animal models, epidemiological studies and
randomised data, with the most extensive evidence pertaining
to colorectal cancer (CRC). Research suggests that aspirin is
effective in primary prevention, reducing the risk of adenomas
[1] and CRC [2•, 3]. There is also evidence for a possible role in
the treatment of cancer, particularly in the adjuvant setting
(preventing recurrence and decreasing the likelihood of metas-
tases after potentially curative therapy) [4, 5•].
The potential benefits of aspirin have to be weighed against
the risk of adverse effects, particularly in the primary preven-
tion setting. Upper gastrointestinal symptoms (UGS) are a
common concern associated with aspirin use, and can limit
adherence, but are usually avoidable. The most undesirable
effect of aspirin is an increased bleeding tendency, which
can manifest as occult gastrointestinal bleeding, epistaxis or
purpura. Serious extra-cranial bleeding is rare (an estimated
3.6 additional events per 10,000 people treated for a year with
aspirin [6]), with the vast majority of bleeding episodes re-
solved without sequelae [7•], and intracranial haemorrhage is
rarer still (an estimated 0.8 additional events per 10,000 peo-
ple treated for a year with aspirin [6]).
Identifying biomarkers or clinical characteristics which
predict benefit from aspirin use could lead to a more targeted
intervention and protect some individuals from unnecessary
treatment and possible side effects. A number of potential
clinical, molecular and genetic biomarkers have been evaluat-
ed including the following: genes mutated in CRC (PIK3CA
and BRAF), molecules proposed to have a role in the mech-
anism through which aspirin exerts its anti-cancer effects (cy-
clo-oxygenase (COX) enzymes and human leukocyte antigen
(HLA) class I expression), and key genetic polymorphisms
that may influence the actions of aspirin.
This review will summarise the current data supporting a
personalised approach to aspirin use in relation to CRC and
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highlight the need to discover and validate biomarkers in on-
going trials. The article is structured into four sections: (i)
primary prevention of CRC, (ii) treatment of CRC, (iii) safety
biomarkers and (iv) other benefit-risk considerations.
Aspirin and Colorectal Cancer Prevention
The ability of aspirin to prevent colorectal carcinogenesis has
been observed in animal models [8–10]. The first clinical ev-
idence emerged in 1988 from a case-control study conducted
in Melbourne, Australia, which showed that aspirin reduced
the risk of developing CRC [11]. This finding was subse-
quently corroborated by several other epidemiological studies,
with a meta-analysis in 2012 of 30 case-control and cohort
studies (n=37,519 CRC cases) showing that aspirin was as-
sociated with a lower risk of developing CRC (relative risk
(RR) 0.73, 95 % confidence interval (CI), 0.67–0.79) [12].
Two large epidemiological studies have recently provided fur-
ther supporting data. The Association of American Retired
Persons Diet and Health study (AARP) included 301,240
adults aged between 50 and 71 years. An estimated 14 %
reduction in CRC was observed with daily aspirin use (hazard
ratio (HR) 0.86, CI 0.79–0.94) during 10 years of follow-up
[13]. A Danish case-control study of 10,280 CRC cases and
102,800 controls showed a reduction in the risk of CRC (odds
ratio (OR) 0.73, CI 0.54–0.99) for those continuously taking
aspirin for at least 5 years [14•].
Randomised data substantiate these observations, with a
meta-analysis of individual participant data on cancer inci-
dence in randomised trials designed to investigate the effect
of aspirin on vascular disease showing that aspirin reduced the
20-year risk of CRC by 24 % (HR 0.76, CI 0.63–0.94), im-
proving to 32 % if taken for ≥5 years (HR 0.68, CI 0.54–0.87)
[3]. Similarly, long-term follow-up from the Women’s Health
Study (WHS), a randomised placebo-controlled trial designed
to assess the effects of aspirin (100 mg on alternate days) in
the primary prevention of cardiovascular disease, showed that
allocation to aspirin reduced the incidence of CRC by 20 %
(HR 0.80, CI 0.67–0.97) [2•].
Recommending aspirin for all has been approached with
caution due to the difficulties of predicting the chance of ben-
efit, and the risk of toxicity on an individual level and there-
fore attention, has naturally turned towards individuals at
highest risk of CRC who may benefit most.
Aspirin and Colorectal Cancer Prevention: Who
Benefits?
Groups at the highest risk of developing CRC include those
with a hereditary CRC syndrome, a history of colorectal ade-
nomas or an inflammatory bowel disease. Aspirin can
exacerbate inflammatory bowel disease and is therefore
avoided, but there is evidence to support an effect of aspirin
in these other high-risk groups.
The most robust evidence exists for Lynch syndrome (hered-
itary non-polyposis colorectal cancer), the most common
inherited CRC syndrome. The CaPP2 (Cancer Prevention Pro-
ject 2) trial randomly allocated patients with Lynch syndrome to
600 mg daily aspirin or placebo and found a reduction in CRC
incidence in those that remained on aspirin for more than 2 years
(HR 0.41, CI 0.19–0.86, p=0.02) [15]. This is in the context of
an overall incidence of CRC in the CaPP2 trial population of
5.6 % (48/861) over 4.5 years of follow-up, and is likely to
represent the group with the highest absolute reduction in risk
of CRC. Intriguingly, a sub-analysis of this trial showed that the
increase in risk of CRC associated with obesity can be abrogated
by aspirin in this population [16•]. Obesity is, thus, a potential
predictive biomarker for aspirin benefit, and further research in
populations other than Lynch syndrome is warranted. Less evi-
dence is available to support an effect of aspirin in familial ade-
nomatous polyposis (FAP), another inherited CRC syndrome.
The CaPP1 trial randomised patients with FAP (prior to preven-
tive surgery), in a 2×2 factorial design, to 600 mg daily aspirin,
resistant starch or placebo. They found a trend towards reduced
polyp load in aspirin users; however, this did not reach statistical
significance (relative risk 0.77, CI 0.54–1.10) [17]. The median
duration of aspirin use was only 17months and it is plausible that
a treatment effect may have emerged with longer exposure.
Adenomas are precursor lesions for most cases of CRC,
and their prevention or regression has been proposed to rep-
resent a surrogate marker for CRC risk [18]. A meta-analysis
of four randomised controlled trials, including 2967 individ-
uals with previous adenomas or CRC (without an inherited
CRC syndrome), found that those allocated to aspirin had a
reduced risk of any subsequent adenoma (risk ratio 0.83, CI
0.72–0.96) or advanced adenoma (risk ratio 0.72, CI 0.57–
0.90) [1]. This corresponded to a reduction in the absolute risk
of any adenoma of 6.7 % (CI 3.2–10.2 %). Further research is
needed to confirm whether individuals with a history of ade-
nomas benefit more from aspirin than those without.
Whilst those at highest risk of CRC are most likely to gain
from chemoprevention with aspirin, it may be possible to
identify those that benefit in lower risk populations. Newly
emerging data show that aspirin users with certain single-
nucleotide polymorphisms (SNPs) have a reduced risk of de-
veloping CRC, and their absence may describe a group who
will not benefit. A case-control study of 840 CRC patients and
1686 matched controls examined CRC risk according to ex-
pression of the T allele of rs6983267, which is associated with
reduced WNT/β-catenin signalling, a major oncogenic path-
way in CRC, proposed to be affected by aspirin. They ob-
served that aspirin reduced CRC risk in the cohort as a whole
(OR 0.71, CI 0.60–0.85), but the effect was most marked in
individuals with a T allele of rs6983267 (OR 0.83, CI 0.74–
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0.94) [19••]. A larger case-control study (8634 cases, 8553
controls) examined the risk of CRC according to expression
of two different SNPs, rs2965667 (located close to the micro-
somal glutathione S-transferase 1 gene, often upregulated in
CRC) and rs16973225 (located close to the interleukin 16
gene, which has been implicated in CRC carcinogenesis)
[20••]. It was observed that use of aspirin and/or non-
steroidal anti-inflammatory drugs (NSAIDs) was associated
with a reduced risk of CRC amongst individuals with TT
genotype of SNP rs2965667 (OR 0.66, CI 0.61–0.70) and
the AA genotype of rs16973225 (OR 0.66, CI 0.62–0.71),
but not in those with other rarer genotypes. Germline genetic
polymorphisms have the potential to identify individuals that
benefit from aspirin, as well as those that do not, within pop-
ulations at lower risk of CRC, and further investigation using
existing datasets is required.
Aspirin and Colorectal Cancer Treatment
In vitro studies show that aspirin inhibits proliferation and
induces apoptosis in CRC cell lines [21, 22] suggesting a
possible role for aspirin in the treatment of CRC. Figure 1
summarises the results of the clinical studies investigating
the effect of aspirin use after a CRC diagnosis. The first epi-
demiological data emerged from the Nurses’ Health Study
(NHS) and Health Professionals Follow-up Study (HPFS)
showing that regular aspirin use after a diagnosis of CRC is
associated with a reduction in CRC deaths (HR 0.71, CI 0.53–
0.95) and overall mortality (HR 0.79, CI 0.65–0.97) [24]. This
has recently been corroborated by a large cohort of CRC pa-
tients from the Cancer Registry of Norway where improve-
ments in overall survival (HR 0.71, CI 0.68–0.75) and CRC-
specific survival (HR 0.53, CI 0.50–0.57) were seen with as-
pirin use after CRC diagnosis [25]. Similar improvements in
mortality were observed in data from the Eindhoven Cancer
Registry (ECR) (overall survival RR 0.77, CI 0.63–0.95) [26]
and in population data collected in Tayside, Scotland (overall
mortality HR 0.67, CI 0.57–0.79, and CRC-specific mortality
HR 0.58, CI 0.45–0.75) [27]. Observational data from the
CALGB 89803 trial (which compared two different adjuvant
chemotherapy regimens in patients with stage III colon can-
cer) has also shown a trend towards improved overall survival
(HR 0.63, CI 0.35–1.12) and disease-free survival (HR 0.68,
CI 0.42–1.11) in those patients using aspirin both during and
after chemotherapy [28•]. A study of 13,994 CRC patients
from the UK General Practice Research Database found a
strong trend towards a reduction in overall mortality; however,
this failed to reach significance (HR 0.91, CI 0.82–1.00) [29].
Data on cancer outcomes from randomised trials investi-
gating the effects of aspirin in vascular disease corroborate the
trends seen in epidemiological studies. A meta-analysis which
included 13,833 individuals who developed CRC in four vas-
cular trials has shown significant reductions in CRC deaths
(HR 0.66, CI 0.51–0.85) [3]. Another meta-analysis of five
vascular trials has shown that aspirin is associated with a re-
duction in the risk of having metastases when CRC is diag-
nosed (OR 0.36, CI 0.18–0.74) and of subsequently develop-
ing them during follow-up when not present at diagnosis (HR
0.26 CI 0.11–0.57) [30].
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Aspirin and Colorectal Cancer Treatment: Who
Benefits?
Much of the work on potential biomarkers relating to aspirin use
as a treatment for CRC has come from three large cohorts (NHS
[24], HPFS [24] and ECR [26]). An initial analysis of the NHS/
HPFS dataset reported that the beneficial effects of aspirin on
CRC outcomes were restricted to individuals whose tumours
overexpressed COX-2 (HR 0.39, CI 0.20–0.76)and not observed
for those with weak or absent expression (HR 1.22, CI 0.36–
4.18) [24]. Whilst inhibition of either COX-1 or COX-2 is suffi-
cient to inhibit tumourigenesis in mousemodels [31], uncertainty
exists about the role of COX enzymes in relation to the anti-
cancer effects of aspirin, particularly given that the daily doses
of aspirin used in vascular prevention are not considered suffi-
cient for sustained COX inhibition in systemic tissues [32]. The
predictive utility of COX-2 has not been seen in other colorectal
studies [33••] or comparative studies in breast cancer [34].
Although the mechanism by which aspirin exerts its anti-
cancer effects remains unknown, one proposed hypothesis
was that aspirin, through its anti-platelet effects, could expose
circulating tumour cells to immune-mediated destruction by
natural killer cells [35] and that this effect would be restricted
to tumours with low or absent HLA class I expression. How-
ever, analyses of a random sample of colon tumour samples
(n=999) from the ECR found that the benefit from aspirin
therapy was largely restricted to tumours expressing HLA
class I antigens (risk ratio 0.53, CI 0.38–0.74), and was not
seen in those who had lost expression (risk ratio 1.03; CI
0.66–1.61) [33••]. This interesting observation, contrary to
the original study hypothesis, requires validation in further
datasets. HLA class I expression is seen in about a third of
colorectal tumours and so could identify a sizeable group who
might benefit from aspirin after a CRC diagnosis.
There has been significant interest in the phos-
phatidylinositol 3-kinase (PI3KCA) gene as a potential bio-
marker of aspirin response (Table 1). This follows the publi-
cation of data from the NHS/HPFS demonstrating that indi-
viduals with PIK3CA mutations taking regular aspirin after a
diagnosis of CRC had markedly improved CRC-specific sur-
vival (HR 0.18, CI 0.06–0.61) compared to those with wild-
type tumours (HR 0.96, CI 0.69–1.32). The same association
was observed for overall survival (mutated PIK3CA HR 0.54,
CI 0.31–0.94, wild-type PIK3CA HR 0.94, CI 0.75–1.17)
[36]. This finding was supported by a small ad hoc analysis
of the randomised VICTOR trial, where rofecoxib (a Cox-2
inhibitor) was being evaluated after CRC resection but the trial
was closed early when rofecoxib was withdrawn from the
market. Individuals with PIK3CA mutations taking regular
aspirin after diagnosis had improved recurrence rates (HR
0.11, CI 0.001–0.83), whereas those lacking PIK3CA muta-
tion did not (HR 0.92, CI 0.60–1.42), although the number of
participants taking aspirin with the mutation was small
(n=14) [37•]. However, data from two recent studies has not
confirmed the association. In the ECR dataset, the survival
benefit associated with aspirin use after a colon cancer diag-
nosis was seen in those with wild-type PIK3CA tumours (rate
ratio 0.55, CI 0.40–0.75), as well as those with PIK3CA-
mutated tumours where there was a trend towards a survival
benefit but this did not reach statistical significance (rate ratio
0.73, CI 0.33–1.63) [33••]. In addition, in a cohort of patients
with PIK3CA-mutated CRCs from the Moffitt Cancer Centre
and Royal Melbourne Hospital (n=1487), no overall survival
benefit was observed (HR 0.96, CI 0.58–1.57) and, whilst
there was a trend towards a CRC-specific survival benefit, this
was not significant (HR 0.60, CI 0.34–1.16) [38•]. PIK3CA
mutations only occur in 10–15 % of patients with CRC,
whereas the epidemiological data suggest that a greater
Table 1 Studies examining PIK3CA mutation, aspirin use and colorectal cancer outcomes
Study PIK3CA
mutation (%)
PIK3CA mutant PIK3CAwild type
No
aspirin
Aspirin Outcome HR 95 % CI
p value
No aspirin Aspirin Outcome HR 95 % CI
p value
NHS and
HPFS [36]
16.7 95 66 OS 0.54 0.31–0.94 p = 0.01 466 337 OS 0.94 0.75–1.17 p= 0.96
CSS 0.18 0.06–0.61 p < 0.001 CSS 0.96 0.69–1.32 p= 0.76
VICTOR
trial [37•]
11.6 90 14 OS 0.29 0.04–2.33 p = 0.19 681 111 OS 0.95 0.56–1.61 p= 0.26
CSS 0.11 0.001–0.83 p = 0.027 CSS 0.94 0.59–1.49 p= 0.79
MCS and
RMH [38•]
12.4 136 49 OS 0.96 0.58–1.57 p = 0.86 Study of PIK3CA-mutated tumours only
CSS 0.60 0.34–1.16 p = 0.14
ECRa [33••] 15.8 73 27 OS 0.73b 0.33–1.63 p = 0.4 348 147 OS 0.55 0.40–0.75 p< 0.001
Multivariate (adjusted) statistics are presented in all cases
OS overall survival, CSS colorectal cancer-specific survival, RFS recurrence-free survival, NHS Nurses’ Health Study, HPFS Health Professionals
Follow-up Study, MCS Moffitt Cancer Centre, RMH Royal Melbourne Hospital, ECR Eindhoven Cancer Registry, HR hazard ratio
a Colon cancer only
b Rate ratio
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proportion of CRC patients benefit from aspirin use after a
CRC diagnosis; therefore, this biomarker needs further inves-
tigation, ideally in randomised trials.
A cohort of 1226 patients with a diagnosis of CRC from the
NHS and HPFS have also been analysed for BRAF mutation
status. The effect of aspirin, after a cancer diagnosis, on
cancer-specific and overall survival did not differ according
to BRAFmutation status, but may have lacked statistical pow-
er. Interestingly, in terms of cancer prevention, aspirin was
associated with a lower risk of developing a BRAF wild-
type CRC (HR 0.73, CI 0.64–0.83), but not with BRAF-
mutated CRC (HR 1.03, CI 0.76–1.38) [39•].
The risk of CRC recurrence after potentially curative treat-
ment depends on a number of prognostic factors, which in-
clude stage, mode of presentation, microsatellite instability
status and whether adjuvant chemotherapy was administered.
Any relative improvement in CRC outcomes with aspirin will
need to be considered in the context of an individual’s abso-
lute risk of recurrence.
Identifying Those at Risk of Toxicity
Aspirin has been used for over 100 years [40] and has a well-
documented toxicity profile. Standard contraindications to as-
pirin use include the following: a history of active or recurrent
peptic ulceration, active gastrointestinal bleeding, previous
intracranial haemorrhage, a haemorrhagic diathesis or a coag-
ulation disorder. Avoiding co-administration of other
NSAIDs, anti-coagulants or corticosteroids also reduces the
risk of adverse effects [41].
UGS are common side effects associated with aspirin, with
one survey reporting 15.4 % (n=152/986) of long-term low-
dose aspirin users experiencing UGS [42]. A history of gastro-
oesophageal reflux disease or dyspepsia prior to starting aspi-
rin has been shown to be strongly predictive of UGS on aspi-
rin (OR 17.6, CI 11.52–26.88) [42]. Helicobacter pylori in-
fection has been proposed to be a marker of increased risk of
developing dyspepsia and a bleeding gastrointestinal ulcer
with aspirin [7•]; however, most data supporting this associa-
tion relates to non-aspirin NSAID use; and therefore, further
data is needed to confirm a relationship with aspirin [43]. The
HEAT trial (ISRCTN10134725), examining H. pylori eradi-
cation to prevent ulcer-related bleeding and dyspepsia in as-
pirin users, is ongoing.
The most common cause for concern in relation to aspirin
use is the risk of bleeding. Data from six cardiovascular pri-
mary prevention RCTs (n=95,000) estimated that aspirin in-
creased the risk of serious bleeding (excluding intracranial
haemorrhage) by 0.04 % per year (from 6.6 events per year
in 10,000 individuals to 10.2 events [6]). Age has been shown
to be a key predictor of bleeding risk with a recent systematic
review estimating that the risk of major bleeding increases
between three- and fourfold between the ages of 50–54 and
70–74 years [7•]. Intracranial haemorrhage is even rarer with
aspirin estimated to increase the risk by less than 0.01 % per
year (from 2.7 events in 10,000 individuals treated for a year
in the control groups to 3.5 events in the aspirin groups, HR
1.39, CI 1.08–1.78) in the aforementioned analysis of six car-
diovascular RCTs of aspirin. This study also revealed that
mean blood pressure is associated with an increased risk of
intracranial haemorrhage (rate ratio 2.18, CI 1.65–2.87) [6].
Certain genetic polymorphisms have been proposed as po-
tential biomarkers for NSAID-induced gastrointestinal ulcer-
ation and bleeding. A study in a Japanese population (n=480)
found that a functional SNP of the COX-1 gene (rs1330344)
has been shown to be significantly associated with gastric
ulceration (OR 5.80, CI 1.59–21.1) [44]. Additionally, two
polymorphisms of CYP2C9 (an enzyme responsible for the
metabolism of aspirin) have been found to be significantly
associated with bleeding risk in NSAID users [45, 46].
Biomarkers including increasing age, previous dyspepsia
and certain SNPs have the potential to identify those at
greatest risk of aspirin toxicity. Furthermore, diagnosing and
treating conditions like hypertension and H. pylori infection
could also reduce the change of adverse effects.
Other Benefit-Risk Considerations
Aspirin is an established treatment for the secondary prevention
of cardiovascular disease but is not generally recommended for
its primary prevention, however a recommendation for its use in
both the prevention of cardiovascular disease and cancer is cur-
rently under consideration by the United States Preventive Ser-
vices Task Force [47]. Little is known about the cardiovascular
benefits of aspirin in those with cancer as this is an exclusion
criterion in most large cardiovascular trials. CRC and cardiovas-
cular disease have a number of common risk factors, including
obesity, high cholesterol and diabetes, and any cardiovascular
benefits might add to the rationale for aspirin use in the context
of CRC prevention or treatment. Data from cardiovascular trials
has additionally suggested that some individuals are resistant to
the biological effects of aspirin [48] which also has the potential
to limit anti-cancer activity. The existence of aspirin resistance is
challenged by the finding that serum thromboxane B2 (a serum
marker of platelet activation) is suppressed by aspirin in 99 % of
healthy subjects [49]. Other explanations to account for the phe-
nomena include variability in some functional assays of platelet
function or undetected poor adherence to aspirin [50]. Fast re-
covery of platelet function in some individuals might have pre-
viously been categorised as resistance, and this might be ad-
dressed with twice daily doses [51]. Both the cardiovascular
effects of aspirin and the possibility of aspirin resistance could
alter the overall risk-benefit profile, and thus require further in-
vestigation in existing datasets and ongoing trials.
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Conclusions
The current data on the benefits and risks of prophylactic aspirin
in the general population has recently been reviewed by Cuzick
et al. who concluded that aspirin use for greater than 5 years (75–
325 mg/day), starting between the ages of 55 and 65, has a
favourable benefit-harm profile [52••]. Phase III trials investigat-
ing the role of aspirin for cancer prevention in the general pop-
ulation are likely to be challenging due to the length of follow-up
and number of participants required. However, in higher risk
groups, trials are more feasible. The CaPP3 trial (Cancer Preven-
tion Project 3), examining different doses of aspirin for the pre-
vention of Lynch syndrome cancer (ISRCTN16261285), and the
seAFOod (Systematic Evaluation of Aspirin and Fish Oil Bowel
Polyp Prevention Trial), examining the effect of aspirin and fish
oil in patients at high risk of colorectal adenomas
(ISRCTN05926847), are ongoing and the results are awaited.
The role of aspirin in the treatment of CRC is also being
evaluated in a number of recruiting phase III trials. Add-
Aspirin (ISRCTN74358648) is a double-blind placebo-con-
trolled trial for patients with colorectal, breast, gastro-
oesophageal and prostate cancer, investigating the effects of
aspirin in the adjuvant setting. Participants are randomised to
aspirin 300 mg, aspirin 100 mg or placebo for at least 5 years,
and it is separately powered for each tumour type to assess the
effects of tumour-specific outcomes. Other ongoing trials in
this setting include ASCOLT (Aspirin for Dukes C and High
Risk Dukes B CRCs, NCT00565708) and ASPIRIN (ATrial
of Aspirin on Recurrence and Survival in Elderly Colon Can-
cer Patients, NCT02301286). There are also three upcoming
trials investigating the effects of aspirin in molecularly strati-
fied groups. In the adjuvant setting, ALASCCA is a
randomised, double-blind, placebo-controlled phase III trial
of aspirin in colorectal patients with mutations in the PI3K
signalling pathway (PIK3CA, PIK3R1 or PTEN mutations),
and SAKK 41/13 (Swiss Group for Clinical Cancer Re-
search), a double-blind, placebo-controlled randomised trial
of adjuvant aspirin treatment in PIK3CA-mutated colon can-
cer patients (NCT02467582). In the advanced setting,
FOCUS4-B (ISRCTN90061546) plans to investigate the role
of aspirin in individuals with PIK3CAmutant advanced CRC.
Prior to being considered as an intervention in randomised
trials, aspirin has not followed the modern target-driven drug
development pathway taken by other anti-cancer agents. Conse-
quently, biomarker discovery and validation is at an early stage.
Ideally, predictive biomarkers are co-developed with a drug and
validated in phase I and II trials prior to defining the population
for phase III trials [53]. However, potential biomarkers for aspi-
rin have mostly emerged from observational studies where there
is a risk of confounding and, therefore, it is highly important that
they are investigated further in ongoing trials. Research into the
mechanisms underlying the anti-cancer effects of aspirin may
also reveal new biomarkers. The likelihood of a single
biomarker that can identify individuals that will or will not ben-
efit from aspirin is low, and thus, it will be important to inves-
tigate patterns of multiple biomarkers to select individuals who
will gain from aspirin therapy.
Aspirin is a low-cost, generic agent, available in both
resource-poor and resource-rich countries. If it can be shown
to be effective, there is the potential for a major impact on the
global burden of CRC. Identifying those who are most likely
to benefit will be essential to maximising this potential.
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Metformin as an adjuvant treatment for cancer:
a systematic review andmeta-analysis
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Background: Metformin use has been associated with a reduced risk of developing cancer and an improvement in
overall cancer survival rates in meta-analyses, but, to date, evidence to support the use of metformin as an adjuvant
therapy in individual cancer types has not been presented.
Patients and methods: We systematically searched research databases, conference abstracts and trial registries for
any studies reporting cancer outcomes for individual tumour types in metformin users compared with non-users, and
extracted data on patients with early-stage cancer. Studies were assessed for design and quality, and a meta-analysis
was conducted to quantify the adjuvant effect of metformin on recurrence-free survival (RFS), overall survival (OS) and
cancer-speciﬁc survival (CSS), to inform future trial design.
Results: Of 7670 articles screened, 27 eligible studies were identiﬁed comprising 24 178 participants, all enrolled in
observational studies. In those with early-stage colorectal cancer, metformin use was associated with a signiﬁcant beneﬁt
in all outcomes [RFS hazard ratio (HR) 0.63, 95% conﬁdence interval (CI) 0.47–0.85; OS HR 0.69, CI 0.58–0.83; CSS HR
0.58, CI 0.39–0.86]. For men with early-stage prostate cancer, metformin was associated with signiﬁcant, or borderline
signiﬁcant, beneﬁts in all outcomes (RFS HR 0.83, CI 0.69–1.00; OS HR 0.82, CI 0.73–0.93; CSS HR 0.58, CI
0.37–0.93); however, there was signiﬁcant heterogeneity between studies. The data suggest that prostate cancer patients
treated with radical radiotherapy may beneﬁt more from metformin (RFS HR 0.45, CI 0.29–0.70). In breast and urothelial
cancer, no signiﬁcant beneﬁts were identiﬁed. Sufﬁcient data were not available to conduct analyses on the impact of
metformin dose and duration.
Conclusions: Our ﬁndings suggest that metformin could be a useful adjuvant agent, with the greatest beneﬁts seen in
colorectal and prostate cancer, particularly in those receiving radical radiotherapy, and randomised, controlled trials
which investigate dose and duration, alongside efﬁcacy, are advocated.
Key words:metformin, repurposing, adjuvant, prostate cancer, colorectal cancer, breast cancer
introduction
Although cancer survival rates in the UK have doubled in the
last 40 years, half of those diagnosed with cancer still die from
their disease within 10 years [1, 2]. Adjuvant treatment after po-
tentially curative cancer therapy improves survival rates, but
relapse rates remain high in some tumour types, and for others,
there are no proven adjuvant treatments. In the quest to
improve cancer outcomes, a number of established medications
with known anti-cancer properties have been considered as
adjuvant anti-cancer therapies. Examples include aspirin [3],
vitamin D [4], bisphosphonates [5], statins [6] and metformin.
Metformin exhibits a number of attributes that make it
appealing for repurposing as an anti-cancer therapy. It has been
in use for over half a century and is the most widely prescribed
anti-diabetic medication in the world [7]. Consequently, it has
been administered alongside most cancer treatments without
the emergence of any important interactions. Additionally, data
on the toxicity proﬁle of metformin in those without type II
diabetes mellitus (DM) are already available from clinical trials
investigating its role as a treatment for polycystic ovarian syn-
drome [8]. Metformin is also generically available worldwide at
low cost.
Metformin has been shown to have anti-cancer activity both in
vivo and in vitro [9], with the underlying mechanism subject to
ongoing investigation. It has been proposed that the anti-cancer
properties of metformin result from both direct effects on cancer
cells, particularly through inhibition of the AMPK/mTOR
pathway [10], and indirect effects on the host, by virtue of its
blood glucose-lowering properties and anti-inﬂammatory effects
[11, 12]. Both mechanisms are anticipated to be important,
although their relative contribution may differ according to
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cancer stage. In vivo evidence has emerged from window studies
showing an anti-proliferative effect in breast cancer [13, 14] and
a reduction in precancerous changes in the colorectum [15].
Meta-analyses have examined the role of metformin in the
primary prevention of cancer, where it was found to signiﬁcantly
reduce overall cancer incidence; however, ﬁndings were inconsist-
ent when individual tumour types were considered [16–20].
Meta-analyses have also investigated the effect of metformin use
across all stages of disease and have found that it reduces overall
cancer mortality rates, but, again ﬁndings are conﬂicting for
individual tumour types [21–28], suggesting analyses are best
conduced for individual tumour types separately. Most recently,
a randomised phase III trial of non-DM patients showed that
low-dose metformin was effective in the chemoprevention of
metachronous colorectal adenomas or polyps when compared
with placebo [29].
Beneﬁts in the primary prevention, or advanced setting, do
not necessarily translate to utility in the adjuvant setting as the
mechanism of action may be different. Our objective was to
conduct a systematic review and meta-analysis of randomised
and non-randomised studies to investigate the effect of metfor-
min use compared with non-use on recurrence-free survival
(RFS), overall survival (OS) and cancer-speciﬁc survival (CSS)
in adults who have potentially curable solid tumours. There
have been a number of calls for systematic reviews and meta-
analyses to be conducted as part of the scientiﬁc justiﬁcation,
and to inform the design, of new clinical trials [30, 31]. This is
particularly relevant in the ﬁeld of drug repurposing. The aim
of this analysis was to advise further clinical investigation of
metformin in the adjuvant setting.
methods
All methods for this systematic review and meta-analysis are
outlined in a prospectively registered protocol available online
[32] (PROSPERO identiﬁer CRD42015020519), and reporting
follows PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines.
eligibility criteria
Eligible studies include randomised, controlled trials and non-
randomised studies (observational, cohort and case–control)
that have investigated the use of metformin, with a comparator
of no metformin, in participants over 16 years old with poten-
tially curable solid tumours (deﬁned as those either undergoing
radical therapy with curative intent or those with an early-stage
cancer where cure is normally the objective of standard treat-
ment). Studies must have reported data on at least one of RFS,
CSS or OS for individual tumour types.
search strategy
Electronic searches of databases (Medline, EMBASE, Cochrane
Central Register of Controlled Trials), clinical trial registries (clin-
icaltrials.gov, ISRCTN and EU Clinical Trials Register) and con-
ference proceedings (American Society of Clinical Oncology, and
European Society of Medical Oncology) were conducted. All
sources were searched from inception until 31 May 2015 (confer-
ence abstracts 2005–2015). Bibliographies of the reports of all
identiﬁed studies and review articles were hand-searched for
further potentially eligible studies. Further details of the search
strategy are available in supplementary data S1, available at
Annals of Oncology online.
study selection
All retrieved studies were assessed for eligibility and, when sufﬁ-
cient information was not available from the title and/or
abstract, the full-text publication or (for conference abstracts)
the associated poster or presentation was acquired and where
this was not available, we contacted the study author. For
studies with multiple publications, or where there was overlap in
the patients studied, the most recent publication was chosen.
Any queries were checked by a second reviewer and resolved by
consensus. No study was excluded for weakness of study design
or quality. For the purpose of this analysis, studies presenting
data separately by tumour type were treated as separate studies.
Articles were grouped by cancer type according to the site of
origin and histology.
data items and collection
Data on patient characteristics, interventions and outcomes
were extracted for all studies into a predesigned table. These
were cross-checked by a second independent reviewer and any
disagreements were resolved by consensus. A list of data
extracted is available in supplementary data S2, available at
Annals of Oncology online. Studies were evaluated to determine
whether they accounted for potential confounding factors [body
mass index (BMI), age, gender, cancer-speciﬁc prognostic
factors and the use of other anti-DM medications], either by
demonstrating that there was no signiﬁcant difference in their
distribution between treatment groups or by inclusion in multi-
variable analyses. In order to minimise the potential for con-
founding by DM status, where the comparator included both
non-DM patients and DM non-metformin users, we extracted
data based on a DM non-metformin comparator in preference.
Where a time-varying covariate was used to model treatment
effect, the most conservative HR was selected. Where reported,
the HR after adjustment for potential confounding factors was
extracted in preference to an unadjusted value. Since all eligible
studies were of cohort design, the Newcastle–Ottawa quality
assessment scale for cohort studies (NOS) [33] was used to
evaluate methodological quality.
statistical analysis
HRs and associated statistics were either extracted directly from
the study reports or estimated from the Kaplan–Meier curves or
summary statistics using published methods [34–36]. Where
sufﬁcient data were available on outcomes for individual cancer
types, a meta-analysis was conducted with a primary outcome
of RFS and secondary outcomes of OS and CSS. HRs were com-
bined across trials using a ﬁxed-effect model. Heterogeneity was
assessed using the χ2 test and the I2 statistic. A random-effects
model (DerSimonian and Laird) [37] was used to assess
whether the results were robust to the choice of model.
Probability values were two-sided, with P < 0.05 considered of
statistical signiﬁcance.
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We also preplanned analyses to explore whether the size or
the direction of the effect of metformin therapy varied accord-
ing to speciﬁc study or patient characteristics, including: DM
status of the comparator group (with and without non-DM
patients in the comparator group), prostate cancer primary
treatment type (prostatectomy or radical radiotherapy) and
study design. The resulting HR estimates from study group
analyses were compared using the χ2 test for interaction. We
also planned to explore the impact of metformin dose/expos-
ure on the outcomes described above where available. We also
conducted unplanned sensitivity analyses for the primary
outcome of RFS where at least two studies were available after
restrictions. This was carried out according to study quality
(restricted to studies with an NOS score ≥ the median); publi-
cation type (restricted to studies where a full publication was
available); setting (restricted to hospital-based studies); follow-
up (restriction of follow-up <3 years); and by the potential
confounding factors accounted for (restricted to studies that
adjusted for BMI, age, gender, cancer-speciﬁc prognostic
factors and other DM medications). An additional unplanned
exploratory analysis was also conducted according to whether
the study was from a Western (North America or Europe) or
non-Western population after a wide geographical distribution
of studies was noted. Study group and sensitivity analyses were
only conducted where study numbers were sufﬁcient to be
meaningful. Statistical analyses were carried out using STATA
version 14.
results
After screening 7670 reports and conference abstracts, we iden-
tiﬁed 23 full publications and 4 conference abstracts that met
our eligibility criteria, comprising 24 178 participants [38–64].
All were retrospective cohort studies except for one prospective
cohort study embedded in a clinical trial [41]. The PRISMA
study selection diagram is shown in Figure 1. The majority of
identiﬁed studies examined the effect of metformin in one of
four tumour types: prostate, colorectal, breast and urothelial
cancer, which, therefore, represent the main focus of this ana-
lysis. A summary of the main characteristics for studies of
breast, colorectal and prostate cancer is presented in Table 1,
and a table of study characteristics for other cancer types is
presented in Table 2.
colorectal cancer
RFS was assessed in two studies (623 patients), OS in ﬁve
studies (1936 patients) and CSS in two studies (535 patients).
Overall, metformin use appeared to demonstrate signiﬁcant
improvements in RFS (HR 0.63, CI 0.47–0.85), OS (HR 0.69, CI
0.58–0.83) and CSS (HR 0.58, CI 0.39–0.86) (Figure 2), although
there was variation between the results of the individual studies
for RFS (I2 = 83.1%, P = 0.015) and OS (I2 = 82.3 P < 0.001).
When the random-effects model was applied, the beneﬁts seen
for both OS (HR 0.62, CI 0.40–0.97) and CSS (HR 0.58, CI
0.39–0.86) remained, but there was no longer a signiﬁcant
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Full text and
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Figure 1. PRISMA study selection diagram.
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Table 1. Main study characteristics: colorectal, prostate and breast cancer
Tumour group Study author Patient characteristics Study characteristics Comparator
DM status
Outcomes Definition of
metformin
exposure
Median
follow-up
(months)
Potential confounders (R = reported
and not significant, M = included in
multivariate model, x = not assessed,
or significant but not adjusted for)
NOS
score
Treatment Stage/other
restrictions
Sample
size (met/
total)
Article
type
Study location Setting
(H = Hospital,
P = Population)
DM Non-DM RFS OS CSS BMI Age Sex Cancer-
specific
variables
Other
DM
meds
Colorectal
adenocarcinoma
Spillane [38] Not specified I–III 207/315 Full Ireland P ✓ X X ✓ ✓ In year before
diagnosis
46 X M M M M 7
Lee, GE [39] Not specified II–III 223/356 Abstract Singapore H ✓ X ✓ ✓ X At diagnosis 78 X M X M X 5
Lee, JH [40] Not specified IIIa 96/220 Full Korea H ✓ X X ✓ ✓ >6 m exposure 41 Mb Mb Mb Mb Mb 8
Singh [41] Not specified III /colon
only
115/267 Abstract USA and
Canada
H ✓ X ✓ ✓ X Before
randomisation
Not given X M M M X 5
Zanders [42] Not specified I–III 512/778 Full The
Netherlands
P ✓ X X ✓ X Cumulative
exposure
41 X M M M M 7
Prostate
adenocarcinoma
Allott [43] Prostatectomy Localised 155/369 Full USA H ✓ X ✓ X ✓ At surgery 59/73c M M n/a M X 8
Kaushik [44] Prostatectomy Localised 323/885 Full USA H ✓ X ✓ ✓ X In 3 months
before surgery
61 M M n/a M R 7
Rieken WJU
[45]
Prostatectomy Localised 287/6486 Full USA and
Europe
H X ✓ ✓ X X At surgery 25 X M n/a M n/a 6
Spratt [46] Radical
radiotherapy
Localised 157/319 Full USA H ✓ X ✓ ✓ ✓ At diagnosis or
after
radiotherapy
104 R M n/a M R 8
Margel [47] Prostatectomy or
radical
radiotherapy
Localiseda/
≥66 years
old
Total 955 Full Canada P ✓ X X ✓ ✓ Cumulative
exposure
56 X M n/a M M 8
Zannella [48] Radical
radiotherapy
Localised 114/504 Full Canada H ✓ ✓ ✓ X X At the time of
radiotherapy
82 X R n/a M X 5
Danzig [49] Prostatectomy Localised 98/767 Full USA H ✓ X ✓ X X At surgery 27 X M n/a M X 6
Taira [50] Brachytherapy Localised 126/2298 Full USA H ✓ ✓ X ✓ X Diagnosis to 3
months after
brachytherapy
100 M M n/a M X 7
Breast
adenocarcinoma
Oppong [51] Adjuvant chemo I–III 76/141 Full USA H ✓ X ✓ ✓ X Diagnosis to 6
months after
87 R M n/a M M 8
Bayraktar
[52]
Adjuvant chemo I–III/triple
negative
63/130 Full USA H ✓ X ✓ ✓ X During adjuvant
chemo
62 M
d
M n/a M R 8
Lega [53] Breast cancer
surgery
Infer I–III/
≥66 years
868/1774 Full Canada P ✓ X X ✓ ✓ Cumulative
exposure
54 X M n/a M M 6
NOS, Newcastle–Ottawa Quality Assessment Scale for Cohort Studies; BMI, body mass index; met, metformin; N/A, not applicable; RFS, recurrence-free survival; OS, overall survival; CSS, cancer-specific
survival.
aData from subanalysis.
bMain analysis only.
cMetformin/non-metformin.
dAdjustment for body weight.
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Table 2. Main study characteristics: other cancer types
Tumour group Study author Patient characteristics Study characteristics Comparator
DM status
Outcomes Definition of
metformin
exposure
Median
follow-up
(months)
Potential confounders (R = reported
& not significant, M = included in
multivariate model X = not assessed,
or significant but not adjusted for)
NOS
Score
Treatment Stage/other
restriction
Sample
size (met/
total)
Article
type
Study
location
Setting
(H = hospital,
P = population)
DM Non-
DM
RFS OS CSS BMI Age Sex Cancer
specific
Other
DM
meds
Urothelial carcinoma Rieken BJU
[54]
TURBT pTa–pT1 N0 M0
/urothelial
carcinoma of
bladder (NMI)
43/1035 Full USA and
Europe
H X ✓ ✓ ✓ X At surgery 64 X M R M n/a 8
Rieken UO
[55]
Radical surgery M0 /invasive
urothelial
carcinoma of
bladder
80/1382 Full USA and
Europe
H X ✓ ✓ ✓ ✓ At diagnosis 34 M M M M n/a 8
Rieken EJS
[56]
Radical surgery M0/upper tract
urothelial
carcinoma
194/2330 Full USA,
Europe
and
Japan
H X ✓ ✓ ✓ ✓ At surgery 36 X M M M n/a 6
Head and neck
(squamous cell
carcinoma)
Kwon [57] Curative surgery
or
radiotherapy
No distant metastases 99/1072 Full Korea H X ✓ ✓ ✓ ✓ Ever exposure 65 M M R M n/a 8
Thompson
[58]
Not specified Disease-free at 3
months/oral-
oropharynx
33/78 Full USA H ✓ X ✓ X X Diagnosis to
relapse
44 X R R R X 5
Renal cell carcinoma Hakimi [59] Partial/radical
nephrectomy
T2–T3 N0 M0 55/784 Full USA H ✓ ✓ ✓ X ✓ At surgery 41 M M R M X 6
Psutka [60] Partial/radical
nephrectomy
Localised 83/200 Full USA H ✓ X ✓ ✓ ✓ In 90 days before
surgery
97 R M R M X 8
Pancreatic
adenocarcinoma
Ambe [61] Radical surgery Resectable 19/44 Abstract USA H ✓ X X ✓ X At surgery Not given R R R R X 7
Non-small-cell lung
carcinoma
Fortune-
Greeley
[62]
Not specified data on stage I–II Not given Abstract USA H ✓ X X ✓ X Not given Not given M M X M X 6
Endometrial cancer Ko [63] Not specified I–IV (RFS data
extracted)
200/363 Full USA H ✓ X ✓ X X At diagnosis 33 R M n/a M R 8
Gastric cancer Lee, CK [64] Gastrectomy I–III 132/326 Full Korea H ✓ X ✓ ✓ ✓ Cumulative
exposure
74 M M M M M 9
NOS, Newcastle–Ottawa Quality Assessment Scale for Cohort Studies; BMI, body mass index; met, metformin; N/A, not applicable; NMI, non-muscle invasive; TURBT, transurethral resection of bladder
tumour; RFS, recurrence-free survival; OS, overall survival; CSS, cancer-specific survival.
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beneﬁt of metformin on RFS (HR 0.62, CI 0.30–1.29). In an un-
planned exploratory analysis that grouped studies with Western
and non-Western populations separately, we found there was a
signiﬁcant interaction between the effect of metformin on OS
and the population studied (χ2 = 14.31, P < 0.001). In studies in
non-Western populations, there was a highly signiﬁcant beneﬁt
of metformin on OS (HR 0.36, CI 0.25–0.53); however, there
was evidence of heterogeneity (I2 = 85.8%, P = 0.013). In studies
with Western populations, only a trend towards a signiﬁcant
effect was identiﬁed (OS HR 0.84, CI 0.68–1.03) with no clear
evidence of heterogeneity (I2 = 4.6%, P = 0.350). In unplanned
sensitivity analyses, there appeared to be a larger relative beneﬁt
of metformin on OS when analyses were restricted to studies
that had follow-up of >3 years (HR 0.64, CI 0.52–0.78). Further
details of study group and sensitivity analyses for all tumour
types are available in supplementary Table S1, available at
Annals of Oncology online.
prostate cancer
RFS was assessed in six studies (9330 patients), OS in four studies
(4457 patients) and CSS in three studies (1643 patients).
Metformin use demonstrated a borderline signiﬁcant improve-
ment in RFS (HR 0.83, CI 0.69–1.00), and signiﬁcant
improvements in OS (HR 0.82, CI 0.73–0.93) and CSS (HR 0.58,
CI 0.37–0.93) (Figure 3); however, the relationship was inconsist-
ent across studies (RFS I2 = 64.8%, P = 0.014; OS I2 = 87.3%,
P < 0.001; CSS I2 = 75.3%, P = 0.017), which was reﬂected when
the random-effects model was applied (RFS HR 0.80, CI 0.57–
1.13; OS 0.69, CI 0.44–1.10; CSS 0.64, CI 0.19–2.12).
In a pre-speciﬁed analysis, there was signiﬁcant interaction
between the effect of metformin and the primary treatment type
on RFS (χ2 test for interaction 9.03, P = 0.003). For patients
receiving radical radiotherapy [46, 48], there was a signiﬁcant
beneﬁt from metformin (HR 0.45, CI 0.29–0.70), whereas no
signiﬁcant beneﬁt was seen for patients who underwent radical
prostatectomy (HR 0.94, CI 0.77–1.15) (Figure 4). Only a single
study was able to provide data on OS and CSS in those having
radical radiotherapy; however, signiﬁcant improvements were
seen in both (OS 0.44, CI 0.27–0.72; CSS 0.19, CI 0.06–0.63)
[46]. We found no evidence of an interaction between the effect
of metformin on RFS and the presence or absence of non-DM
patients in the comparator group (χ2 0.49, P = 0.48).
In unplanned sensitivity analyses, there appeared to be a
larger relative beneﬁt of metformin on RFS when analyses were
restricted to studies that had a follow-up of >3 years (HR 0.77,
CI 0.62–0.96) or considered other DM medications in their
analysis (HR 0.79, CI 0.64–0.98).
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Figure 2. Colorectal cancer outcomes according to metformin use.
 | Coyle et al.
review Annals of Oncology
 at U
CL Library Services on O
ctober 2, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
356
breast cancer
RFS was assessed in 2 studies containing 271 patients and OS in
3 studies including 2045 patients. Metformin demonstrated a
trend towards improvement in RFS (HR 0.77, CI 0.49–1.22)
(Figure 5); however, no effect was seen in OS (HR 0.99, CI 0.92–
1.05). There was no evidence of variation between the results of
the studies either for RFS (I2 = 0.0%, P = 0.74) or OS (I2 = 0.0%,
P = 0.75). As CSS was only available for one study containing
1774 patients, no meta-analysis was possible for this outcome;
however in this study, metformin did not appear to have an
impact on CSS (HR 1.01, CI 0.86–1.19). There were insufﬁcient
study numbers for any meaningful study group or sensitivity
analyses.
urothelial cancer
Studies included patients with upper tract urothelial carcinoma
and urothelial carcinoma of the bladder. RFS was assessed in 3
studies including 4747 patients, and OS in 3 studies including 4747
patients, of which 2 also assessed CSS including 3712 patients.
There was no clear evidence that metformin improved either RFS
(HR 0.91, CI 0.73–1.14), OS (HR 0.94, CI 0.76–1.16) or CSS (HR
0.88, CI 0.66–1.17) (Figure 6). Although there was some evidence
of inconsistency between the results of studies for both RFS
(I2 = 59.0%, P = 0.087) and OS (I2–51.5%, P = 0.127), the results
did not change signiﬁcantly when the random-effects model was
applied (RFS HR 0.84, CI 0.57–1.24; OS HR 1.00, CI 0.72–1.39;
CSS HR 0.88, CI 0.66–1.17). There were insufﬁcient study
numbers for any meaningful study group or sensitivity analyses.
other cancer types
There were insufﬁcient studies identiﬁed to warrant meta-ana-
lyses for other cancer types, the ﬁndings of which are presented
in Table 3. In head and neck cancer, a positive trend towards
improved RFS and CSS was seen in one study [57], but there
Outcome and
Recurrence
0.50 (0.31, 0.81)
0.23 (0.07, 0.73)
0.84 (0.58, 1.22)
0.91 (0.67, 1.24)
0.93 (0.61, 1.41)
1.90 (0.89, 4.06)
0.83 (0.69, 1.00)
0.44 (0.27, 0. 72)
0.46 (0.33, 0.64)
0.95 (0.82, 1.10)
1.16 (0.73, 1.85)
0.82 (0.73, 0.93)
0.19 (0.06, 0.63)
0.59 (0.34, 1.01)
2.89 (0.68, 12.29)
0.58 (0.37, 0.93)
Overall survival
Cancer-specific survival
Spratt[46]
Spratt[46]
Taira[50] (a)
Margel[47]
Margel[47]
Kaushik[44]
Spratt[46]
Zannella[ 48]
Rieken WJU[45]
Kaushik[44]
Allott[ 43]
Allott[ 43]
Danzig[49]
Subtotal (I2 = 64.8%, P = 0.014)
Subtotal (I2 = 87.3%, P = 0.000)
Subtotal (I2 = 75.3%, P = 0.017)
.125 .25
Favours metformin
(a) Hazard rations for Taira et al.[50] were estimated from Kaplan Meier curves and summary statistics using published methods. [29-31]
Favours no metformin
.5 1 2 4 8
study
Hazard ratio
(95% Cl)
Figure 3. Prostate cancer outcomes according to metformin use.
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was no effect on OS. However, the second study identiﬁed
showed a potential detriment of metformin use on RFS [58]. In
renal cell carcinoma, two studies were identiﬁed, both showing a
non-signiﬁcant inverse relationship with metformin use and
RFS, and no signiﬁcant beneﬁt in OS or CSS. Single studies were
identiﬁed showing a signiﬁcant improvement in OS in lung
cancer, RFS and OS in endometrial cancer and RFS, OS and
CSS in gastric cancer. A small single study in pancreatic cancer
did not suggest any effect of metformin; however, this study had
a very small sample size.
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Figure 4. Prostate cancer recurrence-free survival according to metformin use for different treatment groups.
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Figure 5. Breast cancer outcomes according to metformin use.
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duration and dose
The impact of different exposures to metformin on early-
stage cancer outcomes is examined in some of the identiﬁed
studies; however, limited data and differences in the methods
used to investigate exposure preclude any study-group ana-
lyses. In colorectal cancer, Spillane et al. [38] conducted add-
itional analyses on dose intensity and found survival beneﬁts
for high-intensity metformin users not using other diabetic
therapies (CSS HR 0.44, CI 0.20–0.95; OS HR 0.41, CI 0.24–
0.70), but no signiﬁcant beneﬁts were identiﬁed in other sub-
groups. In gastric cancer, Lee et al. [64] found that increased
cumulative duration of metformin use improved cancer-
speciﬁc and all-cause mortality. Single studies in colorectal
[42] and prostate cancer [43] also investigated the impact of
different exposures to metformin but found no signiﬁcant
associations.
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Figure 6. Urothelial cancer outcomes according to metformin use.
Table 3. Cancer outcomes by metformin use for tumour types with limited numbers of studies
Tumour group Study author Sample size Recurrence-free
survival HR (95% CI)
Overall survival
HR (95% CI)
Cancer-specific
survival HR (95% CI)
Head and neck Kwon [57] 1072 0.76 (0.49–1.21) 0.95 (0.59–1.50) 0.79 (0.42–1.50)
Thompson [58] 78 1.26 (0.62–2.56) — —
Renal cell carcinoma Hakimi [59] 784 1.22 (0.66–2.27) — 0.76 (0.21–2.70)
Psutka [60] 200 1.07 (0.61–1.88) 0.74 (0.48–1.15) 0.83 (0.41–1.67)
Pancreas Ambe [61] 44 — 0.54 (0.16–1.68) —
Lung Fortune [62] Not given by stage — 0.85 (0.77–0.93) —
Endometrial Ko [63] 363 0.56 (0.34–0.91) 0.43 (0.24–0..77) —
Gastric Lee, CK [64]a 326 0.86 (0.80–0.94) 0.87 (0.80–0.95) 0.87 (0.78–0.96)
aHR for each 6 months of metformin use.
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discussion
Our analysis suggests that metformin could be a useful adjuvant
agent, particularly in colorectal and prostate cancer. The
number of studies identiﬁed for each tumour type is likely to
reﬂect the incidence and demographics of the disease, particu-
larly the likelihood of presentation with early-stage disease and
a diagnosis of DM.
The variation in the adjuvant effects of metformin according
to tumour type could be explained by differences in both patient
characteristics and tumour biology. The effect of metformin on
AMPK signalling has been hypothesised to be a major pathway
through which metformin exerts its anti-cancer effects [10].
AMPK signalling dysregulation is also associated with metabolic
syndrome [65], a cluster of conditions which include raised
fasting glucose, dyslipidaemia, high blood pressure and central
obesity [66]. Metabolic syndrome is also known to increase the
risk of developing some cancers, particularly colorectal cancer
[67], where it is also associated with poorer recurrence and
survival outcomes [68]. In addition, it is known to develop as a
consequence of androgen deprivation therapy in men with pros-
tate cancer [69]. Metformin may improve OS by reducing the
number of cardiovascular deaths associated with metabolic syn-
drome; however, the improvements in RFS and CSS identiﬁed
suggest a direct anti-cancer effect. In prostate cancer, our study
group analysis suggests that the beneﬁcial effects of metformin
use could be limited to those undergoing radical radiotherapy.
The AMPK pathway is known to play a role in regulating cellu-
lar responses to radiotherapy, [70] and studies in xenograft mice
models suggest that metformin can improve tumour oxygen-
ation and therefore radiation response [71].
The limitations of our meta-analysis include the inherent
weaknesses of observational data, particularly potential meas-
urement errors in the exposure to metformin, and variation in
the deﬁnition of metformin use, and the risk of time-related
biases [72]. A high degree of variation between the results of
studies was observed for a number of the outcomes investigated
in most of the cancer types. Our sensitivity analyses were
designed to explore possible reasons for this to inform future
observational and clinical trial design; however, only a small
number of analyses were possible due to insufﬁcient study
numbers. For both prostate and colorectal cancer, the relative
effect size appeared to increase for studies with follow-up of 3
years or greater, highlighting the importance of ensuring ad-
equate duration of follow-up in future studies. Similarities have
been seen in studies of aspirin, where greater beneﬁts have been
seen with longer follow-up [73–75]. A limited number of
studies investigated the relation with frequency, dose and dur-
ation of metformin in early-stage cancer; however, ﬁndings are
inconsistent and further research is required to better under-
stand this relationship.
Previous studies have suggested that a diagnosis of DM has a
negative impact on cancer outcomes [76, 77]; therefore, inclu-
sion of non-DM patients in comparator groups could underesti-
mate the beneﬁcial effect of metformin. Owing to insufﬁcient
study numbers, it was only possible to analyse the effect of the
presence or absence of non-DM patients in the comparator
group for RFS in prostate cancer, where no evidence for an
effect was found.
Other meta-analyses have investigated the effect of metformin
on survival outcomes, across all stages of cancer, in individual
tumour types, the ﬁndings of which are presented in supple-
mentary Table S2, available at Annals of Oncology online. In
colorectal cancer, four meta-analyses have examined the effect
on OS [21–24], two of which also investigated colorectal CSS
[23, 24]. All meta-analyses identiﬁed signiﬁcant improvements
in these end points, which is consistent with the ﬁndings of this
study. For prostate cancer, ﬁndings are less consistent. Five
meta-analyses have examined the effect of metformin on OS
[22, 23, 25–27], two of which also investigated prostate CSS [25,
26]. Only two meta-analyses identiﬁed a signiﬁcant beneﬁt in
OS [23, 25], with no beneﬁt identiﬁed in prostate CSS. This
differs from the ﬁndings of this study where signiﬁcant beneﬁts
in OS and prostate CSS were identiﬁed, which could suggest that
metformin is better suited to the adjuvant setting for prostate
cancer. In breast cancer, four meta-analyses examined OS [21–
23, 28], two of which investigated breast CSS. Two meta-ana-
lyses identiﬁed a signiﬁcant beneﬁt in OS [21, 23, 28], the other
approached signiﬁcance (HR 0.81, CI 0..64–1.04) [22] and the
two meta-analyses investigating breast CSS also showed signiﬁ-
cant improvements [23, 28]. This differs from the ﬁndings of
this study where no signiﬁcant beneﬁt in OS and breast CSS was
identiﬁed. This could suggest that metformin may be effective in
those with established breast cancer, which is consistent with
the ﬁndings of breast cancer window studies where direct anti-
tumour effects have been identiﬁed [13, 14].
Investigation of metformin in the primary prevention setting
presents a number of challenges, where the balance between
adverse effects and beneﬁts is likely to be less favourable and dif-
ﬁcult to detect in a clinical trial because of the low event rate.
While the advanced setting can provide a sufﬁcient event rate,
there is evidence to suggest that metformin requires long-term
use to exert its anti-cancer effect [78], and therefore, patients
with established cancer with more limited prognoses may not be
able to receive metformin long enough for a therapeutic beneﬁt
to emerge. Therefore, the adjuvant setting could be most suit-
able for investigating the anti-cancer effects of metformin.
current trial activity
In colorectal cancer, a phase III trial of metformin versus standard
care assessing recurrence and survival in stage III disease is now in
set-up phase in South Korea (NCT02614339). In prostate cancer,
the Metformin Active Surveillance Trial (NCT01864096), an
ongoing randomised phase III trial of metformin versus placebo
given before primary therapy is assessing time to progression in
men with low-risk prostate cancer. The STAMPEDE trial
(NCT00268476), a multi-arm multi-stage randomised, controlled
trial investigating a number of agents in the treatment of hormone-
naïve, high-risk, localised and metastatic prostate cancer, aims to
evaluate whether the addition of metformin improves survival in
this group. Recruitment to this comparison is due to open in
autumn 2016. In breast cancer, our results did not identify any
meaningful beneﬁt of metformin use in the adjuvant setting;
however, this could be due to the limited number of studies identi-
ﬁed. Additional supporting data are available in the primary preven-
tion and treatment setting (across all stages), where meta-analyses
have shown a beneﬁcial effect [21, 23, 28, 79]. A randomised phase
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III trial of metformin versus placebo assessing recurrence and sur-
vival in early-stage breast cancer has recently completed recruitment
(MA-32, NCT01101438) and the results are awaited.
conclusions
The ﬁndings of this meta-analysis support the concept of rando-
mised clinical trials using metformin in the adjuvant setting,
with the strongest supporting evidence in colorectal and prostate
cancer, particularly those treated with radical radiotherapy.
Such trials could also further our understanding of the relation-
ships between cancer outcomes and the dose and duration of
metformin. The authors are not aware of any ongoing adjuvant
phase III trials of metformin in prostate cancer, or colorectal
cancer in Western populations. In other tumour types, where
there is currently less evidence, further observational studies are
needed to advise suitability for investigation in any future ran-
domised, controlled trials.
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Abstract
Opportunities to enter patients into more than one clinical trial are not routinely considered in cancer research and experiences with co-enrolment are rarely
reported. Potential beneﬁts of allowing appropriate co-enrolment have been identiﬁed in other settings but there is a lack of evidence base or guidance to
inform these decisions in oncology. Here, we discuss the beneﬁts and challenges associated with co-enrolment based on experiences in the Add-Aspirin trial e a
large, multicentre trial recruiting across a number of tumour types, where opportunities to co-enrol patients have been proactively explored and managed. The
potential beneﬁts of co-enrolment include: improving recruitment feasibility; increased opportunities for patients to participate in trials; and collection of
robust data on combinations of interventions, which will ensure the ongoing relevance of individual trials and provide more cohesive evidence to guide the
management of future patients. There are a number of perceived barriers to co-enrolment in terms of scientiﬁc, safety and ethical issues, which warrant
consideration on a trial-by-trial basis. In many cases, any potential effect on the results of the trials will be negligible e limited by a number of factors, including
the overlap in trial cohorts. Participant representatives stress the importance of autonomy to decide about trial enrolment, providing a compelling argument for
offering co-enrolment where there are multiple trials that are relevant to a patient and no concerns regarding safety or the integrity of the trials. A number of
measures are proposed for managing and monitoring co-enrolment. Ensuring acceptability to (potential) participants is paramount. Opportunities to enter
patients into more than one cancer trial should be considered more routinely. Where planned and managed appropriately, co-enrolment can offer a number of
beneﬁts in terms of both scientiﬁc value and efﬁciency of study conduct, and will increase the opportunities for patients to participate in, and beneﬁt from,
clinical research.
 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Statement of Search Strategies Used and
Sources of Information
The paper largely reﬂects expert opinions and experi-
ences of the authors, and their knowledge of the literature.
The Pubmed database was searched for relevant articles,
but a formal search strategy was not deﬁned.
Introduction
Co-enrolment e entering patients into more than one
clinical trial either concurrently or sequentially e is rarely
reported or discussed in oncology literature. As such, co-
enrolment policies may be speciﬁed in the trial protocol
or decisions made by an institute or recruiting investigator,
without a clear rationale or evidence base. With a lack of
guidance or consensus on when co-enrolment is appro-
priate, it is unsurprising that the decision not to co-enrol
may be seen as the safe option.
Recent trends in oncology research e such as the use of
longer term, maintenance therapies and evaluation of
repurposed agents (whose use alongside other treatments
may already be well documented) e as well as the ever-
increasing number of trials competing for the same pa-
tients, mean that co-enrolment is becoming more relevant.
More routine consideration of opportunities to enter pa-
tients into multiple trials is warranted.
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AviationHouse,125Kingsway, LondonWC2B6NH,UK. Tel:þ44-20-7670-4868.
E-mail address: f.cafferty@ucl.ac.uk (F.H. Cafferty).
Contents lists available at ScienceDirect
Clinical Oncology
journal homepage: www.cl in icaloncologyonl ine.net
http://dx.doi.org/10.1016/j.clon.2017.02.014
0936-6555/ 2017 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
Clinical Oncology 29 (2017) e126ee133
363
Co-enrolment has been explored in other (non-cancer)
settings e particularly those where trial recruitment is
challenging and/or there aremany (large) competing trialse
including resuscitation [1], critical care [2e4] (including
neonatal [5] and paediatric [6] settings) and peri-natal
research [7]. Here, co-enrolment offers the opportunity to
maximise use of the patient population and increase the
speed and efﬁciency of research delivery. In settings such as
HIV [8] and anaesthesia [9], where large, pragmatic trials are
common and/or participants might be receiving several
other medications, co-enrolment may also provide impor-
tant data on drug interactions.
Across different settings, researchers report barriers to
co-enrolment and, frequently, a lack of (universal) support
from the research community or ethics committees [2,6,9].
Common barriers range from ethical and scientiﬁc consid-
erations to safety concerns [1e3,6,7,9]. The need for further
reporting of co-enrolment and more research on this topic,
is noted [4,7,10].
The potential beneﬁts of co-enrolment, as well as
possible barriers, are relevant in oncology trials andwarrant
further exploration. Here, we report our experiences with
exploring and managing co-enrolment opportunities
within a large, multicentre oncology trial.
The Add-Aspirin Trial
The Add-Aspirin trial is a randomised controlled trial
(RCT) assessing whether regular aspirin use after curative
treatment for an early stage tumour can prevent recurrence
and prolong survival (Figure 1) [11e13]. The intervention is
being tested in four tumour types (breast, colorectal, gastro-
oesophageal and prostate) by means of parallel cohorts.
Patients enrol following potentially curative therapy e this
incorporates a range of treatment pathways for each
tumour site, including surgery with any appropriate (neo-)
adjuvant therapies, radical chemoradiation (oesophageal)
and radical radiotherapy (prostate). Participants are rand-
omised to daily aspirin 100 mg, 300 mg or placebo. The trial
is recruiting across the UK, and will also open in India, with
a target of approximately 10 000 participants.
Co-enrolment may be relevant to patients entering Add-
Aspirin subsequent to enrolling in a primary therapy trial
and may also arise at the time of recurrence during partic-
ipation in Add-Aspirin. A proactive approach to exploring
co-enrolment opportunities with other trial teams has been
adopted to agreewhen thismight be appropriate and how it
can be facilitated and managed within the ongoing trials.
Beneﬁts of Co-enrolment
Co-enrolment is particularly relevant in Add-Aspirin as
the intervention is being given after initial treatment, so
participants from trials of primary therapies represent a
signiﬁcant proportion of the eligible population. However,
the potential advantages of co-enrolment apply more
widely to multicentre oncology RCTs e particularly prag-
matic trials e as a number of different interventions will be
relevant to a patient over the course of their disease and
treatment. Allowing appropriate co-enrolment improves
the efﬁciency of recruitment, helping to ensure the feasi-
bility of trials running concurrently, and maximises op-
portunities for patients to participate in, and beneﬁt from,
clinical research.
A further advantage is the opportunity to assess trial
interventions alongside one another, helping to ensure the
Fig 1. The Add-Aspirin trial.
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ongoing relevance of the studies. If two interventions might
potentially both be given to a patient in future practice,
collection of information on their combined use will be
valuable for establishing the importance of each one,
providing more cohesive evidence to inform the manage-
ment of future patients.
There are, of course, potential concerns in allowing pa-
tients to enrol in multiple RCTs. In what follows, we
consider the scientiﬁc, safety and ethical issues.
Impact on Trial Results
A principle concern with co-enrolment is the potential
effect on the results of the trials, particularly when they are
evaluating a common outcome measure. We would argue
that, although this issue deserves careful consideration, in
many cases any effect will probably be negligible, and
should not generally be a prohibitive factor.
In Add-Aspirin, due to the timing of the intervention, we
are commonly considering the case of sequential co-
enrolment e patients entering Add-Aspirin having previ-
ously enrolled in another trial. This would also be the case if
considering trials of second- or third-line treatment after
relapse in patients who had participated in a primary
therapy trial. Here, assuming there is no interaction be-
tween the interventions, there is no concern about an effect
on the results of the second trial (Add-Aspirin). However,
there is the potential for an effect on the results of the ﬁrst
trial if participants from the different arms enter Add-
Aspirin at different rates. This may occur because patients
from one arm of the trial are either more likely to be eligible
(for example, patients need to be disease-free, which may
be more likely in the experimental arm of the ﬁrst trial) or
they are more likely to be willing to participate (for
example, if one arm of the ﬁrst trial has a shorter or less
toxic treatment). In these scenarios, if aspirin is effective, it
will have a differential effect in the trial arms of the ﬁrst
trial with the potential to affect the power. Although
stratiﬁcationwithin Add-Aspirin for the trial arm in the ﬁrst
trial will help to ensure balance in terms of those in-
dividuals entering Add-Aspirin, there may still be an overall
imbalance in terms of aspirin allocation between the arms
of the ﬁrst trial when those who did not join Add-Aspirin
are also considered.
We have estimated the magnitude of any potential effect
in different scenarios and found that it is generally limited
by a number of factors (Figure 2). Statistical modelling, us-
ing ranges of assumptions, suggests that any effect on the
power of the ﬁrst trial will probably be small. Table A1 (web
appendix) provides an example showing selected models,
including some felt to illustrate the largest plausible effect.
Signiﬁcant effects were only anticipated with relatively
large (improbable) differences in participation rates and
were further increasedwhen therewere unexpectedly large
effects of aspirin. Co-enrolling trials could be monitored for
this unlikely set of circumstances, with the potential to stop
co-enrolment if there were concerns. Our models do not
consider the potential effect of aspirin use outside the Add-
Aspirin trial (participants from the ﬁrst trial already taking
aspirin), which may further limit any effect. Similar limiting
factors are noted in other settings [9]. However, this should
be carefully considered on a trial-by-trial basis, before any
co-enrolment, and subsequently monitored.
Interaction Effects
Our modelling has generally assumed that there are no
interaction effects between trial interventions e this is
Fig 2. Factors affecting the potential effect of co-enrolment on power. *Intervention being evaluated in the second trial.
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reasonable in most scenarios considered in relation to Add-
Aspirin. However, others argue that the potential for an
interaction between two trial interventions should not
necessarily prohibit co-enrolment and, in fact, can facilitate
evaluation of the interaction (particularly relevant where
interventions are already in use outside of the trials) [7e9].
The information gained from co-enrolled participants may
be insufﬁcient to formally establish if there is an interaction
but will be more robust data than would otherwise be
available [7e9]. Modelling based on pragmatic anaesthesia
trials suggested that a large detrimental effect on the power
of the ﬁrst trial would only be seenwith a large antagonistic
interaction, substantial co-enrolment and limited use of the
second trial intervention outside of the trial [9].
A factorial randomisation can be viewed as preferable to
co-enrolment between separate trials, butmay not always be
practical or sensiblee for example, if the combination of the
two interventions is only relevant to a small subgroup or, as
with Add-Aspirin, one intervention is given at a later time,
dictating the most appropriate timing for randomisation.
Furthermore, the (statistical) advantages of a factorial design,
compared with co-enrolment, may not be great [4,8,9]. The
potential for loss of power for assessing one intervention, in
the presence of the other, may still exist, and factorial trials
are not normally powered to detect interactions.
Safety Considerations
There may, of course, be safety concerns with patients
receiving interventions from two different trials. This will be
highly dependent on the interventions. If there are concerns
or a high degree of uncertainty about toxicity risks then co-
enrolment will probably be avoided. However, in a trial of a
marketed product or intervention that is already in use in
normal practice, co-enrolmentwill bemore acceptable [9]. In
Add-Aspirin, participants receive low-dose aspirinorplacebo.
In most of the primary treatment trials where co-enrolment
may be relevant, there will already be patients taking
aspirin alongside the trial intervention. Allowing participants
to subsequently enrol in Add-Aspirin may facilitate the
collection of more robust data on the use of aspirin alongside
(or following) the intervention to guide future practice.
Concerns regarding liability, in the event of a personal
injury claim beingmade by a trial participantwho is enrolled
in multiple trials, have been raised as a potential barrier to
co-enrolment, but we do not believe this is justiﬁed. Existing
indemnity arrangements for each trial should sufﬁce.
The Participant’s Perspective
In addition to potential scientiﬁc beneﬁts, allowing trial
co-enrolment, where appropriate, will maximise opportu-
nities for patients to participate in research. However, the
approach must be both ethically sound and acceptable to
(potential) participants e these are perhaps the most com-
plex issues surrounding co-enrolment and there is currently
a lack of guidance or evidence in the literature to inform this.
In our discussions with other trial teams regarding co-
enrolment, some researchers have expressed concerns that
asking patients to join more than one trial may over-burden
them, a view that has proved to be a barrier in other settings
[6]. The participant representatives on the Add-Aspirin Trial
Management Group (co-authors on this paper), have been
strong advocates of co-enrolment from the outset, and
would argue that there is an opposing ethical obligation to
provide all of the information required to allow an individual
to decide for themselves about joining any trial that is
relevant to them. Not approaching a patient to participate in
a trial that they could be eligible for because they are already
enrolled in another study would be denying them an op-
portunity. Similar conclusions were reached in a review of
co-enrolment considerations in the anaesthesia setting, with
the authors feeling that preventing patients from autono-
mously co-enrolling is difﬁcult to justify ethically [9].
A survey of patients in a research-active breast cancer
unit provides evidence to support these views [14]: three-
quarters of respondents (37/50, 74%) would have consid-
ered entering more than one study if adequate written in-
formation was provided. Most (32/50, 64%) did not believe
that participation in clinical research should be restricted to
amaximumnumber of studiese and, of thosewho did, only
two indicated that it should be limited to a single study.
Furthermore, two-thirds of respondent (34/50, 68%) did not
think that involvement in more than one study was a sig-
niﬁcant burden.
A similar survey of 50 families approached aboutmultiple
(up to six) clinical trials in a neonatal intensive care unit
suggested similar attitudes (despite the setting, where the
potential to over-burden families may be even more of a
concern) [5]: three-quarters (74%) of parents indicated that
theywould enrol their baby into two ormore studies; almost
all (98%) felt they wanted to make the decisions about study
enrolment themselves, rather than a clinician deciding.
Although the data from these studies are reassuring, they
are limited and may reﬂect the views of select groups of
individuals. Further exploration with patients and with
groups representing patient and public involvement (PPI) is
warranted.
Measures to Increase Acceptability
Comments from respondents in the breast unit study
emphasised the importance of individual choice as well as
concerns around extra hospital visits interfering with
normal life [14]. These are areas that need to be addressed
in trials where co-enrolment is deemed appropriate.
Researchers have an obligation to carefully consider the
timing of approaching potential participants about each
trial, ensuring that the information provided (not only
about the individual trials but also about the implications of
joining more than one) is clear and there is sufﬁcient op-
portunity for questions. In the paediatric intensive care
setting, Harron et al. [6] advocated careful development and
piloting of a strategy for the whole consent process when
multiple studies may be available to an individual.
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Wherever possible, there should be compatibility be-
tween follow-up schedules for two trials where co-
enrolment is possible in order to minimise the number
of additional hospital visits and assessments/tests
compared with standard care. Ideally, this would be
planned at the design stage. Where co-enrolment de-
cisions may be made during the trial, allowing some
ﬂexibility in schedules will work towards this aim e
enabling research nurses to plan clinic visits that will meet
the requirements of both trial schedules. In Add-Aspirin,
follow-up schedules have been planned to largely align
with standard care e and this will be the case with many
pragmatic trials. Additionally, there is some ﬂexibility
regarding the timing of assessments.
In the above considerations, engagement with and input
from participant representatives and PPI groups is vital to
ensure that the approach is acceptable to participants and
will not lead to unnecessary additional burden.
Ethical Approvals
Some researchers report resistance from ethics com-
mittees as an obstacle to allowing individuals to enter
multiple trials [2,14]. This has not been the experience in
Add-Aspirin e the potential for participants from multiple
primary treatment trials to enrol in Add-Aspirin has been
written into the trial protocol from the outset, and was not
raised as an issue by the ethics committee who approved
the study, nor by the regulators nor funders of the trial.
Thus, there is perhaps a need for a more consistent
approach to trial co-enrolment by research ethics commit-
tees. We would suggest that co-enrolment, where appro-
priate, should generally be supported in order to allow
potential participants the autonomy to decide about
enrolling in any trial that is relevant to them. However, this
should be on the provisos that: the informed consent pro-
cess and trial follow-up schedules have been carefully
considered; the safety of receiving both trial interventions
has been deemed acceptable; and any other appropriate
measures are in place to minimise any extra burden on
participants as far as possible.
The potential scientiﬁc advantages of allowing co-
enrolment (where appropriate), in terms of increasing
both the value and efﬁciency of the research, provide
further ethical justiﬁcation for the approach. Myles et al. [9]
argue that an important ethical consideration in research
planning is the efﬁcient conduct of studies and fairer allo-
cation of resources for research, and that allowing co-
enrolment can contribute to this aim. Furthermore, if two
interventions being evaluated in trials might potentially
both be given to a patient in future practice, there is
Table 1
Proposed measures for trial teams managing co-enrolment within a randomised controlled trial
Proposed measure Purpose
Design Identify trials where co-enrolment may be considered Assess potential impact and agree where co-enrolment is
appropriate in advance
Develop appropriate consent process* Ensure that being approached about multiple studies will
be acceptable to patients
Ensure compatibility of follow-up schedules, allowing
ﬂexibility where possible/appropriate*
Minimise extra visits/assessments, ensuring that
participation in multiple studies will be acceptable to
patients
Provide guidance on co-enrolment in the protocol (and
trial website/other documents as appropriate)
Ensure only appropriate co-enrolment takes place and
follows the strategy developed for consent and follow-up
Consider stratifying by treatment arm in the ﬁrst trial in
the randomisation algorithm for the second trial (where
signiﬁcant overlap is expected)
Ensure treatment allocation in the second trial is balanced
(in terms of those individuals who enter the second trial)y
Conduct Implement eligibility checks around co-enrolment at
entry
Ensure only appropriate co-enrolment takes place
Consider implementation of screening logs Identify any recruitment issues as a result of co-
enrolment decisions or any barriers to co-enrolment
Monitoring Collect and regularly review co-enrolment information,
including treatment allocation in the other trial, on case
report forms
Active monitoring with the potential to take action e by
capping recruitment from one arm, for example e if a
large imbalance occurs (although this is unlikely)
Establish agreements to share information between data
monitoring committees (blinded trials)
It may be appropriate for monitoring to be carried out by
data monitoring committees in the case of blinded trials
* In discussion with participant representatives and/or patient and public involvement groups.
y This will not ensure balance overall if participants from the different treatment arms of the ﬁrst trial enter the second trial at different
rates. Thus, careful monitoring is still required.
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arguably an ethical obligation for researchers to collect in-
formation on the combined use of the therapies in order to
establish the importance and safety of each one in the
context of the other, and provide more cohesive evidence to
inform the management of future patients [7].
Managing Co-enrolment
Where co-enrolment to multiple oncology RCTs is
permitted, given the issues outlined here, it requires careful
management and monitoring. We propose a number of
measures (Table 1).
A precedent for designing and conducting RCTs to facil-
itate co-enrolment has been set in the HIV ﬁeld (Terry Beirn
Community Programs for Clinical Research on AIDS; CPCRA)
[8]. Measures include shared data collection forms; stand-
ardised deﬁnitions and criteria for assessing and reporting
outcomes and adverse events; a single, common follow-up
schedule; and an analysis approach that explores drug
interactions.
Discussion
For the vast majority of trials where co-enrolment with
Add-Aspirin has been considered, we have found that it is
likely to be acceptable both in terms of the safety of par-
ticipants and maintaining the integrity of trial results. As
such, the importance of giving individuals the autonomy to
make their own decisions about trial participation provides
a compelling ethical argument for allowing co-enrolment,
wherever appropriate, providing that it is done in a way
that will be acceptable to participants. We have encoun-
tered a number of perceived barriers that may not be well-
founded and there is a need for further evidence to promote
greater understanding about the potential impact of co-
enrolment.
The beneﬁts of co-enrolment alignwith the original aims
in establishing the National Cancer Research Network,
which include improving the co-ordination and quality of
research, widening participation, increasing the numbers of
patients involved and speeding up the delivery of research
for the ultimate beneﬁt to patients [15]. As such, we suggest
it should be routinely considered by the associated clinical
studies groups in reviewing trial portfolios, with the aim of
maximising co-enrolment opportunities.
The implications of individuals participating in more
than one trial are multifactorial and should be carefully
considered on a trial-by-trial basis. Evidence relating to
acceptability is limited, and more research is needed.
However, as it is probably highly dependent on the patient
group and the speciﬁc trials under consideration, engage-
ment with relevant PPI groups and representatives, from
the planning stage and throughout the trial, is crucial to
ensure that the appropriate measures are in place. There is
an onus on the trial teams to evaluate acceptability and any
potential (scientiﬁc) consequences in advance, and to
monitor co-enrolment closely throughout the trial, man-
aging any issues appropriately with a pre-deﬁned strategy.
Trial protocols should not enforce a complete ban on co-
enrolment without sound justiﬁcation.
Much could be learnt from the CPCRA programme,
where efforts to facilitate co-enrolment led to a quarter
(22.5%) of patients from six RCTs entering more than one
trial [8]. The programme was developed by a single
research group e a high degree of co-operation and strong
lines of communication would be required to achieve
similar where trials are being conducted by different
groups. In other settings, the establishment of co-
enrolment policies or consensus guidelines has been
advocated [4,8,10]. This could be a way forward in
oncology research.
A more considered and co-operative approach to co-
enrolment will not only beneﬁt individual trials, but
may contribute to an evidence base showing the extent of
co-enrolment and any observed impact or issues. Limited
reports from other settings have not indicated any nega-
tive impact [3,6]. Based on the experiences in Add-
Aspirin, we hope that such data might ultimately reas-
sure researchers of the beneﬁts of allowing participants to
co-enrol where there are multiple oncology trials that are
relevant to them. Add-Aspirin opened in October 2015
and, to date, the possibility of co-enrolling relevant pa-
tients has been agreed for 40 other trials, across the four
tumour types. The number of participants who have been
co-enrolled remains small at this early stage of
recruitment.
Conclusions
Opportunities for co-enrolment of participants into
multiple cancer trials should be more routinely considered.
Where planned and managed appropriately, co-enrolment
can offer a number of beneﬁts in terms of both the scien-
tiﬁc value and efﬁciency of study conduct, and will increase
the opportunities for patients to participate in, and beneﬁt
from, clinical research.
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Appendix
Table A1
Example power calculations to assess the potential impact of co-enrolment
Modelling assumptions Estimated impact on trial X
Effect of aspirin on 5 year
survival*
Participation rates in
Add-Aspiriny
5 year survival in trial X
with co-enrolment
Power
(loss/gain in
power)
Extra patients
(OR follow-up)
needed for
80% power
Control Intervention Control Intervention Difference
Trial X result is positive (5 year survival 55% control versus 45% intervention) in the absence of co-enrolment
6% 10% 10% 45.4% 55.4% 10.0% 79.9% 2 (1 month)
20% 20% 45.8% 55.8% 10.0% 79.9% 3 (1 month)
30% 30% 46.2% 56.2% 10.0% 79.8% 5 (1 month)
10% 15% 45.4% 55.6% 10.2% 81.5% e
10% 20% 45.4% 55.8% 10.4% 82.9% e
15% 30% 45.6% 56.2% 10.6% 84.3% e
15% 10% 45.6% 55.4% 9.8% 78.3% 44 (3 months)
20% 10% 45.8% 55.4% 9.6% 76.6% 89 (5 months)
30% 15% 46.2% 55.6% 9.4% 74.8% 138 (8 months)
10% 10% 10% 45.7% 55.7% 10.0% 79.9% 3 (1 month)
20% 20% 46.3% 56.3% 10.0% 79.8% 5 (1 month)
30% 30% 47.0% 57.0% 10.0% 79.8% 7 (1 month)
10% 15% 45.7% 56.0% 10.3% 82.4% e
10% 20% 45.7% 56.3% 10.7% 84.7% e
15% 30% 46.0% 57.0% 11.0% 86.8% e
15% 10% 46.0% 55.7% 9.7% 77.2% 75 (5 months)
20% 10% 46.3% 55.7% 9.3% 74.2% 154 (9 months)
30% 15% 47.0% 56.0% 9.0% 71.1% 244 (15 months)
Trial X result is negative (5 year survival 45% in both arms) in the absence of co-enrolment
6% 10% 10% 45.4% 45.4% 0.0%
20% 20% 45.8% 45.8% 0.0%
30% 30% 46.2% 46.2% 0.0%
10% 15% 45.4% 45.6% 0.2%
10% 20% 45.4% 45.8% 0.4%
15% 30% 45.6% 46.2% 0.6%
15% 10% 45.6% 45.4% 0.2%
20% 10% 45.8% 45.4% 0.4%
30% 15% 46.2% 45.6% 0.6%
Trial X result is negative (5 year survival 45% in both arms) in the absence of co-enrolment
10% 10% 10% 45.7% 45.7% 0.0%
20% 20% 46.3% 46.3% 0.0%
30% 30% 47.0% 47.0% 0.0%
10% 15% 45.7% 46.0% 0.3%
10% 20% 45.7% 46.3% 0.7%
15% 30% 46.0% 47.0% 1.0%
15% 10% 46.0% 45.7% 0.3%
20% 10% 46.3% 45.7% 0.7%
30% 15% 47.0% 46.0% 1.0%
The table illustrates the potential impact of co-enrolment into Add-Aspirin on the power of a hypothetical study, trial X. Selected results are
shown from models performed under a range of assumptions about the factors listed in Figure 2, including scenarios felt to illustrate the
largest plausible impact on power.
Trial X: A hypothetical two-arm superiority randomised controlled trial of a new peri-operative chemotherapy regimen versus standard in
gastro-oesophageal patients. Designed with 80% power to detect a 10% improvement (from 45% to 55%) in survival at 5 years, requiring 500
patients per arm. Patients who are disease free at the end of treatment may become eligible for Add-Aspirin.
* A 6% survival beneﬁt at 5 years is hypothesised in Add-Aspirin (gastro-oesophageal). Models are repeated for larger beneﬁts to illustrate
potential effects on power.
y A range of participation rates are used to assess potential impacte actual rates are unlikely to reach 30% (limited by overlap in recruiting
centres and recruitment periods, as well as trial X participants being ineligible or unwilling to participate in Add-Aspirin). Differences in
rates between arms are also unlikely to be as large as illustrated here.
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